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Abstract 
 
The bile acid receptor FXR maintains bile acid homeostasis through the dynamic 
regulation of transporters, detoxification and biosynthesis enzymes. Intrahepatic 
cholestasis of pregnancy (ICP) is caused by disturbance in bile acid homeostasis in 
predisposed individuals.  
The first genetic variants in FXR, identified in an ICP population, are investigated in 
this thesis using in vitro approaches and a functional effect is demonstrated.  
Reproductive hormones are implicated in the aetiology of ICP but experiments in 
mice suggest that estrogen and progesterone alone are unlikely to be the cause of 
gestational cholestasis.  
Pregnancy increases the metabolic demand on the maternal liver and, in mice, causes 
maternal hepatomegaly that is associated with pro-cholestatic gene expression and 
raised serum and hepatic bile acids. Gestational hepatomegaly is characterised in 
detail for the first time and Fxr is shown to be required to maintain the normal 
mechanisms driving this process. Furthermore, pro-cholestatic gene expression and 
the fact that hepatic bile acids do not accumulate in pregnant Fxr-/- or cholate-fed 
mice suggest that for unknown reasons, gestation could be a period of reduced Fxr 
function. 
Conclusions: Pregnancy causes perturbed bile acid homeostasis in mice. This may 
be a result of Fxr playing a complex role in mediating, or responding to, the 
metabolic demands of gestation. Furthermore, FXR protects individuals from 
developing pregnancy-specific cholestatic disease. 
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1.1 Bile Acids 
Bile acids are amphipathic molecules with a steroid backbone that are synthesised 
from cholesterol in the liver. Bile acids play a crucial role in the liver and the small 
intestine. Their synthesis provides a metabolic pathway for the catabolism of 
cholesterol and their detergent properties promote the solubilisation of essential 
nutrients and vitamins in the small intestine. Bile acids, cholesterol, phospholipids, 
small amounts of bile pigments and proteins compose the bile, which is stored in the 
gall bladder. After ingestion of food, bile flows into the duodenum where it helps in 
the solubilisation and digestion of lipid-soluble nutrients. Subsequently the bile acids 
are absorbed by passive diffusion and active transport form the terminal ileum and 
then transported back to the liver via the portal vein. This process is called the 
enterohepatic circulation (Houten & Auwerx, 2004) and is outlined in Figure 1.1. 
Approximately 95% of bile acids are transported back to the liver whereas 5% of bile 
acids are eliminated daily in the enterohepatic cycle. The liver must synthesise an 
equivalent amount to maintain a constant pool of bile acids. Serum bile acids vary 
during the day following a pattern that is dictated by the ingestion of food. In 
humans, the bile acid levels increase daily in the liver, intestine and systemic 
circulation from 5µM to 15µM in response to ingestion of food (Engelking et al, 
1980). Therefore systemic bile acids act as a signal to the peripheral tissues that a 
meal has been ingested and that energy will become available. On the other hand, 
increased bile acid levels are toxic, and thus their synthesis and enterohepatic 
circulation is tightly controlled. Bile acids inhibit their own synthesis via negative 
feedback pathways, which regulate the expression of a number of transport proteins 
and biosynthetic enzymes crucial to the maintenance of bile acid homeostasis.  
In addition to activating the farnesoid X receptor (FXR; NR1H4) and facilitating the 
absorption of lipid, and fat-soluble vitamins, bile acids have emerged as versatile 
signalling molecules, attributed with several functions. Bile acids are ligands for G-
protein coupled receptors (GPCRs) such as TGR5 (Maruyama et al, 2002). Bile acids 
also modulate several nuclear hormone receptors including FXR (Wang et al, 1999), 
the pregnane X receptor (PXR; NR1I2) (Staudinger et al, 2001), the vitamin D 
receptor (VDR) (Makishima et al, 2002) and the constitutive androstane receptor 
(CAR; NR1I3) (Zhang et al, 2004a). By activating these diverse signalling pathways, 
bile acids regulate their own synthesis in addition to the enterohepatic circulation and 
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pathways of triglyceride, cholesterol, energy and glucose homeostasis. Therefore 
targeting bile acid signalling can be used to develop novel drug targets and 
preventive strategies to treat and manage common metabolic and hepatic diseases.  
 
 
Figure 1.1: The enterohepatic circulation of bile acids. 
The organs involved in enterohepatic circulation are shown. About 500mg of 
cholesterol is converted to bile acids in the hepatocytes on a daily basis. Bile acids 
are excreted from the hepatocyte into bile canaliculi and together with the excretion 
of other substances, bile is formed. Bile is stored in the gallbladder. Upon digestion 
of a meal, the gallbladder contracts and the bile is released into the duodenum. In the 
intestine cholesterol and other toxic compounds are released from the body by 
defecation, the first important function of bile flow. Only 5% of the bile acids are lost 
in the faeces. The rest of the bile acids are reabsorbed in the terminal ileum and 
transported back to the liver. Bile acids that have escaped the first hepatic pass are 
filtrated by the renal glomerulus and reabsorbed in the proximal convoluted tubules 
of the kidney. Taken from (van Mil et al, 2005) 
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1.1.1 Bile Acid Biosynthesis Pathway 
Bile acid synthesis is the primary pathway for cholesterol catabolism. Approximately 
500 mg of cholesterol is converted into bile acids each day in the adult human liver. 
The direct products of bile acid synthesis are called “primary” bile acids. Cholic acid 
(CA) and chenodeoxycholic acid (CDCA) are the primary bile acids formed in 
humans. In rodents, the primary bile acids have a different structure due to 
alternative hydroxylation reactions and they are called α-, β- and γ-muricholic acids. 
The bile acid pool also contains “secondary” bile acids that are formed by the actions 
of the intestinal bacterial flora. In humans, CA and CDCA give rise to the secondary 
deoxycholic acid (DCA) and lithocholic acid (LCA) respectively, which are made 
following deconjugation and 7α-dehydroxylation by microbial enzymes in the colon. 
Most of the bile acids are conjugated to either taurine or glycine before they are 
excreted into bile (Figure1.2) (Russell, 2003).  
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Figure 1.2: Chemical structure of the main human bile acids. 
The most common bile acids in human bile are cholic acid (CA) and 
chenodeoxycholic acid (CDCA). Primary bile acids are synthesised in the liver and 
then further modified by intestinal bacteria to form the secondary bile acids. 
Secondary bile acids are deoxycholic acid (DCA) and lithocholic acid (LCA), which 
originate from cholic acid and chenodeoxycholic acid respectively.  
Modified from (van Mil et al, 2005) 
Chapter 1                                                                                                                               Introduction 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     6 
Bile acid synthesis takes place exclusively in the hepatocytes via two pathways: the 
“classic” or neutral pathway and the “alternative” or acidic pathway. A schematic 
representation of the bile acid synthesis is shown in Figure 1.3. Bile acid biosynthesis 
involves hydroxylation of cholesterol at the C7 position of the steroid ring structure 
or at the C24, C25 or C27 positions at the side chain, modification of the ring structure 
of cholesterol, followed by side ring chain shortening and finally conjugation of the 
bile acid with an amino acid (taurine or glycine) (Russell, 2003). The intermediates 
and enzymes of the classical and alternative pathways are displayed in Figure 1.3.  
The first and rate-limiting enzyme of the classical pathway is cholesterol 7α-
hydroxylase encoded by the gene CYP7A1. CYP7A1 is a microsomal cytochrome 
P450 enzyme that catalyses the hydroxylation step and yields 7α-hydroxycholesterol. 
This enzyme is considered to be of great regulatory importance and accounts for 
most of the bile acid synthesis, as became evident from the phenotype of Cyp7a1 
knockout mice (Ishibashi et al, 1996; Schwarz et al, 1996). These mice display 
increased perinatal mortality due to malabsorption of lipids and lipophilic vitamins. 
Most of these mice die in the first three weeks and produce very small amounts of 
some monohydroxy bile acids that are toxic to the liver. Mice can be rescued by 
supplementing their diet with CA. The “rescued” mice can then produce typical bile 
acids via pathways that include oxysterols rather than cholesterol as substrate for 7α-
hydroxylation. Nevertheless, their bile acid pool is still markedly reduced compared 
to wild type mice (Ishibashi et al, 1996). Also, some mutations have been identified 
in humans and have been shown to correlate with increased occurrence of 
hypercholesterolaemia and atherosclerosis (Beigneux et al, 2002; Pullinger et al, 
2002).  
Mutations have also been found in sterol 27-hydroxylase (CYP27A1), an enzyme 
responsible for the hydroxylation of the cholesterol side chain that yields 27α-
hydroxycholesterol. In both humans and mice, this oxysterol is responsible for 
significant amounts of bile acid synthesis via the “alternative” pathway. 
Approximately 25% of bile acid synthesis is produced by the “alternative” pathway 
in the mouse (Schwarz et al, 2001). However in humans, the “alternative” pathway 
contributes to only 6% in the total BA synthesis (Pullinger et al, 2002). CYP27A1 
deficiency leads to a rare inherited disease called cerebrotendinuous xanthomatosis, 
which is associated with increased levels of circulating cholesterol and deposition of 
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cholestanol in several tissues including the brain. This disorder is characterised by 
early development of atherosclerosis and premature death (Salen & Grundy, 1973). 
Oxysterols undergo further hydroxylation by the enzyme CYP7B1 that yields 25- 
and 27-hydrocholesterol. CYP7B1 is expressed in the liver, brain and kidney and can 
utilise dehydroepiandrosterone as a substrate (Russell, 2003). The Cyp7b1 null mice 
have elevated expression of Cyp7a1 enzyme in order to compensate for adequate bile 
acid synthesis (Li-Hawkins et al, 2000). On the other hand, a mutation found in 
human CYP7B1 gene leads to severe cholestasis and cirrhosis in newborns (Setchell 
et al, 1998), illustrating the importance of the “alternative” pathway in humans.  
The 7α-hydroxy intermediates formed by the actions of CYP7A1 or CYP7B1 are 
then converted to 3-oxo,Δ4 intermediates by the 3β-hydroxy-Δ5-C27-steroid 
(HSD3B7). HSD3B7 catalyses the isomerisation of the double bond from C5 to C4 
position and the oxidation of 3β-hydroxyl to 3-oxo group. Hsd3b7 null mice display 
a similar phenotype to Cyp7a1 null mice. They die within the first three weeks of life 
unless their diet is supplemented with CA and vitamins. The Hsd3b7-/- mice can be 
maintained on the bile acid and vitamin supplemented diet until weaning and then 
switched to normal chow, where they develop normally and show no liver 
impairment except a slightly reduced bile acid pool size (Shea et al, 2007). In 
contrast, an autosomal recessive mutation in the HSD3B7 gene found in children 
results in progressive liver disease characterised by cholestatic jaundice (Cheng et al, 
2003; Schwarz et al, 2000). 
The products of HSD3B7 action can take two routes and yield either CA or CDCA. 
The microsomal sterol 12α-hydroxylase (CYP8B1) acts on 3-oxo,Δ4 intermediates 
and results in production of CA. However, if this step does not take place, the end 
product is CDCA. Therefore, CYP8B1 is responsible for the ratio in which the 
primary BAs are formed (Russell, 2003). 
The next step in bile acid synthesis involves the actions of the Δ4-3-oxosteroid 5β-
reductase (AKR1D1). The 12α-hydroxylated intermediates as well as the 
intermediates that escape the actions of CYP8B1 are subject to reduction of the C4 
double bond by AKR1D1. Abnormal AKR1D1 activity has been found to be the 
cause of severe neonatal intrahepatic cholestasis in identical twins, who had 
increased urinary excretion of unsaturated hydroxy-oxo bile acids (Setchell et al, 
1988). The last step in bile acid synthesis involves the reduction of the 3-oxo group 
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to a 3α-hydroxyl group by 3α-steroid dehydrogenase (AKR1C4). The position of the 
hydroxyl group in the 3α orientation is responsible for the physiochemical 
characteristics of bile acids (Russell, 2003). 
The next steps in the production of bile acids involve the oxidation and shortening of 
the side chain. The enzyme CYP27A1 is responsible for the first steps that include 
the introduction of a hydroxyl group at position C27, the oxidation of this group to an 
aldehyde and then to a carboxylic acid (Pikuleva et al, 1998). Subsequently, the 
oxidised intermediates are transferred from the mitochondria to peroxisomes for 
shortening of the side chain by a mechanism that requires the action of several bile 
acid coenzymes. 
Before transport out of the hepatocytes, primary bile acids are conjugated at their 
side chain with either taurine or glycine, which results in increased hydrophilicity. 
This is a two-step process, which starts with generation of BA-CoA by the enzyme 
BA-CoA synthase (BACS). Subsequently, the formation of the amide linkage is 
catalysed by BA coenzyme A:amino acid N-acyltransferase (BAAT) (Falany et al, 
1994). Most mammals can form both taurine and glycine conjugates and the ratio is 
determined by the availability of taurine, as the enzyme has a higher affinity for 
taurine. Humans mainly form glycine conjugates in a ratio 3:1 to taurine. This ratio is 
often altered in disease states. BAAT seems to be responsible for all conjugation 
taking place in the liver as shown in patients with familial hypercholanaemia, who 
have a homozygous mutation in BAAT and conjugated bile acids are undetectable in 
their serum (Carlton et al, 2003).  
Bile acids can also be conjugated by phase II metabolic reactions, similar to those 
involved in the inactivation of xenobiotics. Conjugation of bile acids with sulfate or 
glucuronidate is an important mechanism of bile acid detoxification. Sulfation of bile 
acids involves the transfer of a sulfonyl group from 3-phospho-adenosine-5-
phosphosulfate to the 3α-hydroxy group of hydrophobic bile acids (i.e. LCA) and is 
catalysed by SULT2A1 (Chatterjee et al, 2005). Glucuronidation of bile acids is 
catalysed by several UDP glucuronosyltransferases. In humans UGT2B4 is 
responsible for glucuronide conjugation at 6α-hydroxy position while UGT2B7 
glucuronidates the 3α- and 6α-hydroxy groups (Gall et al, 1999; Pillot et al, 1993). 
Bile acid conjugation has been suggested to be an adaptive mechanism to cholestasis 
to allow for more effective urinary clearance, as the resulting bile acids are more 
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hydrophilic. Measurement of these metabolites in urine of cholestatic patients has 
confirmed that they have higher concentrations compared to healthy individuals. 
Nevertheless, sulphated and glucuronidated metabolites are excreted in bile in both 
humans and rodents under normal conditions too (Kuipers et al, 1988; Stiehl et al, 
1985).  
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Figure 1.3: Bile acid biosynthesis pathways. 
Bile acids are synthesised from cholesterol via two pathways; the classical or the 
alternative pathway. The classical pathway is responsible for 75% of the bile acid 
pool. Cholic acid (CA) and Chenodeoxycholic acid (CDCA) are the main products of 
these two pathways. The enzymes with the most important regulatory role are 
CYP7A1, CYP27A1 and CYP8B1. CYP7A1 is the rate-limiting step in the classical 
pathway, CYP27A1 catalyzes the first step in the alternative pathway and CYP8B1 
introduces a hydroxyl group at position 12 of the steroid nucleus yielding CA. 
Escaping the actions of CYP8B1 results in synthesis of CDCA. Altogether, CYP7A1 
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determines the size of the bile acid pool, whereas CYP8B1 is responsible for the 
composition. After synthesis of bile acids, they undergo conjugation via the actions 
of two enzyme; BA-CoA synthase (BACS) and BA-CoA:amino acid N-
acyltransferase (BAAT). In humans, bile acids are mainly conjugated with glycine 
and in mice with taurine. After conjugation, bile acids are transported out of liver 
into the gut, where they have several functions and undergo further modification. 
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1.1.2 Bile Acid Transport 
In order to maintain a functional bile acid pool, bile acids are extensively recycled in 
the body by a transport system that includes the liver, the intestine and the kidney 
(Figure 1.3). The coordinated actions of several transporter proteins ensure the 
formation of mixed micelles in bile as well as minimal loss of bile acids through 
faeces and urine. Under cholestatic conditions, bile acid transporters exert critical 
adaptive functions that work as defence mechanisms to reduce the toxic effects of 
bile acid accumulation. Therefore, bile acid transporters are crucial in mediating the 
cycling and homeostasis of bile acids and their expression is mainly regulated at the 
transcriptional level. A detailed description  of the bile acid transport system is 
presented in the next paragraphs and outlined in figure 1.4. 
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Figure 1.4: Schematic representation of the bile acid transport system. 
The canalicular bile salt export pump (BSEP) transports monovavalent (one negative 
charge) tauro- and glyco-conjugated bile acids into bile. Divalent (two negative 
charges) sulphated or glucuronidated bile acids amidated with taurine or glycine and 
redused glutathionine (GSH) are transported in bile canaliculi by the multidrug 
resistance-associated protein 2 (MRP2) and the multidrug export pump 1a 
(MDR1A). The ABCG5/8 heterodimer excretes cholesterol in the bile and the 
multidrug resistance 2 (MDR2) is a phospholipid export pump. At the basolateral 
membrane, MRP3, MRP4, OATP2 and the heterodimeric organic solute transporter 
OSTα/β provide an alternative excretion route for bile acids and other organic anions 
into the systemic circulation. After contraction of the gallbladder, the bile acids are 
released into intestinal lumen. At the terminal ileum, bile acids are taken up by the 
apical Na+ dependendent bile salt transporter (ASBT) and effluxed by OSTα/β, 
MRP3 and a truncated form of ASBT (t-ASBT). At the apical side of the enterocyte, 
MRP2 mediates apical excretion of bile acids and intracellularly the ileal bile-acid-
binding protein (IBABP) stimulates BA flux. Bile acids are recycled to the liver, 
where they are primarily taken up by the Na+ taurocholate cotransporter (NTCP) and 
to some extend by OATP1 and OATP4. Bile acids escaping the first-pass clearance 
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are filtrated by the renal glomerulus and reabsorbed by epithelial cells of the 
proximal convoluted tubules of the kidney.   
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1.1.2.1 Hepatic Bile Acid Transport 
Hepatobiliary transport proteins are essential for bile formation. Bile is formed by 
excretion of BAs and organic ions via ATP-binding cassette (ABC) transporters. 
BAs, such as glycine- or taurine- conjugates of CA, CDCA and UDCA are excreted 
into bile by the canalicular export pump BSEP (ABCB11) (Kullak-Ublick et al, 
2000; Meier & Stieger, 2002). Conjugated bile acids with two negative charges such 
as sulphated tauro- or glycolithocholic acid are transported by multidrug resistance 
associated protein MRP2 (ABCC2) and the multidrug export pump 1a (MDR1A, 
ABCB1A) (Keppler et al, 1999; Keppler & Konig, 2000). MRP2 is responsible for 
bile acid independent flow and for the excretion of other endogenous substances and 
drugs. These include mostly conjugates with glutathionine, glucuronate and sulphate 
formed by phase II reactions in the hepatocytes (Cui et al, 1999; Keppler & Konig, 
2000) and of reduced glutathionine (GSH) (Trauner et al, 1998). The multidrug 
resistance 2 (MDR2, ABCB4) protein is a phospholipid export pump that mediates 
excretion of phosphatidylcholine (PC) in the bile, where it forms mixed micelles with 
bile acids and cholesterol (Ruetz & Gros, 1994). Biliary cholesterol transport is 
mediated by the two half ABC transporters ABCG5 and ABCG8, which form an 
active heterodimer (Graf et al, 2002). Knockout mice for either ABCG5 or ABCG8 
have an 80% reduction of cholesterol excretion in the bile (Yu et al, 2002b).  
Bile in the canaliculus is modified by the bile duct epithelium before excretion into 
the intestine. Bile acids undergo extensive enterohepatic circulation, where they are 
reabsorbed in the intestine and then transported back to the liver. This cycle is 
typically repeated several times before the bile acids are excreted into the faeces. 
Hepatic uptake of bile acids occurs via the Na+/taurocholate cotransporter NTCP or 
via members of the organic anion transporter (OATP) family (Trauner & Boyer, 
2003). 
Bile acid efflux can also take place in the basolateral membrane of the hepatocyte. 
This is thought to be an alternative spillover route, necessary for hepatoprotection in 
case of accumulating bile acids and bilirubin in cholestatic conditions. The 
alternative transport system occurs via MRP3 (ABCC3) and MRP4 (ABCC4) of the 
ABC transporter family. These proteins are only expressed at a very low level under 
normal conditions (Hirohashi et al, 1999; Rius et al, 2003; Zelcer et al, 2003), but 
they can be induced under cholestatic conditions (Schuetz et al, 2001; Zollner et al, 
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2006b). MRP3 is capable of transporting sulphated taurolithocholic acid and 
taurochenodeoxycholic acid with high affinity, whereas studies in the rat have shown 
that it can also transport tauro- and glycocholic acid (Hirohashi et al, 1999; Hirohashi 
et al, 2000). MRP4 can cotransport bile acids with GSH, glycine- and taurine-
amidated CA, CDCA and ursodeoxycholic acid (UDCA) as well as unconjugated CA 
(Rius et al, 2006; Rius et al, 2003). It has also been suggested that MRP4 can 
mediate transport of sulphated bile acids (Zelcer et al, 2003). Recently, another 
transporter has been shown to play a role in the alternative transport at the basolateral 
membrane. The organic solute protein OSTα/OSTβ is a heterodimeric transporter 
expressed in various tissues. In the mouse, it is found in the intestine, kidney and at a 
lower expression in the liver (Dawson et al, 2005; Wang et al, 2001), whereas human 
OSTα/OSTβ is highly expressed in the liver, suggesting that it could have a role in 
alternative bile acid export (Ballatori et al, 2005; Dawson et al, 2005; Wang et al, 
2001). Finally, the organic anion transporting polypeptide 2 (OATP2, SLCO1A4) 
also provides alternative excretion route for bile acids and other organic anions into 
the systemic circulation (Trauner & Boyer, 2003).  
 
1.1.2.2 Cholangiocyte Bile Acid Transport 
Cholangiocytes are the epithelial cells of the bile duct and they are increasingly 
recognised as an important compartment of bile secretion. They contain several 
transport systems for absorptive and secretory processes (Boyer, 1996; Lazaridis et 
al, 2004). The apical bile acid transporter ASBT (SLC10A2) can mediate the 
absorption of conjugated bile acids in a sodium-dependent manner, whereas 
unconjugated bile acids can passively enter the cholangiocytes (Alpini et al, 1997; 
Lazaridis et al, 1997). ASBT is a transporter protein originally identified to mediate 
bile acid uptake in the terminal ileum. On the other hand, MRP3 and OSTα/OSTβ 
have been proposed to mediate the basolateral export of bile acids from 
cholangiocytes (Ballatori et al, 2005; Soroka et al, 2001). 
 
1.1.3 Intestinal Bile Acid Transport 
To complete the enterohepatic circulation, an efficient intestinal transport system is 
also required. The bile acids have to be reabsorbed by the intestine and subsequently 
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delivered to the portal circulation. Under normal conditions, bile is stored in the gall 
bladder and released into the duodenum of the small intestine in response to 
alimentary hormones upon feeding. In the small bowel, conjugated bile acids activate 
specific pancreatic lipases and also form mixed micelles in order to solubilise dietary 
lipids, sterols, and fat-soluble vitamins, which enables the uptake of these nutrients 
into enterocytes. Bile acids move through the small bowel under the actions of 
peristalsis. In the terminal ileum, tauro- and glyco- conjugated bile acids are actively 
taken up into enterocytes by ASBT, whereas unconjugated bile acids are partially 
absorbed by passive diffusion (Dawson et al, 2003; Oelkers et al, 1997). Inside the 
ileocyte, bile acids bind to the ileal bile acid binding protein (I-BABP) that has been 
proposed to mediate transcellular movement (Gong et al, 1994; Kramer et al, 2001; 
Toke et al, 2006). Thereafter bile acids get to the basolateral membrane where they 
exit the ileocyte primarily via the heterodimeric organic solute transporter OSTα/β. 
However, MRP3 (Hirohashi et al, 1998; Zeng et al, 2000) and a truncated form of 
ASBT (t-ASBT) (Lazaridis et al, 2000) have also been proposed to have a role in the 
basolateral bile acid export.  
 
1.1.3.1 Renal Bile Acid Transport 
After the first hepatic pass, bile acids that have not been cleared (less than 10%) or 
have been actively excreted to the sinusoidal blood by hepatocytes are filtrated by the 
renal glomerulus and reabsorbed by epithelial cells of the proximal convoluted 
tubules of the kidney (Wilson et al, 1981). The bile acids are reabsorbed by ASBT, 
localised at the apical membrane of the proximal tubular cells and then excreted into 
systemic circulation by basolateral OSTα/OSTβ (Ballatori et al, 2005; Christie et al, 
1996; Craddock et al, 1998). Bile acids are almost undetectable in the urine of 
healthy individuals, however in cholestatic conditions they become easily detectable 
as renal excretion seems to become a major alternative route (Raedsch et al, 1981). 
This could be due to decreased renal absorption via repressed ASBT and increased 
passive glomerular filtration in order to promote urinary excretion of toxic bile acids 
accumulating in the liver (Lee et al, 2001). In addition to passive glomerular 
filtration, active excretion could also play a role, although it has not yet been proven. 
However, MRP2 and MRP4 have been localised to the apical tubular membrane of 
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the kidney and could be responsible for the transport of sulphated and glucuronidated 
bile acids (Schaub et al, 1999; van Aubel et al, 2002).     
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1.1.4 Bile Acids as Signalling Molecules 
Conventionally, bile acids have been known for their role in dietary lipid absorption 
and cholesterol homeostasis, but they have recently been established as versatile 
signalling molecules. They activate several nuclear receptors and cell signalling 
pathways regulating fat, glucose and energy homeostasis, emerging as important 
regulatory molecules. The nuclear receptor that bile acids primarily act as ligands of 
is the FXR. Apart form activating nuclear receptors, bile acids are also ligands for G-
protein-coupled receptors (GPCRs), such as TGR5 or “membrane bile-acid receptor” 
that has received the most attention (Kawamata et al, 2003; Maruyama et al, 2002).  
Bile acids also activate other G-protein-coupled receptor signalling pathways. In 
1998, it was reported that taurolithocholate could activate cholinergic receptors in 
cells from guinea pig stomach (Raufman et al, 1998). This was the first indication 
that bile acids can activate GPCRs, including the muscarinic receptors. Muscarinic 
receptors are expressed in a wide range of tissues, including the gastrointestinal tract 
and many regions of the central nervous system. There are five muscarinic receptors 
named M1 to M5 and they are coupled to different G protein families. They regulate 
several physiological functions and studies using mutant mice have demonstrated 
that they contribute to neurodegenerative and metabolic disorders (Wess et al, 2007). 
The subtype M3 is mainly expressed in gastrointestinal tissues and can be activated 
by LCA. Glautman et al have demonstrated an important role for the M3 subtype in 
the pancreatic β-cells, where it can regulate insulin release and blood glucose 
homeostasis (Gautam et al, 2006). Although activation of the muscarinic receptors 
requires large quantities of bile acid (mM), it will be interesting to see further 
developments on these intriguing molecules that control such a large number of 
physiological processes and are expressed in a wide variety of tissues.   
Bile acids also act on another family of GPCRs called Formyl-peptide receptors 
(FPRs). FPRs are highly expressed in neutrophils and monocytes and it is thought 
that they transport phagocytes to sites of bacterial invasion and tissue damage. 
CDCA was found to be an endogenous antagonist for FPRs, which further supports 
the notion that bile acids have immunosuppressive properties (Chen et al, 2000).   
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1.1.4.1 TGR5 a GPCR for Bile Acids 
TGR5 was first discovered to be a bile acid-responsive membrane receptor in 2002 
(Maruyama et al, 2002), further cheracterised in 2003 by Kawamata et al (Kawamata 
et al, 2003) and shown to be a Gαs protein coupled receptor. TGR5 is conserved 
among mammals and some aquatic vertebrates, however phylogenetic analysis 
shows that human and rodent TGR5 are divergent. TGR5 is encoded by a single exon 
that maps to chromosome 2q35 in humans and 1c3 in mice. It is ubiquitously 
expressed, with high expression in the gall bladder and lower expression in the liver, 
intestine, brown adipose tissue (BAT), immune cells and some areas of the central 
nervous system (Vassileva et al, 2006; Watanabe et al, 2006). Several bile acids can 
activate TGR5 but LCA is the most potent activator. The biological effect of TGR5 
activation by bile acids is not well understood and is thought to vary depending on 
the tissue, the level and the species of the bile acid present. In brief, TGR5 is 
involved in immune response in monocytes and macrophages (Kawamata et al, 
2003); it regulates hepatoprotection in the liver (Keitel et al, 2007), incretin release in 
the intestine (Katsuma et al, 2005; Keitel et al, 2007), energy expenditure in the 
muscle and BAT (Watanabe et al, 2006). 
Upon activation TGR5 stimulates the synthesis of c-AMP that activates protein 
kinase A (PKA). Activated PKA can phosphorylate c-AMP response element 
binding protein (CREB), which in turn transactivates target genes that have a 
functional CRE element in their promoter. In the intestine, bile acid activation of this 
pathway results in glucagon like peptide 1 (GLP1) or incretin (Katsuma et al, 2005). 
Incretins are the hormones responsible for the increase of insulin secretion from β-
cells after a meal. In the sinusoidal cells of the liver, the nitric oxide synthase (eNOS) 
can also be activated by the bile acid-activated TGR5 pathway. Activation of eNOS 
leads to increased production of endothelial nitric oxide (NO) that can protect the 
liver against hepatotoxicity of bile acids as well as lipid peroxidation (Keitel et al, 
2007).  
In BAT and muscle, the increased production of c-AMP induces the thyroid hormone 
activating enzyme type 2 iodothyronine deiodinase (D2). D2 converts the inactive 
thyroxine (T4) into T3, which is metabolically active thyroid hormone. Activation of 
the thyroid receptor (TR) results in enhanced energy expenditure due to higher 
mitochondrial phosphorylation in muscle and uncoupling in BAT. Hence, feeding 
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mice cholic acid resulted in resistance to diet induced obesity and insulin resistance 
due to activation of TGR5 and enhanced energy expenditure. (Watanabe et al, 2006). 
 
1.2 FXR a Nuclear Receptor for Bile Acids  
FXR is also known as the “bile acid receptor” and is the most studied target of bile 
acid effects. It functions as the main sensor of intracellular levels of bile acids and 
has a crucial role in regulating bile acid homeostasis, lipoprotein and glucose 
metabolism, hepatic regeneration, intestinal bacterial growth and response to 
hepatotoxins. FXR belongs to the family of ligand-activated nuclear receptor 
transcription factors. 
 
1.2.1 Nuclear Receptors  
Nuclear receptors are ligand-inducible transcription factors that regulate the 
expression of a vast array of target genes in response to hormonal signals and 
environmental cues. By regulating gene expression, they play a major role in 
development, homeostasis, metabolism, and reproduction and generally in the 
balance between health and disease  
The nuclear receptor superfamily includes receptors for steroid hormones, thyroid 
hormones, vitamin D, retinoic acid and several small fatty acids that are by-products 
of metabolism (Aranda & Pascual, 2001). The first nuclear receptors were cloned in 
the mid 1980s and include the glucocorticoid receptor (GR) (Greene et al, 1986; 
Hollenberg et al, 1985), estrogen receptor (ER) (Greene et al, 1986; Gronemeyer et 
al, 1987), progesterone receptor (PR) (Gronemeyer et al, 1987), thyroid receptor 
(TR)  (Sap et al, 1986) and vitamin D receptor (VDR) (McDonnell et al, 1987). 
Although their ligands are different, there is some significant homology between 
their primary amino acid sequences. Two zinc finger motifs were identified as a 
DNA binding domain (DBD) that is conserved across the different receptors. Using 
this DBD to screen cDNA libraries and in database searches resulted in the 
identification of novel nuclear receptors, as the retinoic acid receptors (RARs) 
(Mangelsdorf & Evans, 1995). During these studies another group of nuclear 
receptors emerged, the orphan receptors that took their name by the fact that they do 
not have a defined ligand domain. This is either because the ligands are not known, 
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or because the ligand domain of some orphan receptors cannot bind to ligands, as in 
the case of orphan receptor Nurr1 (Wang et al, 2003). In eukaryotes, the nuclear 
superfamily encompasses 48 members and half of the ligands have been identified. 
Nuclear receptors consist of distinct domains, which have a defined structure and 
function (Figure 1.5). A typical nuclear receptor consists of a variable N-terminal 
region, a conserved DNA binding domain, a variable hinge region and a conserved 
C-terminal region, which comprises the ligand binding domain (Mangelsdorf et al, 
1995). In some nuclear receptors the N terminus contains a ligand independent 
transactivation function known as activaton function-1 (AF-1). The activity of this 
region varies according to the receptor and it functions as a ligand independent, 
constitutively active domain. In some receptors, the N-terminus is subject to post-
transcriptional modifications. These modifications attenuate the transcriptional 
activity of the receptor either by changing its cellular localisation or altering the 
formation of transcription ternary complexes (Weigel & Zhang, 1998). The DNA 
binding domain is usually 80-100 amino acids and encompasses two characteristic 
zinc finger motifs. The N-terminal zinc finger binds to specific DNA sequences 
known as hormone response elements (HREs) on the promoters of target genes. The 
C-terminal zinc finger mediates protein-protein interactions and acts as a weak 
dimerisation domain between receptors. The DNA binding domain is linked to the 
ligand binding domain by a variable hinge region that allows flexibility between the 
domains, which has been found to bind coregulators (Kumar & Thompson, 2003). 
The ligand binding domain comprises a ligand binding pocket, ligand dependent 
trans-activation function domain known as AF-2 and the major nuclear receptor 
dimerisation interface, which has also been implicated with cofactor binding 
(Danielian et al, 1992). Some nuclear receptors include an additional region at the C-
terminus, known as the F region. The function of this domain is not entirely known 
although a role in coactivator binding has been proposed (Warnmark et al, 2001). 
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Figure 1.5: A typical nuclear receptor 
A typical nuclear receptor contains a variable N-terminal, a conserved DBD, a 
variable hinge region, a conserved LBD and a variable C-terminal domain. Image 
taken from (Val et al, 2003). 
 
 
Nuclear receptors bind either as monomers, homo or heterodimers to DNA at 
specific cis-acting elements known as hormone response elements. Hormone 
response elements are arranged either as palindromes, direct repeats or inverted 
palindromes. Nuclear receptors have been divided in four main classes, based on 
ligand binding, DNA binding and dimerisation properties (Mangelsdorf et al, 1995). 
Type I nuclear receptors or classical nuclear receptors consists of the ERs, GR, PRs, 
androgen receptor (AR) and mineralcorticoid receptor (MR). These receptors bind as 
homodimers to DNA palindromic sequences and in the absence of ligand they form 
inactive complexes with heat shock proteins. Type II receptors encompass the TRs, 
RARs, VDR, ecdysone and peroxisome proliferative activated receptors (PPARs). 
They bind as heterodimers with retinoid X receptors (RXRs) to direct repeat 
sequence even in the absence of ligand. Type III receptors bind direct repeats as 
homodimers and type IV receptors bind to extended hormone response elements as 
monomers (Mangelsdorf et al, 1995). 
 
1.2.1.1 Regulation of Transcription by Nuclear Receptors 
Transcriptional regulation in eukaryotes is achieved through regulatory complexes 
that bind to specific sequences in the vicinity of the promoter and enhancer elements 
to influence the initiation of transcription (McKenna et al, 1999). Nuclear receptor 
trans-activation is a multi-step process. In a typical model the receptor is activated 
upon ligand binding, undergoes a conformational change, dissociates from an 
Chapter 1                                                                                                                               Introduction 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     24 
inactive complex and is translocated to the nucleus (in the case of GR, MR, AR and 
PR) where upon dimerization it binds to its specific HREs to regulate transcription 
(McKenna et al, 1999). The sequence of events by which the activated DNA- bound 
receptor is able to achieve transcriptional regulation is less well characterized but a 
number of mechanisms that nuclear receptors utilize to affect the rate of transcription 
of target genes have been described. Ultimately it seems that nuclear receptors 
achieve transcriptional regulation of hormone responsive genes by influencing the 
rate of assembly of General Transcription Factor (GTF) complexes and RNA 
polymerase II (RNA pol II), which are components of the preinitiation complex to 
their promoters (McKenna et al, 1999). Cellular factors known as coregulators, act in 
association with nuclear receptors to facilitate them in the regulatory process. 
 
1.2.1.2 Nuclear Receptor Coregulators 
Our understanding of the mechanism by which nuclear receptors regulate 
transcriptional activity has been rapidly expanded in recent years, as a result of the 
isolation and characterization of novel groups of proteins that act as mediators of 
their action. Nuclear receptor coregulators can be broadly defined as cellular factors 
recruited by nuclear receptors to complement their function as mediators of the 
cellular response to endocrine signals (McKenna & O'Malley, 2002a). Coregulators 
can be generally divided into coactivators that mediate the trans-activation functions 
of activated receptors, and corepressors, which transduce the attenuating functions of 
nonactivated receptors (McKenna & O'Malley, 2002b). Although most regulators are 
rate limiting for nuclear receptor activation and repression, they do not significantly 
alter basal transcription (McKenna et al, 1999). Initial evidence for the existence of 
cellular factors other than GTFs and RNA pol II, which were recruited by activated 
receptors, came from yeast experiments based on transcriptional interference and 
subsequently from squelching effects noted between cotransfected receptors in 
reporter assays (Meyer et al, 1989). The tissue specific trans-activation properties of 
receptor activation and repression reinforced the idea of mediators and it is now clear 
that the functional diversity of nuclear receptors is very much attributable to their 
recruitment of coregulators (McKenna & O'Malley, 2002b). 
Most coregulators are large in size, contain more than one receptor interacting and 
activation domains and usually function as components of multiprotein complexes 
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(McKenna et al, 1999). In general nuclear receptor coactivators can be divided into 
three broad classes based on their modes of action; those that alter the 
transcriptionaly repressive chromatin structure to make the DNA of the target gene 
accessible to the components of the basal transcriptional machinery and RNA (eg 
SWI/SNF, CBP/p300, p/CAF, CARM-1, p-160s); those that serve as adapter 
molecules for the recruitment of other coactivators (p160s), and TRAD/DRIP 
mediators that play a role in directly contacting the basal transcriptional machinery 
(McKenna & O'Malley, 2002b). The overall function of coactivators is to create a 
transcriptionaly permissive environment. Conversely, corepressor proteins such as 
NCoR, SMRT, RIP140, LCoR and others act after being recruited to the surface of 
receptors by creating an environment incompatible with proper assembly of the 
preinitiation complex (McKenna et al, 1999).  
 
1.2.2 Characterization of FXR  
FXR is a well-characterised member of the “metabolic” (as opposed to endocrine) 
subfamily of nuclear receptors. The novel cDNA was isolated in 1995 and it was 
then assigned as an orphan nuclear receptor (Forman et al, 1995; Seol et al, 1996). It 
was named farnesoid X receptor because of its weak activation by farnesols and the 
juvenile hormone III (Forman et al, 1995) and later classified as NR1H4.  
In 1997, it was shown that mouse FXR could not be activated by farnesol. However, 
it was potently activated by high concentrations of the synthetic retinoid TTNPB as 
demonstrated in transient transfections using a trophoblast tumor cell line called 
JEG3 (Zavacki et al, 1997). TTNPB was later confirmed as a FXR ligand using 
coactivator recruitment assays (Parks et al, 1999). In 1999, it was established that 
FXR is a transcriptional sensor for bile acids (Makishima et al, 1999; Parks et al, 
1999; Wang et al, 1999) and thus renamed BAR, for bile acid receptor. The first 
evidence for the interaction between bile acids and FXR came from coactivator 
recruitment assays, which probe for ligand induced structural transitions occurring in 
the LBD.  This effect was demonstrated with very small concentrations of both 
conjugated and unconjugated bile acids, similar to those contained in blood serum. 
The hydrophobic bile acid CDCA is the most potent activator of FXR. DCA and 
LCA can both activate FXR, but to a lesser extent. On the other hand, UDCA did not 
activate FXR, indicating specific structure-activity relationships (Makishima et al, 
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1999). Other natural FXR ligands have been reported to be he oxysterol 22(R)-
hydroxycholesterol (Deng et al, 2006) and androsterone (Wang et al, 2006a). 
However, the physiological consequences of FXR activation by these compounds 
have not yet been determined. Synthetic FXR agonists include GW4064 (Maloney et 
al, 2000), fexaramine (Downes et al, 2003), 6EDCA, AGN29 and AGN31 (Dussault 
et al, 2003). The natural compound guggulsterone functions as FXR antagonist 
(Urizar et al, 2002). 
 
1.2.2.1 FXR Organization 
FXR protein has the typical nuclear receptor structure and heterodimerises with the 
retinoid X receptor (RXR). It is composed of an activation function domain (AF1) at 
the N-terminus, followed by a conserved DNA binding domain (DBD) which is 
thought to pre-bind to its response element in DNA, a ligand binding domain (LBD) 
that also contains an activation function domain 2 (AF2) at the C-terminus, as well as 
a hinge region that links the DBD and LBD (Figure 1.6). When a ligand binds to the 
LBD, the AF2 undergoes a conformational change that releases co-repressors and 
recruits coactivators.  
It has been shown that bile acids can influence gene expression through FXR-
independent pathways, however, it is well established that FXR activation by bile 
acids results in the regulation of many genes that control bile acid metabolism. 
Ligand-activated FXR binds to DNA elements called FXR response elements 
(FXREs). FXR binds to FXREs either as a heterodimeric complex with RXR or as a 
monomer to regulate the expression of genes (Claudel et al, 2002). Typical FXREs 
consist of an inverted repeat (IR) of the canonical AGGTCA motif spaced by 0 bp 
(IR-0) (Song et al, 2001) or 1 bp (IR-1) (Ananthanarayanan et al, 2001; Li et al, 
2005b). IR-1 is the primary sequence that FXR binds. Other FXREs include direct 
repeat (DR), everted repeat of the core motif separated by eight nucleotides (ER-8) 
(Huang et al, 2006) and monomeric binding sites (Laffitte et al, 2000; Song et al, 
2001).  
Two groups have elucidated the LBD structure of FXR (Downes et al, 2003; Mi et al, 
2003). The FXR ligand-binding cavity seems to be relatively hydrophilic. The 
glycine- and taurine- residues of the conjugated bile acids cannot insert into the 
LBD. CDCA stabilizes the interactions between the hydroxyl groups and the amino 
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acids in helix 3 and 7. On the other hand, LCA interacts only with helix 7, which 
could be a plausible explanation for being a weaker activator. UDCA contains two 
hydroxyl groups and is unable to bind FXR. FXR/UDCA interaction leads to an open 
conformation of the FXR ligand pocket and thereby destabilization of helix 12, 
which prevents activation of FXR activation (Downes et al, 2003; Mi et al, 2003).   
There are two FXR genes, referred to as alpha and beta. The FXRα gene is conserved 
from human to fish. FXRα binds to specific DNA response elements as a 
heterodimeric complex with the retinoid X receptor (RXR). The FXRα gene in 
humans and mice encodes four isoforms (FXRα1, FXRα2, FXRα3 and FXRα4) as a 
result of the use of different promoters and alternative splicing of the RNA (Huber et 
al, 2002; Zhang et al, 2003). FXRα3 and FXRα4 contain an extended N-terminus, 
which forms the activation function 1 (AF-1) domain. FXRα1 and FXRα3 have an 
insert of four amino acids (MYTG) adjacent to the DNA-binding domain in a region 
called the hinge domain (HD). Most FXR target genes are regulated in an isoform-
independent manner. The ileal bile acid binding protein (IBABP), syndecan 1, 
crystallin α and fibroblast growth factor 19 (FGF19) are exceptions, responding 
better to the isoforms lacking the MYTG (Lee et al, 2005; Zhang et al, 2003). Fxrβ is 
a pseudogene in humans and primates but encodes a functional nuclear receptor in 
rodents, rabbits and dogs. It has been proposed to function as a lanosterol sensor 
(Otte et al, 2003). 
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Figure 1.6: Schematic representation of the organization and isoforms of FXR. 
(a) Structure of the FXRα gene. Mouse and human FXRα consists of 11 exons and 
has two functional promoters, which initiate transcription at exons 1 and 3. 
Alternative splicing produces four mRNAs. Also, the MYTG motif at exon 5 is 
indicated in blue. The two start sites are denoted by asterisks. (b) The four isoforms 
of the FXR protein. (c) FXR binds to DNA (FXR response elements) as a 
heterodimer with RXR. 
Taken from (Lee et al, 2006a). 
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1.2.2.2 Tissue Distribution of FXR 
FXR is predominantly expressed in the gastrointestinal tract. Expression of the 
different FXR isoforms has been detected in the female C57BL/6J mouse. All 
isoforms are expressed equally in the mouse liver and intestine, whereas only 
Fxrα3/4 were found in the stomach and kidney. Lung and fat express very small 
amounts of Fxrα1/2 (Zhang et al, 2003) and Fxr is also detected in white adipose 
tissue (Cariou et al, 2006; Rizzo et al, 2006). In humans, the FXRα1/2 isoforms were 
found in the adrenals and liver, and FXRα3/4 expression was detected in the colon 
and kidney. Equal amount of all FXR isoforms were found in the small intestine and 
duodenum in humans (Huber et al, 2002). Histological analysis in biopsies has 
shown that FXR is also expressed in human heart, suggesting a role for FXR in 
vascular biology (Bishop-Bailey et al, 2004). It has been detected in vascular smooth 
muscle cells from coronary arteries, aortas and atherosclerotic plaques (Bishop-
Bailey et al, 2004), as well as in rat endothelial cells (He et al, 2006). FXR 
expression was found in human peripheral mononuclear cells and subsets of 
lymphocytes and monocytes (Schote et al, 2007). There is also a report showing 
expression of FXR in the placenta and the authors suggest that FXR may play a role 
in the hepatobiliary-like excretory function of the placenta (Serrano et al, 2007).  
FXR expression is affected by the developmental stage as well as several conditions. 
The expression of Fxr is increased in the rat ileum from birth to adulthood and is not 
expressed during rat embryonic kidney development but is highly expressed in the 
proximal tubules in the adult rat (Hwang et al, 2002; Suh et al, 2006). Fxr expression 
increases in response to high glucose and decreases with insulin as shown in 
experiments in rat primary hepatocytes (Duran-Sandoval et al, 2004). In addition 
FXR expression is also repressed during the acute phase response and by interleukin-
1 and tumor necrosis factor-α (TNFα) (Kim et al, 2003). Zhang and coworkers have 
demonstrated that fasting upregulates expression of FXRα3/4 in the liver, through a 
mechanism that involves the transcriptional regulator PGC1α (Zhang et al, 2004b). 
 
1.2.2.3 FXR as a Transcription Factor 
Ligand-specific recruitment of cofactors to FXR has been widely investigated in the 
literature. However, the physiological relevance of these interactions has been 
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questioned. Nevertheless, the recruitment of cofactors is crucial for understanding 
the biology of FXR and the search of this nuclear receptor as a target for disease or 
development of therapeutics. Pineda et al have identified DRIP205, a subunit of the 
mediator complex, as a coactivator for FXR (Pineda Torra et al, 2004). Another 
study in HepG2 cells detected the CARM-1 a secondary coactivator on the promoter 
of BSEP (Ananthanarayanan et al, 2001). This interaction has been associated with 
gene activation through methylation of histone H3 (Bauer et al, 2002). Rizzo et al 
have also described PRMT1 to interact with FXR (Bauer et al, 2002). FXR also 
interacts with an established coactivator for PPAR called PGC1α (Savkur et al, 
2005b; Zhang et al, 2004b). This interaction requires further investigation to 
establish a physiological effect, as ablation of PGC1α has no consequence on liver 
metabolism and the tissue distribution is different to that of FXR (St-Pierre et al, 
2006). On the other hand, this interaction raises questions about different functions 
of FXR in other tissues that are still unknown. Also, IBABP binds to the small 
lipophilic transport proteins CRABP-2 or FABP and coactivates FXR in the small 
intestine (Nakahara et al, 2005). In addition, the G protein pathway suppressor 2 
(GSP2) component of the NCoR corepressor pathway interacts with FXR and 
increases the expression of human CYP8B1 (Sanyal et al, 2007). Corepressors have 
not been investigated but together with coactivators are necessary to evaluate the 
diverse regulatory pathways for FXR activity. 
 
1.2.3 Transcriptional Regulation of Bile Acid Homeostasis  
Research in the past ten years has established that regulation of bile acid biosynthesis 
is mediated by several members of the nuclear hormone receptor family of 
transcription factors, including FXR, VDR, PXR and the Liver X Receptor (LXR; 
NR1H3). FXR, PXR and VDR bind bile acids, whereas LXR is a cholesterol sensor. 
LXR binds oxysterols, the products of the first step in bile acid formation from 
cholesterol. All of these receptors act as heterodimers with RXR.  
FXR regulation requires the actions of two additional nuclear receptors; the short 
heterodimeric partner (SHP; NR0B2), and the liver receptor homologue-1 (LRH-1; 
NR5A2). FXR modulates the synthesis, transport and metabolism of bile acids by 
binding to DNA response elements in the promoter regions of target genes. In 
rodents the basal expression and induction of CYP7A1, the rate-limiting enzyme in 
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the classic pathway, is dependent on LRH-1 and the LXRα respectively. Raised 
cholesterol levels in the hepatocyte result in increased levels of oxysterols. 
Oxysterols activate LXRα which induces Cyp7a1 to convert excess cholesterol into 
bile acids (Peet et al, 1998). This is a mechanism to provide feed-forward regulation 
of cellular cholesterol levels, rather than bile acids. In humans, however, the 
CYP7A1 gene lacks a LXR response element and therefore does not respond to 
oxysterols (Chiang et al, 2001). Increased intracellular bile acid levels result in a rise 
in binding of bile acids to FXR, which then induces transcription of SHP (Brendel et 
al, 2002; Goodwin et al, 2000; Lu et al, 2000). SHP can dimerise with and inactivate 
both LRH-1and LXRα, which normally activate CYP7A1 (Goodwin et al, 2000) and 
CYP8B1 (Nitta et al, 1999), an enzyme of the acidic pathway and as a result bile acid 
synthesis declines. This hypothesis has been confirmed by treating Shp-/- mice with a 
potent synthetic FXR agonist (GW4064), which resulted in failure to repress Cyp7α1 
mRNA levels (Kerr et al, 2002).  
It should be noted that some recent studies have demonstrated that LRH-1 might not 
be as important as previously thought for feedback regulation of bile acid synthesis. 
By using somatic mutagenesis in mouse hepatocytes, Mataki and co-workers 
demonstrated that although the expression of Cyp8b1 is almost abolished and the bile 
acid pool radically altered, the expression of Cyp7a1 is not changed in the liver of 
the mice lacking Lrh-1 (Mataki et al, 2007). In another study by Lee et al, the 
investigators showed by using conditional liver Lrh-1 knockout mice that Lrh-1 
deficiency had no significant effect on the basal levels of Cyp7a1 expression or its 
repression by Fxr (Lee et al, 2008). On the other hand, HNF4α (NR2A1) emerges as a 
critical regulator of BA biosynthesis. Conditional knockout mice for Hnf4α had 
altered expression of several genes involved in BA biosynthesis such as Cyp8b1 and 
Cyp7b1 (Inoue et al, 2006). Also, in vitro studies showed that HNF4α regulates the 
transcription of CYP7A1 (De Fabiani et al, 2001). Although more studies are 
necessary, HNF4α could be another contributor to the feedback regulation of 
CYP7A1 by bile acids.  
The fibroblast growth factor receptor 4 (FGFR4) knockout mouse (Fgfr4-/-) has 
provided insight into a pathway for the regulation of bile acid production 
independent of Shp. FGFR4 is a transmembrane tyrosine kinase receptor found on 
the hepatocyte cell surface. The expression of Cyp7α1 and the bile acid concentration 
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were elevated in the Fgfr4-/- mice. FGFR4 overexpressing mice display the opposite 
phenotype. Activation of FXR in enterocytes resulted in increased production of 
fibroblast growth factor 15, which then binds to FGFR4 and this activated the JNK 
pathway, which repressed CYP7A1 and CYP8B1 (Yu et al, 2000). The presence of 
Klotho and βKlotho is required to activate the FGFR4 signalling pathway. Klotho 
and βKlotho are single-pass transmembrane proteins. The synthesis and excretion of 
bile acids is raised in βKlotho knockout mice as well as the expression of Cyp7a1 
and Cyp8b1. In addition, these mice have a defect in bile acid-dependent induction of 
Shp in the liver but not in the intestine (Ito et al, 2005)  
An alternative pathway that involves Kupffer cells also influences Cyp7α1 
repression. Kupffer cells, which are the resident macrophages of the liver, release 
cytokines in response to bile acids; the cytokines then activate JNK in hepatocytes, 
resulting in repression of Cyp7α1 (Davis et al, 2002). Earlier studies in primary rat 
hepatocytes showed that treatment with bile acids represses Cyp7α1 transcription as 
a result of JNK-c-Jun pathway activation and that this repression is independent of 
Fxr (Gupta et al, 2001). Taken together these data show that CYP7A1 expression is 
tightly regulated in order to ensure that bile acid and cholesterol homeostasis is 
maintained.  
PXR binds to the toxic bile acid LCA. PXR inhibits the transcription of CYP7A1 (Li 
et al, 1990) and stimulates the transcription of CYP3A4 (CYP3A11 in mice), a 
cytochrome P-450 enzyme that detoxifies secondary bile acids leading to formation 
of more hydrophilic bile acids. VDR also binds LCA at low concentrations, which 
results in induction of CYP3A4 in enterocytes and cholangiocytes, protecting them 
from the harmful effects of LCA (Makishima et al, 2002). 
Hepatic BA transporters are also regulated by FXR. SHP inhibits transcription of 
NTCP, the principal importer of bile salts at the basolateral membrane, leading to a 
reduction of bile salt influx into the hepatocyte (Denson et al, 2001). Conversely, 
FXR induces transcription of the genes that encode MDR1A (MDR3 in humans) and 
BSEP, which transport phospholipids and bile acids respectively. Furthermore, 
hepatic enzymes that sulphate (SULT2A1) and glucuronidate (UGT2B4) bile acids 
prior to excretion are under the regulation of FXR. In the intestine FXR induces 
transcription of IBABP leading to enhanced transport through the enterocyte (Grober 
et al, 1999) and via SHP represses the ileal bile acid transporter ASBT (Li et al, 
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2005a), which is responsible for reabsorption of bile acids across the ileal enterocyte 
brush border membrane. Other FXR target genes in the intestine encode the 
heterodimeric organic solute transporter alpha and beta (OSTα and OSTβ), which are 
responsible for transporting bile acids across the enterocyte basolateral membrane 
into the portal circulation (Dawson et al, 2005). Taken together these data 
demonstrate that FXR is the principal bile acid sensor responsible for bile acid 
homeostasis. 
 
1.2.3.1 Adaptive Responses of Bile Acid Metabolism in Cholestasis 
Cholestasis is the impairement or absence of bile flow that could result from a defect 
in the bile formation process in the hepatocyte or cholangiocyte (intrahepatic 
cholestasis) or from an obstruction of bile flow in bile ducts (extrahepatic 
cholestasis). Cholestasis results in accumulation of toxic bile acids in the liver and 
systemic circulation that could lead in liver injury and inflammation. A series of 
adaptive responses take place during cholestasis in order to minimise bile acid 
toxicity. The synthesis of bile acids is inhibited, phase I and II detoxification 
reactions are induced to make the bile acid pool more hydrophilic and alternative 
transport is also induced to eliminate bile acids. FXR, PXR and CAR play a vital role 
in these adaptive responses (Zollner et al, 2006a). Therapeutic strategies would 
include restoration of biliary excretion, decrease in bile acid uptake via NTCP, 
stimulation of detoxification through hydroxylation and conjugation and induction of 
alternative pathways for excretion of bile acids in the urine.  
Modulators of FXR activity have been proposed for treatment of cholestasis. Both 
agonists and antagonists have been reported to have beneficial effects in different 
cholestatic models. Bile duct ligated mice is a model of extrahepatic cholestasis, 
which has been used to investigate the role of Fxr in modulating liver injury. In this 
model, it was shown that an FXR antagonist might be beneficial. Fxr knockout mice 
were protected in obstructive cholestasis. The mechanism proposed for this 
protection includes down-regulation of the biliary transporters Mdr1, Mdr2 and Bsep 
and up-regulation of the alternative export transporter Mrp4 (Stedman et al, 2006). In 
a different study, Fxr knockout mice also showed to be protected by biliary 
obstruction through increased hydroxylation of bile acids (Marschall et al, 2006). On 
the other hand, studies in rats with chemically induced intrahepatic cholestasis or 
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extrahepatic cholestasis via bile duct ligation showed that activation of Fxr was 
advantageous. These rats were treated with GW4064, a potent synthetic FXR ligand, 
and showed decreased markers of liver damage. This protection is thought to be 
through decreased bile acid synthesis and upregulation of genes involved in bile acid 
transport, such as the phospholipid flippase Mdr2 (Liu et al, 2003).  
Also, Fxr null mice were found to be protected compared to wild type mice when fed 
the hepatotoxic bile acid LCA. The authors demonstrated that the Fxr knockout mice 
had increased hepatic sulfating activity and hydroxysteroid sulfotransferases (Kitada 
et al, 2003). In contrast, Yu and co-workers have suggested that LCA acts as an 
antagonist for FXR that reduces the expression of BSEP in HEPG2 cells and 
treatment with FXR ligand could be beneficial in intrahepatic cholestasis (Yu et al, 
2002a). In addition, FXR activation results in reduction of toxic bile acids by 
increased glucuronidation via up-regulation of UGT2B4 (Barbier et al, 2003). 
PXR has also been implicated in the adaptive response of the liver in cholestasis, by 
inducing several genes of the p450 pathway, hepatic transporters and reducing bile 
acid biosynthesis (Staudinger et al, 2001). A double knockout mouse for Pxr and Car 
demonstrated that CAR has an important role in the acute response to the toxic LCA. 
Car was primarily responsible for induction of the Cyp3a4 enzyme and Mdr3 
transporter (Zhang et al, 2004a). A role for Vdr has been described in the intestine, 
where it increases the expression of Cyp3a4 in response to LCA (Makishima et al, 
2002)  
 
1.2.4 FXR in Lipoprotein Metabolism 
The first evidence that FXR might regulate plasma lipid levels came from the Fxr-/- 
mouse, which presents with high cholesterol and plasma triglycerides (Sinal et al, 
2000). FXR was then thought to have a role in the hypotriglyceridemic effect of bile 
acid treatment previously noted in gallstone patients. Gallstone patients were treated 
with CDCA in order to enrich their bile acid pool, which was thought that would 
help in solubilisation of the cholesterol-rich stones. Surprisingly, this treatment 
resulted in reduction of triglyceride levels in the serum of patients (Beil et al, 1982; 
Bell et al, 1973; Miller & Nestel, 1974). Conversely, treatment of dyslipidemic 
patients with bile acid sequestrants (i.e. cholestyramine) increased the levels of 
triglyceride and very-low-density liprotein levels (VLDL) (Beil et al, 1982; Crouse, 
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1987). Several reports using mainly rodents have demonstrated that FXR and bile 
acids influence lipid metabolism. 
Administration of FXR agonists to wild type rats and mice reduces triglyceride (TG) 
levels (Kast et al, 2001; Maloney et al, 2000), an effect that is not seen in Fxr-/- mice 
(Claudel et al, 2003; Ma et al, 2006; Zhang et al, 2006). Activation of FXR also 
improved hypertriglyceridemia in ob/ob (lack of leptin) and db/db (lack of functional 
leptin receptor) mice, which are models for insulin resistance (Cariou et al, 2005; 
Zhang et al, 2006). Furthermore, feeding CA reduced the accumulation of 
triglycerides in the liver, very-low-density lipoprotein (VLDL) production and serum 
triglycerides in a mouse model of hypertriglyceridemia (Watanabe et al, 2004).  
FXR changes the expression of several genes involved in fatty acid and triglyceride 
synthesis, including the insulin and sterol-regulatory element-binding protein-1c 
(SREBP-1c) and its target genes (Watanabe et al, 2004; Zhang et al, 2004b). Fxr 
represses the expression of transcription factor Srebp1-c via a pathway that involves 
Shp, as the reduction in TG after BA treatment is lost in Shp-/- mice when fed a CA 
diet (Watanabe et al, 2004). However, mice over-expressing SHP in the liver 
accumulated TG and had increased levels of Srebp-1c (Boulias et al, 2005).  
To complicate matters more, the importance of SREBP-1c in mediating the 
hypotriglyceridemic effect of FXR is dubious. Treatment of hypelipidemic hamsters 
with CDCA decreased the levels of TG but did not significantly alter the expression 
of Srebp-1c (Bilz et al, 2006). Also, Srebp-1c expression is not increased in Fxr-/- 
mice (Duran-Sandoval et al, 2005; Zhang et al, 2004b) and the hepatic levels of 
Srebp-1c are decreased in diabetic mice treated with a bile acid-binding agent 
(Kobayashi et al, 2007). Collectively these data suggest that FXR regulates 
lipogenesis via both SREBP-1c dependent and SREBP-1c independent mechanisms.  
FXR also regulates genes associated with TG clearance. Activation of FXR increases 
expression of apoC-II (Kast et al, 2001) and decreases the expression of apoC-III 
(Claudel et al, 2003) and ANGPTL3 (Watanabe et al, 2006). ApoC-II stimulates the 
activity if lipoprotein lipase (LPL), whereas apoC-III and ANGPTL3 inhibit it. 
VLDL receptor is also induced by FXR, which could increase the clearance of 
triglyceride-rich proteins (Sirvent et al, 2004). Treatment of primary human 
hepatocytes with GW4064 caused up-regulation syndecan-1 mRNA, which is 
involved in clearance of remnant particles (Anisfeld et al, 2003).  
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In addition, FXR has been reported to induce genes involved in fatty acid oxidation, 
including PPARα (Pineda Torra et al, 2003) and its target gene pyruvate 
dehydrogenase kinase 4 (PDK4) (Savkur et al, 2005a). Taken together these findings 
suggest a mechanism to explain the decreased triglyceride levels after administration 
of bile acids and synthetic FXR agonists.  
FXR also plays a role in high-density lipoprotein (HDL) metabolism. HDL transports 
cholesterol from the peripheral organs to the liver for excretion, in a process called 
reverse cholesterol transport. Fxr-/- mice have increased HDL-cholesterol (HDL-C) 
and reduced hepatic expression of the scavenger receptor SR-B1, which mediates 
clearance of HDL-C from blood (Kok et al, 2003; Sinal et al, 2000). FXR is thought 
to modulate the HDL metabolism by repressing the expression of apolipoprotein A-I 
(ApoA-I) and hepatic lipase genes and inducing the expression of phospholipid 
transfer protein (PLTP). Hepatic lipase and PLTP have a role in HDL remodelling, 
indicating that FXR might be important for this function (Claudel et al, 2002; Urizar 
et al, 2000).  
GW4064 administration in ob/ob and db/db mice improved hypercholesterolemia 
(Cariou et al, 2006; Zhang et al, 2006), but the levels of HDL-C were reduced 
(Watanabe et al, 2004). In accordance, treatment with bile acid sequestrants in 
humans results in raised HDL-C levels (Shepherd et al, 1979), whereas CDCA 
treatment decreases HDL-C levels (Bateson et al, 1978).  
Finally, bile acids and FXR have been found to affect LDL-cholesterol (LDL-C) 
metabolism. CYP7A1 is the rate-limiting step in the conversion of cholesterol into 
bile acids. FXR regulates the activity of CYP7A1 via SHP induction. Therefore, 
FXR can affect the concentration of cholesterol, both in the liver and serum, by 
modulating the activity of CYP7A1. High bile acid flux through the hepatocyte 
activates FXR resulting in increased levels of hepatic and serum low-density 
lipoprotein (LDL) as cholesterol is not converted into bile acids. On the other hand, 
induction of CYP7A1 due to low bile acid flux results in raised conversion of 
cholesterol into bile acids, which decreases the hepatic microsomal cholesterol 
content. As a consequence, the expression of LDL receptor (LDL-R) increases 
followed by reduction of plasma LDL-cholesterol. This mechanism also explains the 
hypercholesterolemic effect of BA sequestrants (i.e. cholestyramine) (Insull, 2006).  
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There have been a number of studies investigating the lowering effect of bile acid 
treatment on LDL cholesterol, as it could be of benefit for the treatment of diseases 
like atherosclerosis. Treatment of hepatic cell lines with CDCA showed that the 
expression and activity of LDL-R is increased, via a mitogen-activated protein kinase 
(MAPK) mediated stabilization of the LDL-R mRNA (Nakahara et al, 2002). On the 
other hand, treatment with CDCA for 20 days in humans did not change the 
concentration of LDL-C (Wang et al, 2006b). Furthermore, long-term (up to 2 years) 
treatment of gallstone patients with CDCA increased the levels of LDL-C by 10% 
(Schoenfield & Lachin, 1981). Nevertheless, CDCA affects multiple pathways in a 
whole organism, which could explain the discrepancy between in vitro and in vivo 
data. Altogether, these data support the notion of FXR as a link between bile acids 
and lipids. 
 
1.2.5 FXR in Glucose Homeostasis 
A study showing improved glycaemic control after treatment with cholestyramine 
was the first evidence that bile acids could affect glucose metabolism (Garg & 
Grundy, 1994). The role of FXR in mediating the effects of bile acids is not very 
clear.   
There are conflicting reports on the effect of insulin on the expression of FXR. 
Zhang et al demonstrated that FXR expression was enhanced by fasting, indicating 
that insulin could repress its expression (Zhang et al, 2004b). On the other hand, 
Duran-Sandoval et al reported that the expression levels of Fxr were decreased in 
mouse models of diabetes and could return to normal with the addition of insulin 
(Duran-Sandoval et al, 2005).  
The role of FXR in gluconeogenesis is also not clear. Studies using rat hepatoma cell 
lines showed that activation of FXR results in increased expression of 
phosphoenolpyruvate carboxykinase (PEPCK) via a mechanism that requires 
induction of PPARα and Tribbles 3 (TRB3). TRB3 mediates the induction of 
gluconeogenesis in periods of fasting and insulin resistance (Stayrook et al, 2005). 
However, bile acids have been found to inhibit gluconeogenesis via repression of 
PEPCK expression both in an FXR-dependent and an FXR-independent fashion (De 
Fabiani et al, 2003; Ma et al, 2006; Yamagata et al, 2004).  
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Activation of FXR also results in decreased hepatic expression of glucose-6-
phosphatase (G6Pase), which might increase the hepatic glycogen levels (Duran-
Sandoval et al, 2005; Zhang et al, 2006). In agreement with this, Fxr-/- mice present 
with decreased hepatic glycogen content (Cariou et al, 2006).  
Also, Fxr-/- mice present with impaired glucose tolerance and insulin sensitivity, 
which could be due to high levels of FFA (Cariou et al, 2006; Ma et al, 2006; Zhang 
et al, 2006). Other studies have demonstrated that Fxr activation in wild type mice or 
diabetic db/db or KKA-9(y) (type 2 diabetes) mice results in hypoglycaemia and 
increased insulin sensitivity, possibly due to reduced levels of FFA (Zhang et al, 
2006).  
Bile acids can also affect gluconeogenesis by FXR-independent pathways, involving 
the activation of the phospho-inositide 3-kinase (PI3K)-AKT pathway (Fang et al, 
2004; Han et al, 2004). 
 
1.2.6 Other Roles for FXR 
As described previously, FXR is expressed in multiple tissues and it has a critical 
role in regulating different aspects of metabolism. Other roles have also been 
described for FXR, which involve processes for protection of the organism as well as 
novel functions in the pathophysiology of different organs.  
 
1.2.6.1 FXR in Liver Regeneration and Hepatocarcinoma 
The liver has a remarkable ability for regeneration after injury or toxic insult. In 
rodents, 70% hepatectomy results in rapid liver growth achieved by hyperplasia. 
Increased levels of bile acids have been found to stimulate liver growth after partial 
hepatectomy. This effect seems to be Fxr dependent, suggesting that Fxr has an 
important role in liver regeneration. Huang et al demonstrated that feeding mice a 
cholic acid supplemented diet resulted in acceleration of regeneration. However, this 
effect was lost in the Fxr knockout mice. Also, the expression of two proliferative 
genes the FoxM1b (Forkhead Box m1b) and its target cdc25B (cell division cycle 25 
homolog B) was decreased in the Fxr null mice, implying that Fxr regulates genes 
that are important in the cell cycling. The authors proposed FXR and other nuclear 
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receptors might regulate the size and regeneration of the liver by sensing the 
concentrations of metabolites, i.e. bile acids (Huang et al, 2006).  
The protective role of Fxr in the liver is also emphasized by the observation that old 
Fxr null mice (15 months of age) have a higher incidence of hepatocellular adenoma 
and carcinoma. High concentrations of toxic bile acids may be responsible for this 
effect as treatment with bile acid sequestrants decreases tumour appearance (Kim et 
al, 2007; Yang et al, 2007)   
 
1.2.6.2 FXR regulation in the Intestine 
FXR is expressed in high amounts in the intestine, with the highest levels found in 
the ileum. There are a few studies showing regulation of BA uptake in the terminal 
ileum by FXR. At the luminal side of the terminal ileum, FXR represses the apical 
sodium-dependent bile acid transporter (ASBT), which results in reduced BA 
absorption (Chen et al, 2003). After entering the intestinal lumen bile acids are 
transported from the apical to the basolateral side by the ileal bile acid-binding 
(IBABP). In vitro studies have demonstrated that FXR can activate transcription of 
IBABP through binding on its promoter (Grober et al, 1999). However, the 
physiological relevance of this transport of bile acids via IBABP remains unclear, as 
Fxr null mice display increased intestinal bile acid absorption although the 
expression of Ibabp is very low (Kok et al, 2003). FXR can also induce the 
heterodimeric BA transporter at the basolateral side of the ileum, Ostα/β. In mice fed 
a cholic acid diet, this effect is blunted by the reduced concentrations of intraluminal 
bile acids due to down-regulation of the importer Asbt (Frankenberg et al, 2006).  
It has been proposed that FXR is also responsible for the control of intestinal 
bacterial growth. Bile duct ligation results in disruption of bile flow, which results in 
bacterial translocation and overgrowth. This effect can be reversed after 
administration of bile acids (Ding et al, 1993; Lorenzo-Zuniga et al, 2003). Inagaki et 
al. demonstrated that Fxr has a role in limiting bacterial overgrowth, therefore 
protecting the intestine from damage (Inagaki et al, 2006). In this study, the authors 
studied the Cyp27 null mice, as these mice have altered bile acid synthesis and 
therefore reduced levels of FXR activation and expression of target genes. They 
treated Cyp27-/- and Fxr-/- mice with the FXR agonist GW4064 and found that only 
the Cyp27-/- mice had repressed bacterial overgrowth and translocation as well as less 
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mucosal injury. In addition, they found novel intestinal Fxr target genes including 
inducible nitric oxide synthase (iNOS), interleukin 18 (IL18), angiogenin and 
carbonic anhydrase 12; genes that have all been described to have an antibacterial 
function. Bile duct ligated mice were also treated with GW4064 and found to have a 
reduced number of bacteria in the ileum (Inagaki et al, 2006).  
 
1.2.6.3 FXR in the Kidney and Adrenal Gland 
Identification of FXR and the FXR target genes ASBT and OSTα/β in the kidney has 
led to the notion that FXR has a role in bile acid reabsorption in this organ (Ballatori 
et al, 2005; Lee et al, 2006b). Bile acids in the systemic circulation are filtered 
through the glomeruli and reabsorbed via renal tubular cells by a Na+ dependent 
process. However more research is necessary to confirm this role of FXR in the 
kidney.  
A recent report by Jiang et al implicates FXR in renal lipid metabolism fibrosis and 
diabetic neuropathy. The authors demonstrated that FXR activation prevented the 
harmful effects of high-fat diet on renal disease. Overexpression of FXR or treatment 
with the FXR agonist GW4064 inhibited SREBP1c and other lipogenic genes. In 
addition, FXR activation prevented the production of oxidative stress enzymes, 
glomerulosclerosis and proteinuria in vivo, suggesting that FXR agonists could be of 
use in the treatment of diabetic kidney disease (Jiang et al, 2007). 
Fxr is highly expressed in the adrenal cortex in the mouse (Forman et al, 1995), 
however its functional role remains unknown. The adrenal cortex is a steroidogenic 
tissue and there is no data suggesting that bile acids reach this tissue. There are a few 
studies that have tried to elucidate the role of FXR in the adrenal gland. Howard et al 
have shown using reporter assays that FXR was transcriptionally active in the 
presence of androsterone, a metabolite of androgen catabolism. However, no 
physiological relevance has been found for this interaction (Howard et al, 2000). Lee 
et al identified Ostα/β to be induced in an FXR-dependent manner in the adrenal. 
The authors proposed that OSTα/β act as multifactorial transporters in order to 
transport bile acids from the blood into the adrenal in situations of high serum bile 
acids and conjugated steroids from the adrenal under physiological conditions (Lee et 
al, 2006b). Transport of conjugated steroid intermediates seems to be a more likely 
function for OSTα/β in the adrenal, as it has been demonstrated that the heterodimer 
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can transposrt dehydroepiandrosterone 3-sulfate out of oocytes (Ballatori et al, 
2005). In agreement with this, Chung et al showed that FXR could induce the 
enzyme dehydroepiandrosterone sulfotransferase. This enzyme is highly expressed in 
the liver, intestine and andrenal cortex and mediates the sulfo-conjugation of 
endogenous hydroxysteroids including bile acids and dehydroepiandrosterone (Song 
et al, 2001). Therefore, it seems that OSTα/β transports conjugated steroids from the 
adrenal cortex into the blood rather than bile acids. More work is needed to establish 
the physiological relevance of FXR in the adrenal cortex. 
 
1.3 FXR: a Candidate for a Cholestatic Disorder? 
The majority of the enzymes and transporters that control the synthesis and 
enterohepatic circulation of bile acids are regulated by FXR. FXR regulated genes 
involve CYP7A1, UGT2B4, BSEP, MDR3, MRP2, ASBT, I-BABP, NTCP and 
OSTα/β. Reduced expression or malfunction of some of these genes has been 
described in patients with several cholestatic disorders (Bertolotti et al, 2001; Bull et 
al, 1998; de Vree et al, 1998; Jacquemin et al, 1999; Zollner et al, 2003b). In 
cholestasis, bile acid-FXR interactions result in a series of adaptive responses in an 
attempt to protect the liver from the toxic effects and further accumulation of bile 
acids. It is the crucial role in the regulation of bile acid synthesis, transport, as well as 
hepatoprotection that has led to the hypothesis that FXR dysfunction could cause 
cholestasis.   
 
1.3.1 FXR Polymorphisms 
Genetic mutations and polymorphisms have been identified in key members of the 
nuclear receptor super-family, such as PPARγ (Meirhaeghe & Amouyel, 2004), VDR 
(Valdivielso & Fernandez, 2006) and HNF4α (Yamagata et al, 1996a) and have been 
associated with metabolic disorders. As discussed before, the central role of FXR in 
bile acid homeostasis has led to the hypothesis that variation in this gene can 
predispose to bile acid metabolism disorders. There are approximately 400 single 
nucleotide polymorphisms (SNPs) or mutations within the FXR gene submitted to the 
NCBI and HapMap databases. Most of these variants are located in the introns or the 
regions flanking the FXR coding sequence. Several reports have identified FXR 
Chapter 1                                                                                                                               Introduction 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     42 
variants and associate them with bile acid disorders. A study of a family with three 
cases of idiopathic bile acid malabsorption did not reveal any mutation in the FXR 
gene (Montagnani et al, 2006). In addition, Kovacs et al genotyped FXR in 481 
cholesterol gallstone patients and 523 control individuals.  There were no 
polymorphisms identified in this study that lead to an amino acid change. However, 
there were some allelic variants in three base positions (-20647T>G and -1G>T in 
the 5’ region and IVS7 -31A>T in intron 7) that were associated with gallstone 
prevalence in the Mexican male population but not in the German or Chilean 
population (Kovacs et al, 2008). 
There is another study in which heterozygous variants of FXR have been isolated in 
patients of Intrahepatic Cholestasis of Pregnancy (ICP) (Marzolini et al, 2007; Van 
Mil et al, 2007). This study by van Mil et al is coming from our group and for this 
study 92 ICP patients of varied ethnic group were genotyped for the coding regions 
and exon/intron boundaries of FXR. Four heterozygous FXR variants were identified: 
-1G>T, 1A>G (M1V), 238T>C (W80R) and 518T>C (M173T). Subsequently, the 
allele frequencies of these variants were further investigated in a case-control study 
in two independent cohorts of Caucasian ICP patients and controls. The variants 
were also cloned into an FXR expression plasmid and tested in functional assays. 
The functional consequences of three of these variants will be described in the result 
section. Briefly, the -1G>T, M1V and M173T variants affect the stability or the 
activity of FXR whereas W80R did not have any functional affects (Van Mil et al, 
2007).  
Another group published a study on FXR polymorphisms in populations of African, 
Chinese and Hispanic ethnicity. One of the variants identified was the substitution in 
the base position adjacent to the translational initiation site -1G>T. Two SNPs that 
changed the coding sequence were also found: 643C>T (H215Y) and 646G>T 
(A216S) but the functional effects of these variations were not investigated. 
Interestingly, the expression of two FXR target genes, SHP and OATP1B3, were 
reduced in the livers of individuals carrying the heterozygous -1G>T variant, 
whereas the level of FXR expression did not change (Marzolini et al, 2007). 
These data strongly suggest that FXR has an important role in cholestatic disorders 
and specifically in ICP, where FXR variants could predispose patients to the disease.  
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ICP is a complex disorder specific to pregnancy, highlighting the burden of 
pregnancy in the liver.   
 
1.3.2 Intrahepatic Cholestasis of Pregnancy (ICP) 
Intrahepatic cholestasis of pregnancy (ICP) is a liver disease with onset in the second 
half of pregnancy which is characterised by pruritus and raised serum bile acids (≥ 
10 µmol/L) and persists until delivery (Lammert et al, 2000). It is the most common 
liver disorder during pregnancy and despite extensive studies the aetiology and the 
pathogenesis of the disease is unknown. To the mother ICP does not impose a major 
risk, however it is associated with fetal risks such as preterm birth, fetal distress and 
intrauterine death (Fisk & Storey, 1988; Glantz et al, 2004; Rioseco et al, 1994). The 
cause and mechanism by which ICP endangers the fetus are unclear but autopsies in 
stillbirths have identified signs of asphyxia.   
Typically, the diagnosis of ICP is based on onset of pruritus with abnormal liver 
function tests in the absence of other conditions. Usually ICP presents with itching in 
the third trimester that starts on the soles and palms and worsens during the night 
disturbing sleep and causing anxiety. The biochemical picture of ICP patients 
comprises an increase (2-10 fold) in levels of serum liver transaminases (ALT) and 
bile acids may be 100 times higher than the normal range in some extreme cases 
(Reyes, 1992). Also, total and LDL-cholesterol levels are higher in ICP pregnancies 
compared to control pregnancies (Dann et al, 2006).  
Although ICP is relatively benign for the mother, it is associated with serious 
complications for the fetus, therefore it is important to identify the aetiology and 
pathogenesis of the disease in order to improve fetal outcome.  
 
1.3.2.1 Bile Acid Profiles in Women with ICP 
As discussed previously, ICP usually presents with raised serum bile acids and 
aminotransferases. The levels of serum alkaline phosphatase (ALP) and bilirubin are 
also high in some patients (Reyes & Simon, 1993). Typically, ICP is diagnosed by a 
rise of serum bile acids above the normal limit of 11µM (Brites, 2002). In addition, a 
study by Glantz et al suggests that there is an increased risk for fetal complications 
with serum bile acids above 40µM (Glantz et al, 2005).  
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Interestingly, there is a subgroup of women who have been identified to have high 
serum bile acids without abnormal liver function tests or itching in pregnancy. These 
women are described as having asymptomatic hypercholanaemia of pregnancy 
(AHP) (Pascual et al, 2002). Several investigators have studied the differences in the 
profiles of serum bile acids between normal, women with AHP and women with ICP 
(Bacq et al, 1995; Castano et al, 2006; Meng et al, 1997).  
They hypothesised that specific serum bile acid profiles would be able to 
differentiate between ICP, normal and hypercholanaemic pregnancies and that would 
help in the diagnosis of these conditions. In a study by Castano and co-workers, it 
was shown that women with ICP had a shift in serum bile acids towards a more 
hydrophobic profile compared to normal women and women with AHP. ICP cases 
had higher levels of free bile acids and an increase of 40-fold in the toxic LCA. 
However, it has to be noted that the LCA concentrations normally found in serum are 
very small and its level was also raised 2-6 fold in normal pregnancy. CA, CDCA 
and DCA were also increased in ICP women.  
LCA has been proposed as a useful parameter for accurate diagnosis of ICP and also 
a biomarker of responsiveness for ICP women undergoing treatment with 
ursodeoxycholic acid (Castano et al, 2006; Lucangioli et al, 2009).  
 
1.3.2.2 Epidemiology 
The incidence of ICP varies between countries. In the UK, the prevalence of ICP is 
0.6% in Caucasian and 1.4% in Indian and Pakistani pregnancies (Abedin et al, 
1999), suggesting that ethnic origin could be a risk factor for the disease. ICP affects 
approximately 1.0-1.5% of pregnancies in Finland and Sweden (Berg et al, 1986; 
Laatikainen & Tulenheimo, 1984) and 0.4-1.0% in France and Italy (Locatelli et al, 
1999; Reyes, 1997; Roncaglia et al, 2002). The highest incidence (14%) has been 
recorded in Chile (Reyes, 1997), however that was found to be lower in later studies 
(2-4%) (Germain et al, 2002). The differences in the diagnostic criteria, genetic 
background and environmental factors may explain this variability. ICP may recur in 
40-70% of subsequent pregnancies (Reyes, 1997) and multiple pregnancies increase 
the risk for developing the disease by 5-fold (Gonzalez et al, 1989; Reyes, 1997).  
ICP has a complex aetiology with genetic, hormonal and environmental factors 
playing a crucial role. However, the studies suggest some risk factors for developing 
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ICP, which include family history, previous pregnancy with ICP and multiple 
pregnancy.  
 
1.3.2.3 Genetic Aetiology of ICP 
A genetic component for ICP comes from the familial occurrence of ICP, as well as 
the increased prevalence in some ethnic groups. Several reports have shown that 
(Holzbach et al, 1983) there is a higher risk for developing ICP between sisters 
(Eloranta et al, 2001; Hirvioja & Kivinen, 1993; Holzbach et al, 1983).  
Our group and others have identified genetic variation in several BA transporters; 
namely BSEP (Dixon et al, 2009; Eloranta et al, 2003), MDR3 (Dixon et al, 2000; 
Gendrot et al, 2003; Jacquemin, 2001; Lucena et al, 2003; Mullenbach et al, 2003), 
FIC1(ATP8B1) (Mullenbach et al, 2005; Painter et al, 2005) and MRP2 (Sookoian et 
al, 2008), as well as in the nuclear hormone receptor FXR (Marzolini et al, 2007; Van 
Mil et al, 2007). Although some of these variants segregate within pedigrees or have 
some functional effect, the significance of these findings is unclear. These genetic 
variations have only been found in a small number of cases, whereas in the majority 
of ICP patients no variants have been identified. Also, some individuals in the 
control population carry them without developing ICP. Therefore, these genetic 
variants are considered to be risk factors for ICP rather than disease causing 
mutations. It is important to highlight that most women identified with these variants 
are asymptomatic outside pregnancy and that gestation unmasks the disease in these 
predisposed individuals.  
At present ICP is regarded as a cholestatic condition with defective bile acid 
transport, because of the cases found to harbour a variation in some of the 
transporters. However the primary events that expose these individuals to develop 
ICP are not known and that suggests that alternative disease mechanisms exist.  
 
1.3.2.4 Reproductive Hormones in ICP 
Reproductive hormones are implicated in the pathogenesis of ICP (Reyes & Sjovall, 
2000). The disease starts usually in the last trimester of pregnancy when oestrogen 
and progesterone concentrations are highest, and resolves 1 or 2 days after delivery, 
when hormone levels return to normal (Palmer & Eads, 2000). Furthermore, twin 
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pregnancies display both a higher incidence of ICP and more pronounced rises in 
hormone levels. Additionally, humans given estrogen and/or progesterone can 
develop biochemical and/or clinical features of cholestasis (Bowling et al, 1995; 
Kreek & Sleisenger, 1970; Kreek et al, 1967). Some ICP patients present with 
cholestasis outside pregnancy when taking oral contraceptives (de Pagter et al, 1976). 
The association of cholestasis and estrogens has been clinically recognised for a long 
time (Reyes & Simon, 1993). Several studies in rats have demonstrated that 
administration of estrogens can reduce bile flow and transport of organic anions 
including bile acids and bilirubin. Also, treatment of rats with ethinyl estradiol 
increased serum levels of bile acids, bilirubin and alkaline phosphatase (Gumucio & 
Valdivieso, 1971; Keefee et al, 1979; Simon et al, 1980). Although there have been a 
number of studies, the mechanism underlying estrogen-induced cholestasis is still 
unclear. Nevertheless, it has sparked a number of hypotheses including; increased 
permeability of the biliary tree, decreased membrane lipid fluidity and NaK-ATPase 
activity as well as decreased function of hepatic transporters. Also, it is not known 
whether the site of action is the sinusoidal or the canalicular domain (Berr et al, 
1984; Bossard et al, 1993). 
There are fewer studies of the influence of progesterone on bile flow or total bile acid 
output. One report demonstrated that medroxyprogesterone had little effect on bile 
flow when administered subcutaneously to rats for seven days (Baker et al, 1987). 
However, another study demonstrated that specific metabolites of estrogen and 
progesterone, e.g. estrogen 17β-D-glucuronide (E217G) and sulphated progesterone 
metabolites, have a more potent cholestatic effect than the non-metabolised 
hormones (Vallejo et al, 2006). Sulphated progesterone metabolites are the major 
steroids in serum during pregnancy (Sjovall, 1970a; Sjovall, 1970b). The 
concentrations of all sulphated progesterone metabolites increase in the plasma as 
pregnancy progresses. There are a few studies where the levels and profiles of 
progesterone metabolites were compared between normal and ICP pregnancies. It 
was shown that the profiles of steroid sulphates in ICP are different from normal. 
The ratios between certain steroids are altered in ICP, in particular the increased ratio 
of 3α-hydroxy- to 3β-hydroxy- steroids is of diagnostic significance (Sjovall & 
Sjovall, 1970). However, there is no correlation between the levels of steroid 
sulphates and the levels of bile acids in humans. Analyses of serum, urine and bile 
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suggests that ICP patients have a higher proportion of sulphated progesterone 
metabolites than healthy pregnant women (Laatikainen & Karjalainen, 1973).  
The aetiology of ICP remains unknown and abnormal progesterone metabolism 
could play a major role. It has been proposed that large amounts of these metabolites 
in genetically predisposed individuals may result in saturation of the hepatic 
transport system necessary for biliary excretion of these compounds. The effect 
could be amplified if the same system is used by estrogen metabolites and other 
components. Indeed, the biliary excretion of estrogen metabolites has been shown to 
decrease in ICP (Adlercreutz & Martin, 1980). If the bile acid transport system 
shares some components with the steroid sulphate system, then bile formation and 
secretion could be affected. Although this is just a hypothesis, there have been 
reported cases of ICP in whom the steroid sulphate abnormalities were noted before 
the appearance of cholestasis with increased serum bile acids (Sjovall & Sjovall, 
1970). Hormone-induced cholestasis could play a big part ICP and further 
investigation is necessary to identify the exact mechanism and site of action of these 
cholestatic compounds that rise significantly during pregnancy.   
 
1.3.2.5 Treatment of ICP 
Ursodeoxycholic acid (UDCA) is the drug most commonly used to treat ICP and 
other cholestatic conditions. UDCA is a naturally occurring hydrophilic bile acid, 
which is also a constituent of human bile (1-3% of human bile acids). UDCA is the 
predominant bile acid in the Chinese black bear and it has been used in traditional 
Chinese medicine as a remedy for liver and other disorders.    
UDCA administration in ICP improved maternal pruritus, reduced ALT and serum 
BA levels and improved fetal outcome (Glantz et al, 2005). UDCA is administered 
orally in its unconjugated form and has been found to have no adverse effects on the 
mother or the fetus (Kondrackiene et al, 2005). The mechanism and sites of action of 
UDCA treatment in ICP and other cholestatic disorders are not fully understood. It 
has been proposed that UDCA changes the bile acid pool to become more 
hydrophilic and therefore less toxic for the liver (Lucangioli et al, 2009). Other 
studies have also suggested that UDCA stimulates impaired hepatocyte secretion of 
bile acids by increased synthesis and membrane insertion of transporters mostly at 
the post-trascriptional level (Beuers, 2006; Paumgartner & Beuers, 2002; Serrano et 
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al, 1998). In addition, UDCA is a ligand for PXR (Karpen & Crawford, 1999) and to 
a smaller extent for FXR (Zollner et al, 2003a), which suggests that treatment with 
UDCA can stimulate the hepatic response to raised bile acids thereby protecting the 
liver.  UDCA has also been found to have anti-apoptotic effects on the mitochondria 
of the hepatocytes (Beuers, 2006). 
Several other drugs have also been used for the treatment of ICP, such as 
phenobarbital, dexamethasone, cholestyramine and rifampicin. They all have been 
shown to reduce the levels of bile acids in serum or to relieve pruritus. However, 
most studies were small and more work needs to be done to prove the benefits and 
identify the exact mode of action. It has been suggested that phenobarbital can 
induce the hepatic microsomal enzymes and in that way increases the export of bile 
acids (Davidson, 1998). Dexamethasone belongs to the family of glucocorticoids and 
it is thought to exert its effect through activation of xenobiotic receptor PXR 
(Goodwin et al, 2003). A recent trial demonstrated that dexamethasone cannot 
ameliorate pruritus or ALT levels and is less effective in lowering serum bile acids 
compared to UDCA (Glantz et al, 2005). Cholestyramine is a cholesterol lowering 
agent, administered orally to bind bile acids. Cholestyramine combines with bile 
acids in the intestine to form non-absorbable complexes that are excreted in the 
faeces. It has mainly been used to treat pruritus in cholestatic conditions. In a trial 
with UDCA, cholestyramine was shown only slightly to reduce aminotransferases, 
pruritus and BAs and had some adverse effects (Kondrackiene et al, 2005). 
Therefore, cholestyramine is not a treatment of choice of ICP. Rifampicin has been 
used to treat some ICP patients who are unresponsive to UDCA (Williamson, 2001). 
Rifampicin is a potent PXR and CYP3A4 activator, which is the predominant 
cytochrome P450 enzyme expressed in the liver and intestine and plays a critical role 
in detoxifying bile acids and drugs, and protecting against cholestasis (Li & Chiang, 
2006). Therefore, rifampicin could exert its effect through increased PXR mediated 
detoxification.   
 
1.4 Pregnancy 
Significant metabolic and hormonal changes occur during pregnancy, which are 
designed to support fetal growth.  
 
Chapter 1                                                                                                                               Introduction 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     49 
1.4.1 Metabolic Changes in Pregnancy 
Early to mid-gestation is characterized by increases in maternal fat stores, which is 
mediated by hyperinsulinaemia. Food intake and insulin secretion rises by 10-15 and 
60% respectively. Insulin sensitivity and fasting glucose concentrations do not 
change significantly. At this stage, leptin concentration increases, whereas plasma 
lipid and insulin growth factor I (IGF-I) decrease (Butte, 2000; Freemark, 2006; 
Herrera, 2000).  
In late gestation, the food intake and fat mass are still increasing. Insulin 
concentration and mode of action change considerably, resulting in mobilization of 
maternal nutrient stores for fetal growth and placental support. In skeletal muscle, 
insulin-dependent glucose uptake decreases by 40%, whereas smaller reductions 
have been described in the adipose tissue and heart. Insulin sensitivity in late 
pregnancy is 45-70% lower compared to non-pregnant women. FFA also increase 
significantly in late pregnancy and it is believed that they mediate the decreased 
insulin sensitivity in the skeletal muscle. As a result of the increased insulin 
resistance, the pancreatic beta cells increase insulin production significantly in late 
gestation. It should be noted that beta cell mass is 10-15% increased in late 
pregnancy (Butte, 2000; Freemark, 2006; Herrera, 2000). 
The rise in insulin production and decrease in insulin sensitivity mediate efficient 
nutrient storage during feeding and fast nutrient usage in periods of fasting. 
Hyperinsulinaemia represses lipolysis and ketogenesis but stimulates amino acid 
uptake thereby enhancing fat storage and tissue protein synthesis. The fetus in the 
last trimester of pregnancy needs higher amounts of glucose. Increased insulin 
resistance in skeletal muscle is mediating high maternal levels of glucose for transfer 
to the fetus. During periods of fasting, the levels of both glucose and insulin decline 
in the maternal circulation. As a result of hypoglycaemia, the adrenal and 
sympathetic nervous system promote hepatic gluconeogenesis, ketogenesis, FFA 
production and utilization of maternal nutrient stores. During fasting, FFA and 
ketones are used as an energy source by the maternal tissues in order to spare glucose 
for the fetus (Butte, 2000; Freemark, 2006; Herrera, 2000). 
Serum cholesterol and triglycerides rise progressively throughout pregnancy in 
humans and other species (Feingold et al, 1983; Lesser & Carpenter, 1994). In 19-
day pregnant mice, serum triglycerides and non-HDL cholesterol are increased, and 
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HDL cholesterol is reduced. This occurs in conjunction with reduced expression of 
nuclear receptors that influence bile and lipid homeostasis (Sweeney et al, 2006). 
Triglycerides are cleaved by placental lipases to provide a source of fatty acids for 
the fetus. Cholesterol is necessary for placental steroid synthesis and its levels rise by 
20-30% in the maternal circulation in humans. In addition, plasma VLDL increases 
up to 2.5 fold during late gestation, due to increased hepatic production and 
decreased hepatic lipase activity and the actions of lipoprotein lipase in adipose 
tissue. Amino acid levels decrease in the maternal circulation in late pregnancy due 
to elevated utilization by the mother for gluconeogenesis and protein synthesis as 
well as placental transport to the fetus.  
Other changes in maternal physiology during pregnancy include increased cardiac 
output, blood volume and uterine blood flow (Butte, 2000; Freemark, 2006; Herrera, 
2000).  
 
1.4.2 Hormonal Regulation of Metabolism in Pregnancy 
Hormones produced by the pituitary gland, ovaries and placenta orchestrate the 
metabolic changes taking place in pregnancy.  
 
Early Pregnancy 
Following fertilization of the egg, implantation occurs and syncytiotrophoblast 
produces human chorionic gonadotrophin (hCG). hCG is responsible for maintaining 
the activity of the progesterone-producing corpus luteum in the ovary for the first 6 
weeks. After 6 weeks of pregnancy, the placenta produces sufficient amounts of 
estrogen and progesterone for the corpus luteum to become redundant in humans. It 
should be noted that the mouse ovary is active throughout pregnancy (Matabosch et 
al, 2009). Estrogen and progesterone increase exponentially during gestation. Other 
hormones that increase in the maternal circulation during early to mid pregnancy 
include; prolactin (Prl), which is produced by the pituitary of the mother and the 
decidua and placental lactogens (PL-I and PL-II, or collectively PL), which are 
produced by syncitiotrophoblast and have many similarities to prolactin and growth 
hormone (GH). On the other hand, GH levels decrease during early and mid-
pregnancy (Butte, 2000; Freemark, 2006; Herrera, 2000).  
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The increased levels of progesterone, prolactin and placenatal lactogen in the 
maternal circulation have been found to mediate hyperphagia and weight gain. 
Indeed, studies in rodents demonstrated that progesterone enhances food intake and 
fat deposition by stimulating adipogenesis and fatty acid synthase expression in 
preadipocyte precursor cells (Grueso et al, 2001). The lactogens, PL and Prl are also 
known to increase body weight and fat depots in mice, as demonstrated by mice 
deficient for the prolactin receptor (Flint et al, 2003; Freemark et al, 2001). The exact 
mechanism by which the lactogenic hormones stimulate hyperphagia and fat 
deposition is unclear.  The decline in GH in early pregnancy also stimulates fat 
storage by increasing insulin sensitivity, stimulating adipogenesis and reducing 
lipolysis (Butte, 2000; Freemark, 2006; Herrera, 2000).  
 
Late Pregnancy 
Late pregnancy is characterised by insulin resistance, which is accompanied by 
increased insulin production, enhanced lipolysis and mobilisation of fat store during 
periods of fasting. Many factors contribute to the pathogenesis of this state.  
Insulin resistance is accompanied by a significant increase in insulin secretion by the 
pancreatic islet cells. During this period, islet cells express higher levels of prolactin 
receptors. The prolactin receptors can bind both prolactin and placental lactogen. The 
concentration of PL continues to rise in late pregnancy. PL replace pituitary growth 
hormone and prolactin from the 8th day of gestation in mice (Ogren & Talamantes, 
1988) but not in humans. PL are capable of stimulating pancreatic islet cell growth 
and proliferation in vivo (Vasavada et al, 2000). In addition, deletion of the prolactin 
receptor in the mouse causes a decrease in β-cell mass and the pancreatic expression 
of insulin mRNA (Freemark et al, 2002). Therefore, secretion of PL is necessary for 
β-cell proliferation and insulin secretion in pregnancy. PL can also increase 
lipogenesis and lipolysis in fat cells (Fleenor et al, 2005), suggesting that placental 
lactogens could play a role in insulin resistance in late pregnancy.  
Another hormone that could give rise to insulin resistance is the growth hormone 
produced in the syncytiotrophoblast of the placenta by the growth hormone variant 
gene (GH-V). Placental GH differs from the pituitary GH by 13 amino acids. After 
15-20 weeks of gestation, the levels of placental growth hormone rise gradually to 
peak near term. Placental GH replaces pituitary GH, which is almost undetectable in 
Chapter 1                                                                                                                               Introduction 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     52 
the second half of pregnancy. Placental GH has high somatogenic (binds to GH 
receptors with high affinity) and low lactogenic (binds prolactin receptor with low 
affinity) activity. Mice overexpressing the human placental GH-V gene present with 
increased body weight (84%), raised IGF-I concentrations (56%) and decreased body 
fat (15%). These mice also have decreased insulin sensitivity and the fasting insulin 
levels are higher when compared to wild-type mice (Barbour et al, 2004; Barbour et 
al, 2002). These data suggest that the placental GH could have a major role in the 
rise of insulin resistance during late gestation. Interestingly, rodents do not synthesise 
placental GH (Soares, 2004), suggesting that different hormones mediate these 
effects in these species. The secretion of lactogen and growth hormone in rodents is 
depicted in Figure 1.7.  
Other factors that could contribute to maternal insulin resistance include high 
concentrations of progesterone and TNF-α. A report by Picard et al investigated the 
progesterone effects on gestational diabetes. They demonstrated that female but not 
male progesterone knockout mice had improved glucose homeostasis and increased 
insulin synthesis and β-cell proliferation. They also showed that female db/db mice 
developed diabetes more quickly after administration of progesterone (Picard et al, 
2002). TNF-α is secreted by the adipose tissue and the placenta and increases after 
30 weeks of gestation. Raised concentrations of TNF-α cause reduced 
phosphorylation of the insulin receptor and its substrates, which results in enhanced 
lipolysis in white adipose tissue and decreased insulin-mediated glucose uptake by 
the skeletal muscle (Kirwan et al, 2002). 
Finally, plasma cortisol levels increase significantly in the maternal circulation in the 
third trimester of pregnancy. Cortisol also represses insulin-mediated glucose uptake 
in the skeletal muscle as well as promoting gluconeogenesis in the liver (Lecavalier 
et al, 1990). Therefore, cortisol together with the actions of the other hormones could 
also contribute to the insulin resistance state seen in late gestation.   
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Figure 1.7: Representation of lactogenic hormone secretion during pregnancy in 
mice and rats. 
In early gestation, prolactin is the main lactogenic hormone and is secreted in twice-
daily surges by the maternal pituitary. At mid-gestation, the placental lactogen I (PL-
I) takes over and during late gestation placental lactogen II (PL-II) peaks. At term, 
the fetal pituitary also produces prolactin. Taken from (Soares, 2004). 
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1.4.3 Pregnancy-induced Liver Growth 
In rodents, the maternal liver increases to almost double its original size during 
pregnancy. Gestational liver enlargement was first reported in 1958 (Paschkis & 
Cantarow, 1958) followed by a few old studies investigating the mechanism 
underlying this phenomenon. A report by Hollister et al showed that the liver growth 
during pregnancy was reversible and was associated with hepatocyte swelling 
without an increase in the number or DNA content of the cells (Hollister et al, 1987). 
Nevertheless, the mechanism of gestational liver enlargement is not known and there 
have been no reports on the signal driving this growth. The increase in liver size is 
considered to be an adaptation to raised metabolic demand on the liver during 
pregnancy.  
Liver growth has not been investigated in human pregnancy. Differences in fetal 
number, duration of pregnancy and mass of the fetal-placental unit between humans 
and rodents, suggest that the changes in liver size, if any, will be of smaller 
magnitude in humans. However, investigation of the mechanism underlying liver 
growth is of great interest, as it resembles the physiological response of an organ in 
stress.  
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1.5 Hypotheses and Aims  
Hypotheses 
1. Genetic variation in the nuclear receptor FXR causes functional effects on the 
protein, thereby contributing to the aetiology of ICP. 
2. High concentrations of circulating estrogen and progesterone are responsible 
for increasing the risk of developing perturbed bile acid homeostasis during 
pregnancy. 
3. The adaptations of the maternal liver to the physiological demands of 
pregnancy influence the ability of the hepatocyte to maintain bile acid 
homeostasis during cholic acid challenge. 
4. FXR-mediated BA homeostasis is required for maintenance of pregnancy-
specific physiological adaptations of the maternal liver. 
5. Liver growth during pregnancy is achieved by FXR-dependent mechanisms 
that influence bile acid signalling.  
Aims 
Human studies: 
1. To further investigate the influence of FXR mutations (–1g>t, M1V and 
M173T) on FXR translation and transcriptional activation of target genes.  
Rodent studies: 
1. To compare different models of reproductive hormone administration to wild 
type mice with regard to expression of genes that influence bile homeostasis. 
2. To utilise Fxr null and wild type mice to investigate the influence of estrogen 
and progesterone on: 
• expression of genes that influence bile homeostasis  
• serum markers of cholestasis 
3. To study the effect of normal and cholestatic pregnancy on bile acid 
homeostasis.  Wild type mice fed a normal or a 0.5% cholic acid diet will be 
used.   
4. To investigate pregnancy in Fxr-/- mice. 
5. To utilise wild type mice, wild type mice fed a 0.5% cholic acid diet, wild 
type mice treated with reproductive hormones and Fxr-/- mice to study the 
mechanisms of gestational liver growth. 
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2.1 Materials 
All chemicals and solvents used were of analytical grade and obtained from Abbot 
Labs (Queensborough); Abcam (Cambridge, UK); Abgent (San Diego, USA); 
Affymetrix (Santa Clara, USA); Ambion (Abingdon, UK); Amersham Biosciences/ 
GE Healthcare (Amersham, UK);  Applied Biosystems (Cheshire, UK); Bio-Rad 
(Hemel Hempstead, UK); Calibrochem (Beeston, UK); Beeston, UK Cambrex (Ioa, 
USA); Invitrogen (Paisley, UK); Cell Signalling Technology (Danvers, USA); 
Chemicon (Harrow, UK); Corning (New York, USA); DAKO (Glostrup, Denmark); 
Fisher Scientific (Loughborough, UK); Millipore (Watford, UK); National 
Diagnostics (Georgia USA); New England Biolabs (Hitchin, UK); Perkin Elmer 
(Massachusetts, USA); Pierce (Illinois, USA); Promega (Southampton, UK); Qiagen 
(Craley,UK); Raymond A Lamb (Eastbourne, UK); Roche (Lewes, UK); Santa Cruz 
Biotechnology (Santa Cruz, USA); Sentinel Diagnostics (Milan, Italy); Sigma-
Aldrich (Poole, UK); Stratagene (Texas, USA); Thermo-Scientific (Fife, UK); 
Vector (Peterborough, UK); VWR, (Lutterworth, UK);  
 
2.1.1 Chemicals and Solvents 
17β-estradiol       Sigma-Aldrich 
17α-estradiol       Sigma-Aldrich 
30% Hydrogen Peroxide    VWR 
Absolute Alcohol     Fisher Scientific 
Acrylamide      Bio-Rad 
Agarose      Cambrex 
Ammonium Persulphate    Sigma-Aldrich 
Ampicillin      Sigma-Aldrich 
β-mercaptoethanol     Sigma-Aldrich 
Bovine Serum Albumin (BSA)   Sigma-Aldrich 
Bromophenol Blue     Bio-Rad 
Chloroform      Fisher Scientific 
Cholic Acid      Sigma-Aldrich 
Corn Oil      Sigma-Aldrich 
DEPC-Treated Water     Ambion 
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DMSO       Sigma-Aldrich 
Eosyn       Raymond A Lamb 
Ethidium Bromide     Invitrogen 
Ethyl Chloride      Roche 
Ethylenediaminetetraacetic Acid (EDTA)  Sigma-Aldrich 
Haematoxylin       VWR 
HistoClear      National Diagnostics 
Hoechst 33342     Invitrogen 
Isofluorane       Abbott Labs 
Isopropanol      Fisher Scientific 
KCl       Sigma-Aldrich 
Methanol      Fisher Scientific 
MgCl2       Sigma-Aldrich 
NaAc 3M       Sigma-Aldrich 
NaCl       Sigma-Aldrich 
NaOH       Sigma-Aldrich 
Progesterone      Sigma-Aldrich 
Propidium Iodide     Sigma-Aldrich 
S.O.C. media      Invitrogen 
Sodium Acetate 3M pH5.5 (AnalaR)   Ambion 
TEMED      Bio-Rad 
Tris Base      Sigma-Aldrich 
Tris HCl      Sigma-Aldrich 
Triton X-100      Sigm-Aldrich 
Tween 20      Bio-Rad 
 
2.1.2 Enzymes 
DNase I (RNase-free)     Invitrogen  
DNA Polymerase I (Klenow)    Amersham Biosciences 
Proteinase K      Gibco BRL 
Restriction Endonucleases New England Biolabs 
RED Taq DNA Polymerase    Sigma 
Ribonuclease A     Sigma 
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RNasin RNase Inhibitor    Invitrogen  
RNase H      Invitrogen  
RNase OUT      Invitrogen 
SuperScript II Reverse Transcriptase   Invitrogen Life 
T4 DNA Ligase     New England Biolabs 
T4 Polynucleotide Kinase    New England Biolabs 
Taq DNA Polymerase     Qiagen 
 
2.1.3 Membranes 
Nitrocellulose      Schleicher and Schuell 
 
2.1.4 Miscellaneous 
ALT measuring kit     Thermo-Scientific 
ABC detection kit     Vector Labs 
BCA Protein Assay Reagent    Pierce 
Big-Dye Terminator II Applied Biosystems 
Bile Acid measuring kit Sentinel Diagnostics 
Cholesterol measuring kit Thermo-Scientific 
Coelenterazine Substrate    Calibrochem 
Centrifugal Concentrators    Millipore 
Complete Protease Inhibitors    Roche 
DNA Ladders      Bioline 
DNA Maxiprep/Miniprep kit    Qiagen 
ECL Plus Western Blotting Detection System Amersham Biosciences 
Film       Amersham Biosciences 
Filtration Units     Millipore 
Fugene 6 Transfection Reagent   Roche  
Gene-Chip Cleanup Module    Affymetrix 
Geneclean Column Kit    Bio101, Carlsbad, UK 
Kodak D19 Developer    Sigma-Aldrich 
LucLite Reporter Assay kit    Perkin Elmer 
Oligonucleotides     Invitrogen 
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One-Cycle cDNA Synthesis kit   Affymetrix 
One-Cycle Target Labelling Reagents  Affymetrix 
Protein A/G Sepharose    Amersham Biosciences 
QIAprep Spin Miniprepep kit    Qiagen 
QuickChange Site Directed Mutagenesis kit  Stratagene 
RNeasy MiniElute Cleanup kit   Qiagen 
See-Blue Molecular Weight Marker    Invitrogen 
Skimmed Milk Powder    Marvel 
Superscript II First Strand Synthesis System  Invitrogen 
SYBR Green I      Sigma-Aldrich 
Taqman mix      Applied Biosystems 
TRIZOL Reagent     Invitrogen  
TOPO Cloning Kit     Invitrogen 
TNT Coupled Reticulocyte in vitro Translation Kit Promega 
TUNEL assay kit     Promega 
 
2.1.5 Special Diets 
0.5% Cholic Acid Supplemented ERD Diet     Special Diet Services (SDS) 
ERD Diet       SDS 
 
2.1.6 Plasmids 
pCI       Promega 
pGL3       Stratagene 
pCMV-Renilla     Promega 
pGL3-BSEP/IBABP Dr Klaas Nico Faber (University 
Hospital Groningen, The 
Netherlands) 
pcDNA3.1-FXRα2     Dr Saskia van Mil 
pSG5-RXRα/Gal4DBD-RXRα Dr Eric Kalkhoven (UMC 
Utrecht, The Netherlands) 
For plasmid maps and primers used for generation of mutant plamids see Appendix I. 
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2.1.7 Bacterial Strains 
 
DH5α 
[∅80dlacZ∆M15, rec A1, end A1, gyr A96, thi-1, hsd R17 (rk-, mk+), sup E44, rel 
A1, deo R, ∆ (lacZYA-argF) U169] 
 
XL-1 Blue (Statagene) 
RecA, end A1, gyrA96, thi-1 hsdR17, supE44, relA1, Lac, (F’proAB 
lacIZAM15Tn10), Tetr. 
 
2.1.8 Cell lines 
293-T human embryonic kidney cells (HEK293T) 
Human Hepatocellular Liver Carcinoma cells (HepG2) 
Human Hepatoma cells (HuH7) 
 
2.1.9 Cell Culture Materials 
Dulbeco’s Modified Eagle Medium (DMEM) Sigma-Aldrich 
Fetal Bovine Serum (FBS)    Invitrogen 
L-Glutamine      Sigma-Aldrich 
Optimem      Invitrogen 
Penicillin (100 U/mL)     Sigma-Aldrich 
Phenol Red Free DMEM    Sigma-Aldrich 
Streptomycin (50 µg/ml)    Sigma-Aldrich 
Tissue Culture Plastic-ware Corning 
Trypsin       Sigma-Aldrich 
 
2.1.10 Antibodies  
Primary 
β-catenin (H-102) Rabbit Polyclonal   Santa Cruz Biotechnology 
Cyclin-D1 (M-20) Rabbit Polyclonal   Santa Cruz Biotechnology 
FXR Mouse Monoclonal     PPMX, Japan 
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FXR Rabbit Polyclonal    Santa Cruz Biotechnology 
GAPDH Rabbit Polyclonal     Abcam 
Ki-67 (TEC-3) Rat Polyclonal   DACO 
p16 (M-156) Rabbit Polyclonal      Santa Cruz Biochemicals 
p21 (C-19) Rabbit Polyclonal    Santa Cruz Biochemicals 
p27 (C-19) Rabbit Polyclonal    Santa Cruz Biochemicals 
p53 (FL-393) Rabbit Polyclonal    Santa Cruz Biochemicals 
Phospho Histone-H3 Ser 10 Rabbit Polyclonal Cell Signalling Technology 
 
Secondary 
Anti- mouse HRP     DACO 
Anti- Goat HRP     DACO 
Anti- Rabbit HRP     DACO 
Anti- Rat HRP      DACO 
 
2.1.11 Buffers and Solutions 
All solutions were made with water that was deionised and distilled. Solutions were 
stored at room temperature unless otherwise stated. 
 
Annealing Buffer 0.1M NaCl, 10mM Tris-HCl pH 7.5,  
 1mM EDTA 
 
Cell Lysis Buffer 50mM Tris-HCl pH 8.0, 100mM 
EDTA, (Proteinase K) 100mM NaCl, 
1% (w/v) SDS 
 
CIP Buffer (10x)    0.5M Tris-HCl pH8.5, 1mM EDTA 
      (Stored at 4 oC) 
 
Coomassie Brilliant Blue Stain 30% (v/v) Methanol, 10% (v/v) Acetic 
Acid, 
2.5% (v/v) Coomassie Brilliant Blue 
R250 
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DAB solution 20µl H2O2, 1ml PBS and 0.5ml DAB 
(1mg/ml) 
 
Dextran Coated Charcoal   1% (w/v) Activated Charcoal, 
0.1% (w/v) Dextran T70  
 
DNA Loading Buffer (10x) 0.2% (w/v) Bromophenol Blue, 80% 
(v/v) Glycerol, 0.1M EDTA 
 
DNA Precipitation Mix  0.1M NaCl, 66% (v/v) Ethanol  
 
Fix / De-stain solution 30% (v/v) Methanol, 10%  (v/v) Acetic 
Acid  
 
LucLite Buffer    0.5M HEPES pH 7.8, 2% Triton N101, 
      1mM CaCl2, 1mM MgCl2  
      (Stored at 4 oC) 
 
LucLite Reagent (2x) 10ml LucLite buffer containing 1mM 
MgCl2, 1mM CaCl2 / pot of LucLite 
luciferase reagent 
      (Stored at 4°C) 
 
Neutral Buffered Formalin  40% (v/v) Formaldehyde, 282mM 
NaH2PO4, (NBF) 471mM 
Na2HPO4 
      (Stored at 4°C) 
 
Neutralisation Buffer     0.2M Tris-HCl pH 7.5, 0.1x SSC 
 0.1% (w/v) SDS 
 
Phosphate Buffer i) 0.2M Na2HPO4 and ii) 0.2M 
NaH2PO4 pH 7.6 
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NB: mix in a ratio of 87ml of i and 
13ml ii.  
 
Phosphate Buffered Saline (PBS) 140mM NaCl, 2.5mM KCl, 
1.5mM KH2PO4 pH7.2, 10mM Na2HPO4     
pH7.2, 
 
Protein Loading Buffer (2x) 10% (w/v) SDS, 20% (v/v) Glycerol, 250mM 
Tris-HCl pH6.8, 0.7M β-Mercaptoethanol, 
0.02% (w/v) Bromophenol Blue 
     (Stored at -20 oC) 
 
Qiagen Buffers: 
P1 (Resuspension)   50mM Tris-HCl pH 8.0, 10mM EDTA, 
100µg/ml RNase A  
(Stored at 4 oC) 
 
P2 (Lysis)     200mM NaOH, 1% (v/v) SDS 
 
P3 (Neutralisation)   3M KAc pH 5.5  
(Stored at 4 oC) 
 
QBT (Equilibration)   750mM NaCl, 50mM MOPS pH 7.0, 
     15% (v/v) Isopropanol, 0.15% Triton X-100 
 
QC (Wash)    1M NaCl, 50mM MOPS pH 7.0, 
     15% (v/v) Isopropanol 
 
QF (Elution)    1.25M NaCl, 50 mM Tris-HCl pH 8.5 
     15% (v/v) Isopropanol 
 
Renilla Buffer    0.5M HEPES pH 7.8, 40mM EDTA 
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Renlite Reagent Renilla buffer with the addition of 
Coelenterazine to 10ng/µl (Stock 1mg/ml) 
(Stored at -20°C) 
 
Reverse Transcription buffer (10x) 200mM Tris-HCl, pH 8.4, 500mM KCl 
 
RIPA lysis buffer   150mM NaC, 1% NP-40, 0.5% Deoxycholic 
     acid, 0.1% SDS, 50mM Tris pH 8.0 
     Roche Complete Protease Inhibitor Tablets 
 
SDS-PAGE Buffer (10x) 250mM Tris-Base, 1.9M Glycine, 1% (w/v) 
SDS 
 
Sodium Acetate Buffer pH5.0 100mM Na-Acetate 3x H2O adjusted to pH 5 
with acetic acid. Stored at -20oc 
 
Stripping Buffer (Protein)  100mM β-Mercaptoethanol, 2% (w/v) SDS, 
     62.5mM Tris-HCl pH 6.7 
 
T4 Kinase Buffer (10x) 0.5M Tris-HCl pH 7.6, 0.1M MgCl2, 50mM 
DTT, 1mM EDTA  
(Stored at –20 oC) 
 
T4 Ligation Buffer (10x) 0.5M Tris-HCl pH7.8, 0.1M MgCl2, 0.1M 
DTT, 10mM ATP, 250µg/ml BSA 
(Stored at -20 oC) 
 
TE Buffer (1x)   10mM Tris-HCl pH 8.0, 1mM EDTA pH 8.0 
 
TBE Running Buffer (10x)  0.9M Tris-Borate, 20mM EDTA pH 8.0 
 
Western Blocking Solution  0.05% (v/v) Tween-20, 
5% (w/v) non-fat milk in PBSA 
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Western Incubation Buffer  0.05% (v/v) Tween-20, 0.3% (w/v) BSA, 
 
Western Washing Solution  0.05% (v/v) Tween-20, PBSA 
 
Western Transfer Buffer  25mM Tris-Base, 192mM Glycine, 
20% (v/v) Methanol, (pH 8.3) 
 
2.1.12 Bacterial Media 
All organic compounds listed below were supplied by Difco Laboratories. 
 
L-agar     1% (w/v) Bactotryptone, 
0.5% (w/v) Yeast Extract, 0.5% (w/v) NaCl,  
0.1% (w/v) Glucose, 1.5% Bactoagar 
 
L-broth    1% (w/v) Bactotryptone, 
0.5% (w/v) Yeast Extract, 0.5% (w/v) NaCl, 
0.1% (w/v) Glucose 
 
2.1.13 Databases/ web sites 
https://analysis.ingenuity.com/pa/login/applet.jsp 
http://www.ensembl.org/ 
http://genome.ucsc.edu/ 
http://www.genome.jp/kegg/pathway.html 
http://www.ncbi.nlm.nih.gov/ 
http://www.nursa.org/ 
 
2.1.14 Software Packages 
CellProfiler cell image analysis software 
Image Processing and Analysis in Java (ImageJ) 
Ingenuity Pathway Analysis (Ingenuity Systems) 
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Pirouette v4.0 (Infometrics) 
Primer Express Oligo designTM version 1.5a (Applied Biosystems) 
Rosetta Resolver (Rosetta Inpharmatics) 
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2.2 Methods 
 
2.2.1 Manipulation of mice 
2.2.1.1 General maintenance 
Wild type mice were C57Bl/J6 strain and purchased from Harlan Laboratories (UK). 
For the experiments in this thesis the mice used were bred and maintained at the 
animal facilities of Imperial College London. They were maintained and studies were 
conducted in accordance with The Animals (Scientific Procedures) Act 1986. Mice 
were housed under standard conditions on a 12-hour daylight cycle and were fed a 
standard diet (ERD) of food and water. Age and weight matched groups of 10-12 
week old female mice were used for all experiments. Pxr-/- mice (Staudinger et al, 
2001) were provided under a materials transfer agreement with GlaxoSmithKline. 
Fxr-/- mice were generated in the laboratory of Prof Johan Auwerx and Dr Kristina 
Schoonjans. 
 
2.2.1.2 FXR null mice (brief note)  
Fxr-/- mice generated and validated (Appendix II) in the laboratory of Prof Johan 
Auwerx and Dr Kristina Schoonjans, provided under a MTA with the ICS (GIE-
CERBM). Briefly, for the generation of Fxr knock-out (Fxr-/-) mice, genomic DNA 
covering the Fxr locus was amplified from the 129Sv strain using high fidelity PCR. 
The resulting DNA fragments were assembled into the targeting vector that after 
linearization was electroporated into 129Sv ES cells. G418-resistant colonies were 
selected and analyzed for homologous recombination. The karyotype was verified 
and several correctly targeted ES cell clones were injected into blastocysts from 
C57BL/6J mice. These blastocysts were transferred into pseudo-pregnant females, 
resulting in chimeric offspring that were mated to female C57BL/6J mice that 
express Flp recombinase under the control of the ubiquitous CMV promoter. 
Offspring that transmitted the mutated allele, in which the selection marker was 
excised and that lost the Flp transgene were selected, mated with CMV-Cre mice to 
excise the LoxP site (Fxr+/- mice) and intercrossed to generate wild type (Fxr+/+) and 
knockout (Fxr-/-) mice. 
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2.2.1.3 Pregnancy experiments 
Age matched (10-12 week old) female C57BL/6 or Fxr-/- mice were either fed a 
control diet (ERD) or a diet supplemented with 0.5% cholic acid (RM3+0.5% CA) 
for two weeks prior to the start of experiment. After adding the male mice, female 
mice were checked for vaginal plugs daily. Circulating reproductive hormones are 
thought to have a significant effect on liver metabolism, therefore non-pregnant 
animals were sacrificed at day 1 of pregnancy, which controls for the stage of the 
menstrual cycle and therefore referred to as “non-pregnant”. Gestation in mice lasts 
between 20-21 days. In order to avoid the significant effects of labour, term pregnant 
animals were sacrificed at day 18 of gestation. Tissues were also collected from day 
5 and twelve of pregnancy. The weight of animals was also closely monitored. At the 
day of sacrifice mice were starved for 4-5 hours, with free access to water before 
sample collection. Livers, intestine, kidneys, placentas (from 18 day pregnant mice), 
fetal liver and biofluids were collected for every mouse. All tissues were snap frozen 
in liquid nitrogen, or kept in 70% ethanol after fixation in paraformaldehyde for 
histological analysis. Livers were weighed before freezing. 
 
2.2.1.4 Reproductive hormone treatment 
 
Injections 
Age matched female C57BL/6 mice were ovariectomised and allow to recover for 
two weeks. The recovery time is essential so that the remaining ovarian hormones 
are excreted. After recovery mice were injected with two different types of estrogen, 
17α-ethinylestradiol (EE2), which is an artificial stable estrogen and 17β-estradiol 
(E2), which is a non-synthetic less stable estrogen. The dose used for both estrogens 
was 10µg/g, which is approximately the same as has been used in previously 
published work (Yamamoto et al, 2006). It was also decided to use another lower 
concentration of 17β-estradiol (5µg/g), which is a more physiological dose (Milligan 
& Finn, 1997). A control group was also included, which was injected with 100µl 
vehicle alone. One group of mice was injected for one day and the other group for 
five days. Three mice were used per group. Mice were starved for 4-5 hours prior to 
sacrifice and sample collection. 
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Implants 
Silastic implants containing steroids have been used to provide long-acting hormone 
treatment in several species including sheep, rats and mice. The implants can be 
filled with crystalline steroid or with suspensions of the steroid in peanut (arachis) 
oil. Such implants can deliver controlled concentrations of steroids over prolonged 
periods. Milligan and coworkers have developed suitable slow release implants for 
the controlled delivery of hormones to mice over the normal physiological range 
(Cohen & Milligan, 1993; Milligan & Cohen, 1994; Milligan & Finn, 1997). In these 
experiments, the implants were filled with a suspension of steroid (17β-estradiol: 
33µg/ml and progesterone 0.5g/ml) in peanut oil. Silastic implants (~ 2 cm long) 
containing the steroids were prepared in advance and kept at 4°C in PBS for 24 
before implantation They were implanted two weeks post-ovariectomy and they were 
either left untreated (implanted with 100µl of peanut oil), or implanted with the oil 
containing β-estradiol (E2), or progesterone (Pn), or with both (EPn) for either 1, 5 or 
18 days. The time point of 18 days was chosen in order to mimic normal pregnancy, 
as the aim of this experiment is to create a model where the influence of hormones in 
pregnancy could be studied. Five mice were used per group. 
 
2.2.2 Cell Culture 
2.2.2.1 Maintenance of cell stocks 
Mammalian cells were routinely grown as a monolayer on 175cm2 tissue culture 
flasks at 37oC in a humid atmosphere maintained at 10% (v/v) CO2. Cells were 
maintained in DMEM supplemented with 10% (v/v) fetal bovine serum (FBS). Cell 
cultures were divided once or twice a week depending on growth rate. The medium 
was removed and the cells were washed once with 25ml PBS before 2.5ml of pre-
warmed trypsin mix was applied. The cells were incubated within this minimal 
volume of trypsin mix at 37oC for 2 minutes (except for in the case of HEK293-T 
cells which require only 30 seconds incubation). The flask was gently tapped until 
the majority of the cells were dislodged and 10ml pre-warmed DMEM added (10% 
(v/v) FBS) to neutralise the trypsin. The cell suspension was transferred to a sterile 
15ml tube and centrifuged at 1000rpm in a bench top centrifuge for 5 minutes. The 
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pellet was gently re-suspended in fresh pre-warmed growth medium and cultured at a 
suitable dilution. 
 
2.2.2.2 Storage of cell stocks 
Sub-confluent monolayer cultures were trypsinised and pelleted as described above. 
The cell pellet was then re-suspended in 3.5ml of DMEM containing 10% (v/v) FBS 
and 10% (v/v) DMSO. 1.5ml aliquots were made in cryo-vials, which were wrapped 
in tissue and frozen at -20oC for 2 hours at -70oC overnight and then transferred to 
liquid nitrogen for long-term storage. Cells recovered from liquid nitrogen were 
thawed rapidly at 37oC. These were pelleted by centrifugation at 1000rpm and 
DMSO-containing media was removed by aspiration. The cell pellet was then re-
suspended in 10ml pre-warmed growth medium and plated out in a tissue culture 
flask.  
 
2.2.2.3 Charcoal treatment of serum 
FBS contains endogenous steroid hormones that might mask the effect of 
exogenously added ligand in transfection experiments. Serum used for transfections 
was therefore pre-treated with dextran coated charcoal (DCC) which removes all 
such small molecules from the serum, including steroid hormones. 500ml of dextran 
coated charcoal suspension was divided equally among four 250ml disposable 
centrifuge bottles and spun at 2000x g for 5 minutes at 4oC. The supernatant was 
removed and the pellet was resuspended with 250ml of FBS. The suspension was 
shaken vigorously at 55oC for 30 minutes and then re-spun. The serum was decanted 
into bottles containing a fresh dextran coated charcoal pellet, re-incubated and re-
spun as above. The treated serum was sterilised by filtration twice using a 0.45µm 
and 0.22µm Nalgene filter unit, aliquoted and stored at -20oC. 
 
2.2.3 Transient Transfection 
HEK293-T, HepG2 and Huh7 cells were routinely transfected by using the FuGENE 
6 transfection reagent method (Roche).  
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2.2.3.1 Transfection in 96-well microtitre plates using FuGENE 6 
method 
Cells were seeded at so that 50-70% confluency was achieved the next day by 
diluting the required number of cells in phenol red-free DMEM containing 5% (v/v) 
DCC-treated FBS and adding 100µl of the cell suspension per well. Briefly, master 
mixes of all common, plasmid DNA components were made up and divided 
appropriately. Any variable plasmid DNAs were then added separately. In a separate 
tube FuGENE 6 reagent (0.15µl / well) was added to Optimem (4.2µl / well) and 
gently mixed. The DNA solution was then added to the FuGENE / Optimem mix and 
incubated at room temperature for 15 minutes. The appropriate volume of each 
precipitate was then added to the cells, typically each was done in quadruplicate. 
This quantity of FuGENE 6 is capable of transfecting up to 500ng total DNA per 
well. Cells were then incubated for approximately 16 hours at 37oC in a humid 
atmosphere maintained at 10% (v/v) CO2.  Following incubation, the medium was 
gently removed by pipetting and replaced with fresh DMEM containing 5% (v/v) 
DCC-treated FBS. If required, ligand / treatment was added to the media prior to this 
step and the cells incubated at 37oC in a humid atmosphere maintained at 10% (v/v) 
CO2 for a further 24 hours before harvesting.  
 
2.2.3.2 Transfection in 6-well plates using FuGENE 6 method 
The procedures were essentially the same as above except for the following.  The 
cells were seeded at 50-70% confluence by diluting the required number of cells in 
DMEM containing 5% (v/v) DCC-treated FBS and adding 2ml of the cell suspension 
per well.  Each precipitate was prepared separately and contained a total of 2µg 
plasmid DNA mixed with 3µl FuGENE 6 and 97µl Optimem. 
 
2.2.3.3 Reporter assays for 96-well plate transfection 
Transiently transfected cells were harvested 24 hours after the addition of ligand, 
using a method based on the LucLite luciferase reporter gene assay (Packard). Using 
a multipipette, 50µl of culture medium was removed from each well, followed by the 
addition of 50µl of 2x LucLite reagent. After incubation at room temperature for 10 
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minutes in the dark, the assay mix (100µl) containing the LucLite reagent, media, 
and lysed cell contents were transferred to a 96-well MICROLITE plate (Dynex), 
and the firefly luciferase activity was measured using the MLX microplate 
luminometer (Dynex). 
The Renilla (internal control) luciferase assay was carried out in the same 96-well 
MICROLITE plate containing the firefly luciferase reaction. The Renilla reagent was 
prepared by diluting the substrate, Coelenterazine (dissolved in DMSO at 1mg/ml 
and stored at -20oC), in Renilla buffer to a final concentration of 10ng/µl (1/100 
dilution).  Using a multipipette 25µl per well of the Renilla luciferase reagent was 
then added to the firefly luciferase reaction (250ng/well). After incubation in the dark 
at room temperature for 10 minutes, the signal was measured using the MLX 
microplate luminometer (Dynex). The EDTA in the Renilla buffer chelates the 
divalent cations required for firefly luciferase reaction and quenches the light 
emission, allowing the Renilla luciferase signal to be detected.  
 
2.2.4 Bacteria 
2.2.4.1 Storage of bacteria 
The Escherichia coli strain DH5α was used for the propagation of all plasmids. All 
plasmids described in this thesis carry either the ampicillin (Ampr) or kanamycin 
(Kanr) resistance genes. Bacterial transformants were grown in L-broth or on L-agar 
containing 50-100 µg/ml ampicillin or 10-50 µg/ml kanamycin. Bacteria were then 
stored in L-broth containing 50% (v/v) glycerol at -70°C for up to one year. 
 
2.2.4.2 Preparation of competent bacteria for transformation by 
heat shock 
Bacteria were streaked out on L-agar plates without antibiotic and incubated at 37°C 
overnight. A single colony was then used to inoculate 5ml of L-broth, which was 
then grown at 37°C with continuous shaking overnight.  After incubation, 100µl of 
the saturated culture was used to inoculate 100ml of pre-warmed L-broth.  This 
culture was then incubated at 37°C with continuous shaking until the OD600 reached 
0.3. At this point bacteria were placed on ice for 5 minutes and subsequently 
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centrifuged at 3000x g for 6 minutes at 4°C. Subsequently, the cell pellet was re-
suspended in 20ml (20% of original volume) of ice-cold 100mM MgCl2 and 
immediately re-centrifuged at 3000x g for 7 minutes at 4°C. The cell pellet was 
finally re-suspended in 20ml (20% of the original volume) of ice-cold 100mM CaCl2 
/ 10% (v/v) glycerol and incubated on ice for 30 minutes. The cell suspension was 
snap frozen on dry ice in aliquots of 0.5ml and then stored at -70°C. 
 
2.2.4.3 Transformation of competent bacteria by heat shock 
Competent cells were thawed on ice and typically, 50µl and 100µl of cells were used 
for the transformation of pre-chilled supercoiled DNA and ligation products 
respectively (less than 1ng DNA per µl cells).  After 15 minutes on ice, cells were 
heat shocked at 42°C for 90 seconds and then placed on ice for a further two 
minutes. Then 250 µl L-broth was added to the reaction and the cells incubated at 
37°C for 45 minutes. Finally the cells were then spread on L-agar plates containing 
100µg/ml ampicillin or 50µg/ml kanamycin, inverted, and incubated at 37°C 
overnight. Competent DH5α cells typically gave between 106 and 108 bacterial 
colonies per µg of supercoiled DNA. 
 
2.2.5 DNA manipulation and cloning 
2.2.5.1 Preparation of Plasmid DNA 
Depending on the quantity required, plasmid DNA was prepared by both small and 
large-scale methods. 
 
2.2.5.2 Small-scale preparation of plasmid DNA (Miniprep) 
The Qiagen miniprep kit was routinely used to prepare up to 15µg of high-copy 
plasmid DNA. Individual bacterial colonies were used to inoculate 5ml of L-broth 
containing 50µg/ml ampicillin or 10µg/ml kanamycin and incubated overnight at 
37°C with vigorous shaking. Plasmid DNA prepared by this method was used for 
sub-cloning and sequencing. Typically, 3ml of overnight culture was pelleted using a 
microcentrifuge and the plasmid DNA prepared according to the manufacturers’ 
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protocol.  The procedure is based on alkaline lysis of bacterial cells followed by 
adsorption of the DNA onto silica in the presence of high salt. Bacteria were lysed 
under alkaline conditions in the presence of RNaseA, and the lysate was 
subsequently neutralised and adjusted to high-salt binding conditions, ready for 
purification on a silica-gel membrane. The membrane allowed selective adsorption of 
plasmid DNA in a high-salt buffer and elution in low-salt buffer. RNA, cellular 
proteins and metabolites were not retained on the membrane but found in the flow 
through. If required endonucleases from endA+ strains such as HB101 were removed 
by a wash step with a buffer containing chaotropes, to ensure that plasmid DNA was 
not degraded. After removing the salts, plasmid DNA was eluted with either 50µl 
water or 10mM Tris-HCl pH 8.5. Typically, the recovery efficiency was higher than 
85%. In addition it should be noted that this procedure can also be carried out using 
the Bio Robot 3000 (Qiagen). This is run as a service ‘in house’ at the Institute of 
Reproductive and Developmental Biology. 
 
2.2.5.3 Large-scale preparation of plasmid DNA (Maxiprep) 
The Qiagen maxiprep kit was routinely used to prepare up to 500µg of high-copy 
plasmid DNA. Plasmid DNA prepared by this method was used for sub-cloning, 
transient transfection, in vitro transcription/translation and sequencing. Individual 
colonies or 5µl of saturated bacterial culture were used to inoculate 200ml of L-broth 
containing 100µg/ml ampicillin or 10µg/ml kanamycin and incubated overnight at 
37°C with vigorous shaking. The bacteria were harvested by centrifugation at 4000x 
g for 15 minutes at 4°C. The pellet was then processed according to the 
manufacturers’ protocol. The protocol was based on a modified alkaline lysis 
procedure in which bacterial cells are lysed in NaOH-SDS in the presence of 
RNaseA. SDS solubilises the phospholipid and protein components of the cell 
membrane, leading to cell lysis and the release of cell contents. NaOH denatures 
chromosomal DNA, plasmid DNA, and proteins; while RNaseA digests the RNA 
liberated during lysis. The lysate was neutralised by the addition of acidic potassium 
acetate. The high salt condition caused SDS to precipitate with the denatured 
proteins, chromosomal DNA, and cellular debris trapped in salt-detergent complexes.  
Plasmid DNA is smaller and covalently closed, therefore it re-natured and remained 
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in the solution. Bacterial lysates were cleared by high-speed centrifugation with the 
plasmid DNA remaining in the cleared supernatant. This was then loaded onto a pre-
equilibrated anion-exchange column, which operates by gravity flow under low-salt 
and low pH conditions. A medium ionic strength wash buffer was used to remove 
RNA, protein, dyes and low molecular weight impurities.  Plasmid DNA was eluted 
in a high-salt buffer and then concentrated and desalted by an isopropanol 
precipitation and a subsequent 70% ethanol wash. The purified DNA was air-dried 
and re-dissolved in 10mM Tris-HCl pH 8.5. The DNA concentration and purity were 
determined by measurement of the OD260 and OD280 on a spectrophotometer 
(Sambrook et al, 1989a; Sambrook et al, 1989b). 
 
2.2.5.4 Restriction endonuclease digestion 
Restriction enzyme digestions were performed at 37°C in the buffers recommended 
and supplied by the manufacturer. DNA was digested with 5-10 fold excess of 
enzyme, with the final volume not exceeding 5% (v/v) glycerol. For analysis of 
digestion products, reactions were terminated by the addition of DNA loading buffer 
to 10% (v/v) of the total volume, and analysed by gel electrophoresis. Alternatively, 
DNA digestions were stopped by loading the entire reaction into Geneclean spin 
columns (Bio101) for purification. (See purification of DNA by Geneclean methods). 
 
2.2.5.4.1 DNA agarose gel electrophoresis 
Agarose gels of 0.8-2 % (w/v) were prepared by dissolving agarose in fresh 1x TBE 
and heating the suspension in a microwave oven until boiling. The solution was 
allowed to cool to approximately 60°C, 0.2µg/ml ethidium bromide was added, and 
poured into an appropriate gel mould. Once set, the gel was submerged in 1x TBE 
buffer in a gel tank, and DNA samples containing 10% (w/v) DNA loading buffer 
were loaded into the wells. Electrophoresis was carried out at 100V until the DNA 
fragments were resolved. DNA was visualised by illumination on a long wave UV 
light box and photographed. The size of the DNA fragments was estimated by 
comparing their relative mobility to that of restriction fragments of known size, 
typically 1 Kb markers (BioLine). 
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2.2.5.5 Precipitation and concentration of DNA with ethanol-salt 
Restriction fragments, plasmid or genomic DNA were precipitated and concentrated 
in 1.5ml tubes by the addition of DNA precipitation mix. Once added, the DNA 
precipitate was allowed to form by incubating the mix at -20°C for at least 30 
minutes. At this temperature it is possible to recover DNA at concentrations as low 
as 20ng/ml using micro-centrifugation. After incubation, precipitated DNA was 
pelleted by centrifugation at 13000 rpm for 20 minutes. The DNA pellet was then 
washed with 70% ethanol and spun for a further 8 minutes. After removal of the 
supernatant and air-drying, the pellet was re-suspended in 20-200µl TE buffer.  
 
2.2.5.6 Purification of DNA by Geneclean method 
Restriction fragments and PCR products (>200 bp) were purified from TBE agarose 
gels using Geneclean Spin kit (BIO 101) according to manufacturers’ protocol.  For 
each spin column, up to 5µg of DNA was purified from a gel slice (<300µl in 
volume) containing the fragment of interest. The method is based on the principle 
that DNA binds to silica in high concentrations of chaotropic salt and elutes in low 
salt. The mechanism of DNA binding to silica involves the chaotropic salt disruption 
of water structure around a negatively charged silica; allowing it to form a cation 
bridge with the negatively charged phosphate backbone of DNA. Elution of DNA 
with water is facilitated by the re-hydration of the silica matrix, which breaks the 
attraction between the matrix and DNA. Adequate recovery of purified fragments 
was confirmed by gel electrophoresis of a recovered aliquot, and typically, the 
recovery efficiency was higher than 90%. 
 
2.2.5.7 Preparation of vectors 
In order to prepare vectors for cloning, 2µg of plasmid DNA was typically digested 
with the appropriate restriction enzyme(s) and subjected to agarose gel 
electrophoresis. After purification by Geneclean method, the digested DNA was 
treated with 20 units of calf intestinal phosphatase (CIP) in 1x CIP buffer. CIP 
removes the 5′ terminal phosphates from the cut end of the vector so that self-ligation 
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is prevented. After incubation at 37°C for 20 minutes, the DNA was re-purified by 
Geneclean and eluted in water at a final concentration of 30-50ng/µl. 
 
2.2.5.8 Oligonucleotide phosphorylation and annealing 
Oligonucleotides were synthesised by Thermoelectron GmBH, Germany, with 
hydroxyl groups at both 5′ and 3′ termini. In order to ensure efficient ligation, the 5′ 
ends were phosphorylated prior to annealing. 100ng of oligonucleotide was 
incubated with 1x T4 DNA ligase buffer (containing 1mM ATP) and approximately 
10 units of T4 polynucleotide kinase in a final volume of 20µl at 37°C for 30 
minutes. After the addition of 80µl annealing buffer, the complementary 
oligonucleotides were mixed and the solution heated to 90°C for 5 minutes. The 
solution was allowed to cool slowly to room temperature to facilitate the annealing of 
the oligonucleotides. 
 
2.2.5.9 Ligations 
Ligations were performed with 30-50ng of vector DNA and typically a 1:1 and 1:5 
molar ratio of vector to insert DNA was used (either a purified DNA fragment, or a 
pair of annealed oligonucleotides). All ligation reactions were performed in a final 
volume of 10µl containing 1x T4 DNA ligase buffer and 1µl T4 DNA ligase (6 
units). All reactions were incubated overnight at 16°C. 
 
2.2.5.10 Polymerase Chain Reaction 
Polymerase chain reactions (PCR) were performed using DNA polymerase 
(Quiagen), or REDTaq DNA polymerase (Sigma). A 50µl reaction included 200µM 
of each dNTP (dATP, dCTP, dGTP, dTTP), 1.25µl (0.5ug/ul) of each primer, 20ng 
plasmid or 0.5µg genomic template DNA, 1x Taq buffer containing 1-2mM Mg2+ as 
supplied by the manufacturer, and 0.5-2.5 units of enzyme. DNA templates were 
initially denatured by heating the reaction to 94°C for 2 minutes, the reaction mixture 
was then subjected to 30 thermo-cycles of: 94°C for 30 seconds, (Tm of the primers -
5°C) for 40 seconds, and 72°C for 1.5 minutes. This was followed by a final 
Chapter 2                                                                                                           Materials and Methods 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     79 
extension of 72°C for 5 minutes. Final products were analysed by gel 
electrophoresis, then purified and resuspended in 20-50µl water as necessary using 
Geneclean protocols. 
 
2.2.5.11 Site Directed Mutagenesis 
The mutation of individual base pairs in plasmid DNA was achieved using the 
QuickChange Site Directed Mutagenesis Kit (Stratagene) according to 
manufacturer’s instructions. This involves the construction of complementary 
oligonucleotides of approximately thirty base pairs spanning the region of interest. 
These oligos incorporate changes in base pairs necessary to alter the coding sequence 
and subsequently the amino acid sequence of the resulting protein. These oligos 
(125ng each) are used in a PCR reaction including 10x reaction buffer, 10mM each 
dNTP, 10ng template DNA and 2.5 Units of PfuTurbo DNA polymerase in a total 
volume of 50µl. The reaction mixture is heated to 95oC for 30 seconds followed by 
annealing at 55oC for 1 minute with extension at 68oC for 20 minutes for 18 cycles. 
Following the PCR, the reaction is treated with DpnI for 1 hour at 37oC to remove 
the template (this enzyme digests methylated DNA and is used to selectively digest 
the plasmid DNA template) and transformed, in parallel with a control PCR that has 
not been treated with DpnI, into XL1 Blue chemically competent cells (Stratagene). 
The success of the mutagenesis is initially determined by observing the plates. 
Ideally there is a large number of colonies on the non DpnI treated DNA plate and 
fewer on the DpnI treated one. DNA from candidate colonies is then isolated by 
mini-prep and sequenced to verify the presence of the appropriate mutation. 
 
2.2.5.12 DNA sequencing 
Maxi- or mini-preparations of DNA were sequenced by a linear PCR method using 
dye-labelled terminators from Applied Biosystems. The sequencing reactions 
consisted of: 0.5-1µg plasmid DNA, 8µl of Terminator Ready Mix (containing Taq 
polymerase and dye-labelled terminators) and 30ng of primer in a 20µl reaction.  
PCR reactions typically consisted of 25 thermo-cycles of: 94°C for 30 seconds, 50°C 
for 15 seconds and 60°C for 4 minutes. Following the PCR, the DNA was 
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precipitated by addition of 80µl 75% (v/v) isopropanol, followed by incubation at 
room temperature for 15 minutes. The DNA was pelleted by centrifugation at 13000 
rpm for 20 minutes and washed with 70% (v/v) isopropanol. The air-dried pellet was 
then processed by the sequencing service run ‘in house’ at the Institute of 
Reproductive and Developmental Biology. 
 
2.2.5.13 Genomic DNA preparation from mouse tail snips 
Genomic DNA isolation from mouse tissues was achieved by Proteinase K digestion 
followed by a subsequent isopropanol precipitation. Individual mouse tails 
(approximately 5mm) were digested in 0.7ml cell lysis buffer containing 25µg/ml 
Proteinase K and incubated overnight at 55°C. The genomic DNA was then 
precipitated by the addition of 0.6ml isopropanol and vigorous shaking at room 
temperature for 1 minute. DNA was pelleted by centrifugation at 13000 rpm for 30 
minutes. The pellets were then washed with 1ml 70% ethanol, re-pelleted and air-
dried. The DNA was re-suspended in 50-200µl DEPC-treated water depending on 
the size of the pellet. 
 
2.2.5.13.1 Genotyping 
A 25µl reaction included dNTPs (2µM), 100µM of each primer, 1µl genomic 
template DNA, 10x Taq PCR buffer containing 1-2mM Mg2+ as supplied by the 
manufacturer, 5µl Q solution (Qiagen) and 0.25µl of enzyme. DNA templates were 
initially denatured by heating the reaction to 94°C for 3 minutes followed by 33 
cycles of: 94°C for 1 minute, 62°C for 1 minute, and 72°C for 2 minutes.  This was 
followed by a final extension of 72°C for 3 minutes.  Two primer sets were used to 
genotype FXR knockout mice; an FXR WT primer set and an FXR null primer set; 
the products were then analysed by gel electrophoresis. Used in combination these 
two sets of primers distinguish between the three possible genotypes, wild type (FXR 
WT band only), heterozygote (one FXR WT band and one FXR null band) and 
knockout (FXR null band only). For primer sequences see Appendix III.  
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2.2.6 RNA Manipulation 
2.2.6.1 Isolation of RNA from cells and tissue 
RNase-free plastic ware and RNase-free water was used to prepare solutions. Total 
RNA was isolated from cells and tissue using TRIzol® reagent. Samples were 
processed according to the manufacturer’s protocol. TRIZOL reagent is a mono-
phasic solution of phenol and guanidine isothiocyanate that maintains the integrity of 
RNA during tissue homogenisation or cell lysis, whilst at the same time disrupting 
cells and dissolving cellular components. Following homogenisation (2x 10 seconds 
on high speed using the Ultra-Turrax T25 basic (IKA Werke) polytron in 1ml of 
TRIZOL) 0.2ml chloroform is added followed by centrifugation, separating the 
solution into an aqueous phase and an organic phase. The RNA remains exclusively 
in the aqueous phase, which was then transferred to a second 1.5 tube. Total RNA 
was precipitated from the aqueous phase by the addition of 0.5ml of isopropyl 
alcohol (stored at -20ºC), vortex to mix. The samples were left on ice for 10 minutes, 
and then centrifuged at 9000 rpm for 15 minutes at 4ºC and the supernatant 
discarded. The RNA precipitates forming a gel like pellet on the side and bottom of 
the tube. The pellet was washed with at least 1ml of 75% ethanol (stored at -20%) 
and centrifuged at 9,000 rpm for 15 minutes at 4ºC. Purified RNA was briefly air-
dried and re-dissolved in RNase-free water. The RNA concentration and purity were 
determined by measurement of the OD260 and OD280 on a spectrophotometer. An 
OD260/ OD280 ratio of around 2 was taken to indicate good quality RNA. Finally, all 
RNA samples were stored at -70ºC 
 
2.2.7 cDNA synthesis 
2.2.7.1 DNaseI treatment 
Total RNA preparations may contain small quantities of genomic DNA which would 
be amplified along with the target mRNA. To remove any such contamination 1µg of 
total RNA is digested with 0.5µl DNaseI (Invitrogen) in 1x DNaseI reaction buffer in 
a total volume of 5µl at room temperature for 15 minutes. The reaction is stopped by 
the addition of 0.5µl 25mM EDTA and incubation at 65oC for 15 minutes. The whole 
of this reaction is then used for first strand cDNA synthesis.  
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2.2.7.2 First strand synthesis using Random hexamers 
DNase-treated RNA (5µl) was reverse transcribed using the Superscript First strand 
synthesis system for RT-QPCR (Invitrogen Life Technologies) following the 
manufacturers instructions. SuperScript II Reverse Transcriptase (RT) catalyses the 
first-strand cDNA synthesis reaction. The system uses oligo (dT) to hybridise to a 3’ 
poly (A) tails, which are found in the majority of eukaryotic mRNAs.  
 
2.2.7.3 RNaseH digestion 
This is carried out to remove the residual RNA template from the newly synthesised 
cDNA:RNA hybrid molecule and increase the sensitivity of the PCR amplifying the 
cDNA. Following cDNA synthesis samples are incubated with 1µl RNaseH (2 
units/µl) at 37oC for 20 minutes. cDNA is diluted 1:1 with DEPC-treated water and 
stored at -20oC. 
 
2.2.8 Gene expression analysis using Real Time PCR 
2.2.8.1 Amplification of the target cDNA (principal) 
After cDNA synthesis target cDNA was amplified using specific primer pairs by 
Real-time QPCR (RT-QPCR). RT-QPCR was carried out using the ABI PRISM 
7700 Sequence Detection System (Applied Biosystems) or the MJ Opticon2 (Bio 
Rad). Briefly, this system is comprised of a 96-well plate thermal cycler to which 
laser light is distributed via optical fibres. This leads to the excitation of flurophores 
in the samples and the resulting emitted fluorescence passes back through the optical 
fibres and is directed to a spectrograph attached to a charge coupled device camera 
detector. This is then analysed by sequence detection software. The method used 
utilizes the fluorescent dye SYBR Green I, which has undetectable fluorescence in its 
free form but emits fluorescence once incorporated into double stranded DNA. 
Therefore as the PCR progresses and more double stranded DNA product 
accumulates, the more fluorescent signal is produced. Increases in fluorescence 
intensity are read by the sequence detector throughout the reaction and a computer 
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program calculates the change in intensity ∆Rn = Rn+ - Rn-, where Rn+ is the 
fluorescence emission product and each time point and Rn- is the fluorescence 
emission of the baseline. The software constructs amplification plots using this 
information of ∆Rn vs cycle number. During the early stages of the reaction the ∆Rn 
values do not exceed the baseline so an arbitry threshold is chosen calculated on the 
variability of the baseline, usually determined as 10 times the standard deviation of 
the baseline from cycles 3 to 15. This can be altered between experiments as 
necessary. The threshold cycle value (Ct value) is then calculated as a quantitative 
measurement of the input target. The Ct value is seen to decrease with increasing 
target cDNA. It is expressed as a cycle number by determining the point at which 
fluorescence exceeds the chosen threshold limit (Giulietti et al, 2001). 
 
2.2.8.2 Amplification of the target cDNA  
Genes of interest were amplified using either the SYBR Green I master mix. The 
reactions were prepared in 96-well plate format and each reaction contained 1µl, 
12.5µl 2x master mix (either SYBR Mix) the appropriate ratio of primers / probe are 
made up to a total volume of 25µl with DEPC-treated water. Negative controls of 
reaction mix without cDNA template were included. All reactions were carried out in 
duplicate with the following thermocycler conditions: 94°C for 2 minutes, 95°C for 
15 seconds, 60°C for 30 seconds and 72°C for 30 seconds for a total of 40 cycles.  
 
2.2.8.3 RT-QPCR primer design 
Primers were designed within a short sequence of cDNA to give a product of 
approximately 100 base pairs crossing, where possible, intron exon boundaries to 
eliminate the possibility of amplifying genomic DNA. Sequences were obtained from 
the Ensembl mouse genome database 
(http://www.ensembl.org/Mus_musculus/index.html) and applied to the 
software Primer Express Oligo designTM version 1.5a (Applied Biosystems). On 
arrival primers were dissolved in DEPC-treated water to a final concentration of 100 
µmol/µl, this is then diluted again to a working concentration of 20µmol/µl. For 
primer sequences see Appendix III. 
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2.2.8.4 Relative Quantification 
The method used for quantification was the comparative Ct method which uses 
arithmetic manipulations to calculate the relative expression of a gene compared to 
that of a known internal control gene (L-19 or cyclophilin) and of a control 
(untreated) sample. The method is based on the idea that the difference in the 
threshold cycles (∆Ct) between the gene of interest and the housekeeping gene, ∆Ct 
= Ct (target gene) –Ct (L-19) is proportional to the expression level of the gene of 
interest. The amount of target normalised against L-19 and relative to the calibrator 
is then given by 2-∆∆Ct where ∆∆Ct = ∆Ct (sample) - ∆Ct (calibrator). The equation 
then represents the normalised expression of the target gene in the unknown sample 
relative to the normalised expression of the calibrator sample. 
 
2.2.9 Protein Analysis 
2.2.9.1 In vitro protein synthesis 
A coupled rabbit reticulocyte lysate system was used to synthesise proteins in vitro 
(Promega). In a typical reaction, 250ng/µl of plasmid DNA template and 0.5µl of 
cold methionine were used in a 12.5µl reaction assembled according to the 
manufacturer’s protocol. Reactions were carried out with T7 polymerase at 30°C for 
120 minutes, and then stored at –70°C.  
 
2.2.9.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were analysed on discontinuous polyacrylamide gels using the Biorad slab 
gel analysis chamber. Gels were prepared from two solutions to form the stacking 
and resolving gels. The resolving gel typically contained 10% acrylamide (30% 
acrylamide 0.8% bis-acrylamide stock), 375mM Tris-HCl pH 8.8 and 1% SDS.  The 
stacking gel contained 5% acrylamide, 125mM Tris-HCl pH 6.8 and 1% SDS. 
Polymerisation of the resolving gel was initiated by the addition of TEMED and 
ammonium persulphate.  The solution was then poured between the gel plates to 
within 2cm of the base of the prospective wells and overlaid with distilled water 
saturated with butanol. Once polymerisation was complete, the distilled 
water/butanol was poured off.  Again polymerisation of the stacking gel was initiated 
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by the addition of TEMED and ammonium persulphate. This solution was then 
poured on top of the resolving gel and an appropriate comb inserted. Once the 
stacking gel had set, the comb was removed and the wells were rinsed with distilled 
water to remove any unpolymerised acrylamide. Protein samples, containing protein 
loading buffer, were boiled for 5 minutes before loading as well as prestained 
molecular weight markers. Gels were run in 1x SDS-PAGE buffer at 30mA (per gel) 
until the dye front had migrated to the bottom of the gel. The plates were then 
separated and the gel removed and subjected to western blotting.  
 
2.2.9.2.1 2D gel electrophoresis 
For second dimension SDS-PAGE, 7 cm pH 6.2–7.5 immobiline gel strip (IPG) 
strips (GE Healthcare) were rehydrated with 0.6µl of in vitro synthesized protein in 
IEF buffer (8M urea, 4% (w/v) CHAPS, 40mM Tris) overnight. Iso-electric focusing 
was performed on a IPGphor (Pharmacia Biotech) using the following program: 0.5h 
100V, 0.5h 200V, gradient to 1000V in 1h, gradient to 3000V in 2h, gradient to 
6000V in 1h, gradient to 8000V in 1h, 8000V for 1h followed by 1h at 500V and 
frozen at -20°C. Strips were equilibrated for 15 minutes in 50mM Tris-HCl pH 6.8, 6 
M urea, 30% glycerol and 2% SDS containing 65mM DTT and then in the same 
buffer containing 240mM iodoacetamide. Equilibrated IPG strips were then 
transferred onto 1.5 mm thick 15% polyacrylamide gels.  Strips were overlaid with 
0.5% low melting point agarose in electrophoresis buffer with bromophenol blue. 
Gels were run at 30mA per gel and subjected to western blotting. 
 
2.2.9.2.2 Western blotting 
Protein samples were resolved by SDS-PAGE and then transferred to a nitrocellulose 
membrane using a wet blotting method (Sambrook et al, 1989a). A ‘sandwich’ was 
assembled which consisted of a fibrous pad, two pieces of Whatman 3MM paper, the 
gel, a piece of nitrocellulose membrane, another two pieces of Whatman 3MM paper 
and another pad. The paper, pad and nitrocellulose had all been pre-equilibrated in 
Western transfer buffer, and the ‘sandwich’ is put together carefully under the buffer 
to ensure no air bubbles were present. The ‘sandwich’ was then enclosed in a case 
and placed in Western transfer buffer in the blotting tank (Bio-Rad) with the 
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nitrocellulose towards the anode and the gel towards the cathode. Transfer was 
performed at 350mA for 1 hour at room temperature. Following transfer, the blotting 
apparatus was disassembled and the membrane was incubated with gentle shaking, in 
Western blocking solution for 1 hour at room temperature. The membrane was then 
incubated overnight at 4°C with the primary antibody. Typically, the primary 
antibody was diluted to 1:1000 in western blocking buffer. After incubation with the 
primary antibody, the membrane was washed three times (10 minutes each wash) 
with Western washing solution, and then incubated for 1 hour at room temperature 
with horse-radish peroxidase (HRP) conjugated antibody against the primary 
antibody (1:2000 dilution) in washing solution. The membrane was finally washed 
three times (10 minutes each wash) with Western washing solution and processed for 
enhanced chemilluminescence (ECL+) according to manufacturers’ protocol 
(Amersham Biosciences). 
 
2.2.9.3 Stripping antibodies from Western blots  
To re-probe nitrocellulose membranes with different primary antibodies and 
background signals were not desired, antibodies were stripped off by treating the 
membranes with Western stripping buffer and at 60°C for 30 minutes with gentle 
shaking. The membrane was then washed three times (10 minutes each wash) with 
Western washing solution before being blocked and incubated with antibodies again 
as described above.  
 
2.2.10 Microscopy and Histological Analysis  
2.2.10.1 Embedding of tissues and paraffin sectioning 
Fixed liver samples were embedded in hot paraffin wax then, once poured the mould 
was placed onto a cold plate so that the paraffin wax solidified, encasing the sample. 
Prior to sectioning, embedded blocks were placed on ice for 10 minutes. Then 
ribbons of sections were cut (knife angle of inclination 10°) at a thickness of 5 
microns and placed in a clean 40°C water bath using forceps. Sections were 
recovered onto polysine slides, labelled, and placed in a drying oven at 37°C 
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overnight. Once dried, sections were either used directly for immunohistochemistry 
or stained with haematoxylin and eosin (H&E). 
 
2.2.10.2 Protein labeling in mouse tissue by      
Immunohistochemistry 
Immunohistochemistry was performed by the ABC peroxidase technique using the 
Vector ABC kit. Sections were de-waxed and re-hydrated, and then endogenous 
peroxidase was blocked by immersing slides in methanol/hydrogen peroxide for 30 
minutes. After washing with PBS, the slides were incubated for 30 minutes with 
blocking solution (PBS + normal serum + 4% BSA) to block non-specific antibody 
binding. Then slides were dried and the primary antibody diluted in PBS was 
applied. Typically the dilution used for primary antibody was 1:50. A negative 
control was also included, where blocking buffer was added instead of the primary 
antibody. The slides were incubated with the primary antibody at 4ºC overnight in a 
moist staining chamber. After incubation the slides were washed three times with 
PBS for ten minutes. The secondary antibody (supplied in Vector Staining kits) was 
applied after dilution in PBS (1:100). The slides were incubated for 30 minutes and 
then rinsed again in PBS twice. After rinsing, the ABC complex was applied and 
incubated for 30 minutes. The third layer is referred as the ABC complex. 10 µl of 
reagent A and 10µl of reagent B were added to 1ml of PBS and left at room 
temperature for at least 30 minutes before use. After incubation with the ABC 
complex the slides were washed twice in PBS. The colour reaction was developed 
using diaminobenzidine (DAB). 2.5-5mg of DAB and 20µl of hydrogen peroxide 
were added to 10ml PBS. The DAB solution was applied onto slides and they were 
incubated for 10 minutes. When DAB development completed, the slides were rinsed 
in running tap water for 5 minutes. The sections were then counterstained with 
haematoxylin, dehydrated through ascending alcohols (70% ethanol, absolute 
ethanol), cleared in Histoclear and mounted in DPX (Distrene Plasticiser Xylene) in 
a fume cupboard for imaging.  
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2.2.10.3  H&E and Fibrosis staining 
H&E and fibrosis staining was performed on 5µm section using standard protocols. 
Briefly, sections were de-waxed in Histoclear and re-hydrated through a series of 
ethanol washes at descending concentration followed by immersion in distilled 
water. For H&E, sections were immersed for five minutes in Haematoxylin, washed, 
and immersed in Eosin solution for five minutes. For fibrosis, sections were stained 
with Aniline Blue for ten minutes and counter-stained with Haematoxylin Weigert 
for five minutes. All sections were de-hydrated to 100% ethanol and cover slips 
mounted using a permanent fixative. 
 
2.2.10.4 Apoptosis staining 
Detection of fragmented DNA (indicating apoptosis) was carried out using the TdT-
FragEL DNA fragmentation detection kit according the manufacturers instructions 
(Calbiochem). The assay is based upon the binding of a terminal deoxynucleotidyl 
transferase to exposed 3’-OH ends of fragmented DNA generated in response to 
apoptotic signals and catalyses the addition of biotin-labeled and unlabeled 
deoxynucleotides. Biotinylated nucleotides are detected using a streptavidin-
horseradish peroxidase conjugate. Diaminobenzidine reacts with labeled sample to 
generate an insoluble colored substrate at the site of DNA fragmentation. 
 
2.2.10.5 Quantification of nuclear DNA content 
Hoechst staining 
Hoechst 33342 is a fluorescent stain that was used to quantify nuclear DNA as it 
binds stoichiometrically to DNA. Histological tissue sections were stained with 
Hoechst and then used for quantitative fluorescent microscopy as described by 
Toyoda et al (Toyoda et al, 2005). 5µM liver tissue sections were mounted on 
Polysene-coated slides, de-waxed in HistoClear and re-hydrated in H2O. Slides were 
immersed in Hoechst 33342 solution (1.62nM) for 20 minutes followed by three 
washes in H2O. Samples were mounted with glycerol and kept in the dark. A Zeiss 
Axiovert 35 (Carl Zeiss, Gottingen, Germany) inverted microscope with Zeis Plan 
Axiovert 40x objective was used for the analysis. Images were captured in grey-scale 
using a charged couple camera (KAF 1400-G2, Arizona, USA). The analysis was 
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performed in 12 bits using the CellProfiler software (Carpenter et al, 2006). Only 
hepatocyte nuclei were used for the analysis and debris, whereas the program 
excluded other cell types and overlapping nuclei. Proximity measurements identified 
bi-nucleate hepatocytes, which were counted but excluded from the analysis. The 
software-processed images were also inspected manually. The nuclear DNA content 
of each nucleus is defined as the sum of the fluorescence of each pixel within the 
identified nucleus. At least 200 nuclei were assessed per tissue, these were taken 
from at least five images that were selected for imaging randomly but contained the 
same proportion of periportal, centrolobular and mediolobular areas.  
 
FACS analysis 
In order to confirm the results of the Hoechst staining, FACS analysis was also 
performed. A small piece of fresh liver tissue was gently mashed in PBS solution and 
the homogenate was passed through a fine mash to separate individual cells. The cell 
suspension was fixed overnight in cold 75% ethanol, centrifuged at 2000 rpm and the 
pellet re-suspended in PBS. The suspension was centrifuged again at 2000 rpm and 
the pellet re-suspended in propidium iodide (50µg/ml) and subjected to FACS 
analysis generating histograms of fluorescence intensity.  
 
2.2.11 Gene expression analysis using Affymetrix Microarray 
DNA microarray Chips are a powerful technology that are used to compare the gene 
expression profiles of different samples in one experiment. The gene expression 
profile of a particular sample obtained from using a DNA Chip forms a unique 
signature pattern. The protocols described below are based on those provided by 
Affymetrix but include modifications from the CSC/IC Microarray Centre. Optimal 
RNA samples were prepared and screened and then transferred to the array centre for 
hybridisation and scanning. The raw data was then returned in the form of CEL files 
and all analysis on this was performed.  
 
2.2.11.1 Treatment groups and screening 
The livers of non-pregnant and pregnant wild type on normal diet and diet 
supplemented with 0.5% CA and FXR knockout mice of 10-12 weeks in age were 
Chapter 2                                                                                                           Materials and Methods 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     90 
used for the microarray. The livers of wild type and FXR mice that received silastic 
implants with either vehicle or 17β-estradiol and progesterone were also used for the 
microarray experiment. RNA was extracted from the livers and 1µg total RNA used 
to synthesise cDNA. This cDNA was then used to screen genes, using real time PCR, 
to confirm that the animals had responded to the hormones and bile acids as expected 
and that there were not any gross outliers. There were six samples in each group 
except for in the hormone treated mice in which there were 5 samples. In total there 
were 10 groups with 56 samples that went forward for array analysis. This is outlined 
in Figure 2.1. 
 
 
FIGURE 2. 1: GROUPS FOR MICROARRAY EXPERIMENT 
Liver samples were collected form female mice 10-12 week of age. Wild type mice 
were either non-pregnant or 18 day pregnant. These mice were fed either a normal 
diet (ERD) or a 0.5% supplemented diet. Wild type mice were also ovariectomised 
and received silastic implants containing either vehicle (peanut oil) or 17β-estradiol 
and progesterone. Fxr knockout mice were also used either non-pregnant or pregnant 
and fed a normal diet (ERD). 
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2.2.11.2  First strand cDNA synthesis 
All RNA samples used for this procedure must be of high quality and purity. The 
advised ratios for the absorbance of the total RNA at 260nm and 280nm are between 
1.9 and 2.1 as determined within the linear range of the spectrophotometer. The 
Invitrogen system was used according to manufacturer’s instructions. To label the 
RNA with the T7 adaptor a total of 10µg total RNA was mixed with 100 pmol T7-
(T)24 primer (GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-
(T)24), 1µl Poly A+ controls and DEPC-treated water to a final volume of 11µl. This 
mixture was incubated at 65°C for 10 minutes and subsequently cooled on ice for 1 
minute. Then a master mix containing 4µl First Strand Buffer (5x), thawed quickly at 
37°C, 2µl DTT 0.1mM and 1µl dNTPs (10mM each dATP, dTTP, dCTP and dGTP) 
was added to each sample, mixed and centrifuged. The reaction was incubated at 
42°C for 2 minutes, 2µl Superscript II reverse transcriptase (400 U) added and then 
incubated for a further hour at 42°C. The reactions were then stopped on ice before 
proceeding to the second strand cDNA synthesis step.  
 
2.2.11.3 Second strand cDNA synthesis. 
To each of the first strand reactions a master mix containing 30µl Second Strand 
Buffer (5x), 3µl dNTPs (10mM each), 1µl DNA Ligase (10 Units), 4µl DNA 
Polymerase I (40 Units) 1µl RNase H and DEPC-treated water up to 130µl was 
added. The reactions were then incubated at 16oC for 2 hours using a water bath in 
the cold room to reduce condensation, stopped on ice and the clean-up protocol 
carried out.  
 
Clean up of double stranded cDNA 
The double stranded cRNA was purified using the GeneChip Sample Cleanup 
Module (Affymetrix) according to the manufacturer’s instructions. This is based on a 
spin column approach. Briefly, 600µl cDNA binding buffer was added to the second 
strand cDNA reaction. Then the sample was applied/bound to the cDNA cleanup 
spin column in two halves and centrifuged each time at 10,000 rpm for 1 minute. The 
sample was then washed over a clean 2ml collection tube with 750µl cDNA wash 
buffer and the membrane dried by centrifugation with the cap open. The cDNA was 
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finally eluted with 15µl of cDNA Elution Buffer directly onto the middle of the spin 
column membrane and incubating at room temperature for 1 minute before 
centrifuging at maximum speed for 1 minute. The cDNA was then stored at -70oC 
until the in vitro transcription reaction. 
 
2.2.11.4 Preparation of cRNA  
Synthesis of labelled cRNA was conducted using One-Cycle Target Labelling 
Reagents (Affymetrix). The following reagents were added to 6µl of eluted double 
stranded cDNA, 14µl H2O, 4µl IVT Labelling Buffer, 12µl labelled NTP mix and 
4µl IVT labelling enzyme mix. The samples were incubated at 16oC for 16 hours. 
Following this the samples were then cleaned up using the clean-up of cRNA 
protocol. 
 
Clean up of cRNA 
The removal of unincorporated ribonucleotides is very important to the overall 
quality of the cRNA. This method uses the GeneChip Sample Cleanup Module 
according to manufacturer’s instructions and is essentially the same as the cDNA 
clean up protocol again, using a spin column approach. The cRNA labelling reaction 
was mixed with 60µl DEPC-treated water and 350µl IVT cRNA binding buffer and 
250µl 100% ethanol. This was applied/bound to an IVT cRNA cleanup spin column. 
The cRNA was washed once, into a fresh 2ml collection tube, with 500µl IVT cRNA 
wash buffer and once with 80% ethanol before the membrane was dried by 
centrifugation in a clean collection tube for 5 minutes. The cRNA was then eluted 
into a RNase-free tube by adding 11µl DEPC-treated water to the column, incubating 
at room temperature for 2 minutes and centrifugation for 1 minute at maximum speed 
followed by the addition of a further 11µl of DEPC-treated water, a second 
incubation of 2 minutes and a second centrifugation of 1 minute. 
 
The concentration of cRNA was determined at 260nm and 280nm and the total yield 
was in the expected range of between 40 to 110µg. This is calculated based on the 
fact that the reaction was started with 10µg total RNA and 1 OD260 unit is equivalent 
to 40µg/ml single stranded RNA. The cRNA was aliquoted for bioanalyser analysis, 
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cDNA synthesis and array hybridisation and snap frozen on dry ice before storing at 
–70°C. 
 
2.2.11.4.1 Analysis of RNA and cRNA using the Bioananalyser 
To assess the quality of the cRNA samples, prior to hybridisation on test arrays the 
original total RNA and the cRNA can be analysed using the Agilent 2100 
Bioanalyser. This machine runs a simulated Northern blot of samples loaded into a 
RNA Nano Labchip® (Agilent Technologies) against a nano6000 marker to assess 
the size and integrity of the RNA/cRNA samples. 
 
2.2.11.4.2 Fragmentation and Hybridisation to Chips (CSC Microarray   
Centre) 
For each sample 20µg cRNA is mixed with 4µl fragmentation buffer (5x) and 
DEPC-treated water to give a final volume of 20µl and incubated at 95oC for 35 
minutes. Then to 15µl of this reaction add 150µl hybridisation buffer (2x), 5µl 
control oligonucleotides B2 (3nM) (Affymetrix), 15µl 20x eukaryotic hybridisation 
controls (BioB, BioC, BioD, cre) (Affymetrix), 3µl herring sperm DNA (10mg/ml) 
(Invitrogen) and 109µl DEPC-treated water. Two lots of this reaction are required to 
cover one array. These were stored at -70oC until hybridisation to the arrays. 
 
The arrays used were 430 2.0 mouse whole genome arrays (Affymetrix). These 
Chips display 39,000 transcripts covering 34,000 well characterised mouse genes. 
Each gene is represented by at least one probe set, bringing the total number of probe 
sets on the array to 45,000. The probe sets were derived from GenBank®, dbEST 
and RefSeq. The oligonucleotides are designed to be complementary to the 
corresponding sequence and are synthesised in situ on the array. Each probe set 
consists of eleven pairs of oligonucleotides probes leading to eleven different 
independent measurements for every transcript. Each pair includes a perfect match 
(PM) and a mismatch (MM) probe, the mismatch has only one base pair altered from 
the original sequence and each pair is randomly placed over the whole chip surface. 
These probes are used to measure the level of transcription of each sequence that is 
represented on the array. 
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The arrays were equilibrated at room temperature for 30 minutes before use. The 
frozen, fragmented cRNA was heated at 99oC for 5 minutes and then centrifuged at 
high speed for 5 minutes to precipitate any particulate matter. During these 
incubations the arrays were pre-wet with 200µl 1x hybridisation buffer and incubated 
at 45oC in a rotisserie oven at 60rpm for 10 minutes. The arrays were then carefully 
drained, 200µl fragmented cRNA added and incubated at 45oC, 60 rpm for 16 hours. 
 
GeneChip wash and stain 
Following the hybridisation step the cRNA is removed, and re-frozen at -80oC. The 
array was then filled with 200µl Wash Buffer A. The washing and staining procedure 
is computerised and uses the EukGE-WS2v4 protocol of the GeneChip® Scanner 
3200 station (Affymetrix). A master mix of SAPE (streptavidin-phycoerythrin) 
staining solution is then made up, for each array 600µl stain solution, 540µl RNase-
free water, 48µl (50mg/ml) BSA, 12µl SAPE (Molecular probes) is used and divided 
in two, one aliquot was used for the pre-antibody staining. The array was then 
stained in a solution of 300µl 2x stain buffer, 266.4µl RNase-free water, 24µl 
(50mg/ml) acetylated BSA, 6µl (10mg/ml) normal goat serum and 3.6µl biotinylated 
antibody (Vector Labs) followed by another wash in the pre-stain solution. This is 
then translated as a fluorescence intensity image file. 
 
2.2.11.4.3 Data analysis and Software 
The scanned array data was converted to CEL files which were subsequently 
analysed using the Rosetta Resolver software package (Vardhanabhuti et al, 2006). 
The CEL files are raw intensity values calculated from the individual gene probe sets 
on each array. Experimental definitions were “built” and the individual CEL files 
were assigned to treatment groups. The initial analysis included normalisation of the 
different arrays. The normalisation function takes into account the varying brightness 
between arrays and allows separate arrays from the same experiment to be compared. 
The median CEL intensity of each array is calculated and then a baseline array is 
chosen based on the median value of all the arrays combined. All of the arrays, 
except the baseline array, are then normalised to that. 
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Unsupervised principal component analysis was performed on the entire dataset. 
Data reduction techniques were performed in order to only include genes that are 
expressed at a level above a certain threshold (Schnoes et al, 2008). Following 
discussions with experienced collaborators on array analysis at GlaxoSmithKline, it 
was decided that probe sets with a mean, scaled intensity of less than 30 U in both in 
both groups of a two-way comparison were excluded from further analyses.  
Rosetta Resolver software was used to create lists of fold-change, p-value, 2D 
hierarchical clustering, Venn diagrams and canonical pathway analysis. Ingenuity 
pathway analysis was also used to investigate disease-related pathways and networks 
of interacting genes. 
 
2.2.12 Hormone and Bile Acid measurement 
Metabolic profile of intact liver was performed by magic angle spinning (MAS) 1H 
magnetic resonance spectroscopy (MRS). 
 
2.2.12.1 Serum ALT measurement 
Serum alanine aminotransferase (ALT) is used as a marker for liver disease and 
hepatocellular damage. High serum concentrations of ALT suggest abnormal liver 
function. ALT was measured in mouse serum using the Infinity ALT Liquid Stable 
Reagent (Thermo-Scientific) according to manufacturer’s instructions. ALT 
catalyses the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-
glutamine. Next, pyruvate and NADH are converted by LDH to form L-lactate and 
NAD. The oxidation of NADH decreases the absorbance of the sample at 340nm and 
the rate of decrease is proportional to the ALT content in the sample. Reactions were 
performed in duplicate. 10µl of serum was combined with 100µl of working 
reagentand read at 340nm every 10 seconds for 5 mins. ALT activity (U/L) is 
proportional to the change in absorbance per minute during the linear phase of the 
reaction.  
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2.2.12.2 Bile acid extraction and measurement 
Bile acids were determined in the serum and liver. In order to measure the bile acids 
in the liver, bile acids had to first be extracted. A piece of liver was weighed and 
homogenised in 20x volume 75% ethanol. The homogenate was left to shake for two 
hours at 55ºC and then centrifuged at 13000 rpm and the supernatant was used for 
the assay. Three pieces of liver per mouse were used for the extraction. All samples 
were diluted or concentrated in order to fall in the normal range of the assay. 
In order to quantitate total bile acids in serum and liver extracts, an enzymatic assay 
from Sentinel Diagnostics was used. The reactions required that bile acids were first 
oxidised to 3-oxo bile acids in a reaction catalyzed by 3α-hydroxysteroid 
dehydrogenase. During this oxidative reaction, an equimolar quantity of NAD is 
reduced to NADH. Then the NADH is oxidized to NAD with concomitant reduction 
of nitro blue tetrazolium salt (NBT) to formazan by the catalytic action of 
diaphorase. The formazan has an absorbance maximum at 530nm. The intensity of 
the colour produced is directly proportional to the bile acid concentration in the 
sample. In duplicate, 20µl of sample or standard was combined with 40µl Reagent 1 
and incubated at room temperature for 10 minutes. 10µl of Reagent 2 was added to 
one of the wells of the duplicate (test) and 10µl of dH2O was added to the other well 
of the duplicate (blank). Reactions were incubated at 37ºC for 20 minutes and 
measured at 546nm. Bile acid concentrations were measured based on the standards 
after subtracting the blanks.  
 
2.2.12.3 Lipid extraction 
Lipids were measured in the serum and liver. Folch’s method, with slight 
modifications, was used for the lipid extraction from the mouse livers (Folch et al, 
1957). A piece of liver was weighed and homogenised in 20x volume 
chloroform/methanol (2:1) solution and then incubated with shaking at room 
temperature for 20 mins. The homogenate was centrifuged at 13000 rpm for 20 
minutes and the supernatant was recovered. The supernatant was washed by adding 
0.2 volume 0.9% NaCl and shaking. This solution was centrifuged at 2000 rpm for 
15 mins. Then, the upper phase was discarded while the lower phase, which contains 
the lipids, was evaporated under a stream of N2. The lipid residue was resuspended in 
PBS-Triton X-100. Three pieces of liver per mouse were used for the extraction. 
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2.2.12.4 Cholesterol measurement 
Cholesterol was quantified in serum and liver extracts using the Infinity Cholesterol 
Liquid Stable Reagent (thermo-Scientific) according to the manufacturer’s 
instructions. The reactions that take place are as follows; cholesterol esters are 
hydrolysed to free cholesterol. The free cholesterol is then oxidized by cholesterol 
oxidase and produces hydrogen peroxide. The hydrogen peroxide then combines 
with hydroxybenzoic acid and 4-aminoantipyrine to form a quinoneimine dye that is 
measured at 550nm. Samples were assayed in triplicate. 10µl of sample or calibrator 
was combined with 100µl of reagent and incubated at 37°C for 15 minutes. Then, the 
plate was read at 550nm. Cholesterol concentration was calculated based on the 
absorbance readings of the calibrator.  
 
2.2.13 Magnetic Resonance Spectroscopy and data analysis 
The metabolic profiling of intact liver tissue was investigated by magic angle 
spinning (MAS) 1H magnetic resonance spectroscopy. These experiments were 
performed in collaboration with The translational MR Spectroscopy Grouping, 
Division of Clinical Sciences, imperial College London. Sample preparation, data 
acquisition and data analysis was performed as described previously (Cobbold et al, 
2008). Slightly thawed tissue was spun (4000 Hz) at 4ºC in sealing cells (Doty 
Scientific Inc., Columbia, South Carolina, USA) using a MAS probe (Doty Scientific 
Inc.) interfaced with a JEOL Eclipse 500+ spectrometer (JEOL Ltd, Welwyn Garden 
City, UK) and an 11.75T superconducting magnet (Oxford Instruments, Oxford, 
UK). Sequences were used to establish total lipid content, lipid and choline 
resonances, and smaller metabolites respectively. 
The data analysis was performed by Dr Jeremy Cobbold. KnowItAll® Informatics 
System v7.8 (Bio-Rad, Philadelphia, USA) was used to process the spectra. The 
spectra were scaled to the sum of the total spectral integral to enable relative 
quantitative analysis of metabolites between samples. Partial least squares 
discriminant analysis (PLS-DA) with orthogonal signal correction was used to 
determine factors associated with class membership using Pirouette v4.0 software 
package (Infometrics, Washington, USA). A leave-one-out algorithm was used to 
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determine the predictive power of the model and the Q2 value indicated the validity 
of the discrimination, with values >0.05 considered significant. Examination of 
individual spectral resonances and assignment of peaks was performed by Dr Jeremy 
Cobbold  as previousy described (Cobbold et al, 2008). Indices of total lipid content, 
lipid polyunsaturation, choline content and composition were derived as defined in 
the supplementary methods. Comparison of mean index values between groups was 
performed using a paired t-test. 
 
2.2.14 Statistical analysis 
All values are expressed as mean +/- SEM for biological replicates or SD for 
technical replicates. Where appropriate, data are represented as histograms in order 
to better illustrate the results. Rosetta Resolver, Ingenuity Pathway Analysis and 
KnowItAll software have integrated special statistical algorithms for calculating 
statistical significance. Data were analysed using a two-tailed student’s t-test, one-
way and two-way ANOVA for significant differences between the mean values of 
each group. P values representing statistical significance between groups (P<0.05 or 
P<0.01) are indicated. 
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3.1 Introduction  
The farnesoid X receptor (FXR) is a key regulator in bile acid homeostasis. It acts by 
binding to DNA response elements in promoter regions of target genes regulating 
their transcription (Makishima et al, 1999; Parks et al, 1999). The physiological 
importance of FXR has been demonstrated in studies of Fxr knockout mice, which 
are shown to develop several disorders including dyslipidemia (Sinal et al, 2000), 
cholesterol gallstones (Moschetta et al, 2004), cholestasis (Liu et al, 2003), hepatic 
steatosis and impairement of regenerative capacity (Huang et al, 2006), 
hyperglycemia (Ma et al, 2006; Zhang et al, 2006), peripheral insulin resistance 
(Cariou et al, 2006) and loss of intestinal bacterial defence (Inagaki et al, 2006). 
These studies suggest that the development of FXR agonists might be of use for the 
treatment of several metabolic disorders including diabetes, cholesterol gallstones, 
atherosclerosis and hepatic and intestinal toxicity. Considering the critical role of 
FXR in metabolism, the existence of functional genetic polymorphisms in FXR 
would have a great impact in multiple pathways governing bile, lipid and glucose 
homeostasis. Mutations and polymorphisms have been identified in several nuclear 
hormone receptors such as VDR (Valdivielso & Fernandez, 2006), PPARα (Tai et al, 
2002), PPARγ (Meirhaeghe & Amouyel, 2004), LXR (Dahlman et al, 2006), SHP 
(Nishigori et al, 2001), HNF1α (Yamagata et al, 1996b) and HNF4α (Yamagata et al, 
1996a) which are associated with various metabolic disorders. To date, there are two 
reports identifying and describing functional FXR polymorphisms (Marzolini et al, 
2007; Van Mil et al, 2007). Marzolini and colleagues identified FXR polymorphisms 
in several ethnic groups (Marzolini et al, 2007) and van Mil et al from our group has 
isolated heterologous FXR functional variants from ICP patients (Van Mil et al, 
2007). This study will be further discussed below.  
 
3.2 FXR Mutation Analysis 
In an initial screen, sequencing of the entire FXR coding region including 
intron/exon boundaries in 92 British OC cases of mixed ethnicity revealed four novel 
heterozygous variants in FXR (Figure 1.1). M1V was only detected in one British 
case, and the W80R variant was not detected in any white Caucasians. Subsequently, 
these variants were genotyped in 342 cases and 355 controls of British and Swedish 
white Caucasian origin. Alleles of variants are shown in Table 3.1. M1V and W80R 
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were not found in controls, while the -1g>t and M173T variants were present in cases 
and controls. There was no significant difference in the allele frequencies of -1g>t in 
British cases (n=293) and controls (n=296).  In contrast to the UK results, the -1g>t 
variant is more common in cases (n=49) than controls (n=59) in the Swedish 
collection, although numbers are very low (2 in cases and 1 in controls). Combined 
analysis of the two studies gives no evidence for association of the -1g>t variant with 
ICP (odds ratio=0.68, 95% CI=(0.27,1.65), p=0.42). Carriers of M173T are more 
frequent amongst British cases than controls (odds ratio 2.26, 95% CI=(0.72,8.4)), 
but this difference does not reach statistical significance (p=0.14). In the Swedish 
case control study, M173T carriers are again more common in cases, with 4 copies in 
cases and none in controls (p =0.04) and combined analysis of both collections gives 
weak evidence for an association of ICP with M173T (odds ratio 3.2, 95% CI=(1.1, 
11.4), p=0.02).  Table 3.1 summarizes the results from the mutation analysis in the 
ICP patients. The genotyping was performed by Dr Saskia Van Mil (a postdoctoral 
scientist in our group) and the -1g>t, M1V and M173T variants were further 
investigated in this project to identify whether they have any functional effect.  
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Table 3. 1: Allele frequencies of the FXR variants in ICP cases and controls for 
a British and Swedish white Caucasian collection. 
Exon Nucleotide 
alteration 
Predicted 
effect 
Cohort1 Case 
carriers 
Control 
carriers 
Allele 
freq.cases 
Allele 
freq. 
controls 
British 8 14 1.2% 2.4% 3 -1g>t Translation 
defect Swedish 2 1 2.0% 0.8% 
3 1a>g M1V British 1 0 0.1% 0.0% 
   Swedish 0 0 0.0% 0.0% 
4 238t>c W80R2 British 0 0 0.0% 0.0% 
   Swedish 0 0 0.0% 0.0% 
5 518t>c M173T British 11 5 1.9% 0.8% 
   Swedish 4 0 4.1% 0.0% 
1The British cohort consists of 293 cases and 296 controls, the Swedish cohort of 49 cases and 59 
controls. 
2This variant was only present in one UK case of Asian origin. 
 
 
Figure 3.1: Distribution of the FXR variants 
Schematic representation of the FXRα1/2 cDNA and protein showing the locations 
of the four variants detected in OC patients (DBD=DNA binding domain; 
LBD=ligand binding domain). 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                                                                                         Results 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     103 
3.3 Results 
 
3.3.1 Functional Analysis of the -1g>t and M1V Variants 
It was hypothesized that the -1g>t and M1V variants influence translation as they are 
located one nucleotide before or at the published ATG for human FXR. There are 
two ATG codons at the amino terminus of human FXRα1 and α2 separated by 4 
amino acids (Figure 3.2A). In contrast the mouse and rat lack the upstream ATG 
codon (Figure 3.2B). Therefore, before finally characterizing -1g>t and M1V, it was 
necessary to investigate which ATG is used to initiate translation in humans.  
 
 
 
Figure 3. 2: Representation of the two methionines in the FXRα1/α2. 
(A) Schematic diagram of the human DNA sequence around first methionine in the 
FXRα1/α2 open reading frame. -1g>t and M1V are indicated (shaded), the M1 and 
M5 ATG codons are boxed. (B) Species alignment of the amino terminus of 
FXRα1/α2. The M1 and M5 are indicated with arrows. 
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B 
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HEK293T cells were transfected with 0.5ng plasmids of FXR WT, FXR M1V, FXR 
M5V, FXR -1g>t or a combination of variants, harvested after 72 hours and 30 mg of 
protein was used for immunoblotting. One dimensional SDS-page gels were 
electrotransferred to nitrocellulose membranes and probed with anti-FXR (1:1,000, 
PPMX, Tokyo, Japan) and anti-βactin (1:5000, Dako) as the housekeeping gene. The 
intensity of the bands was determined by ImageJ and expressed as percentage of β-
actin expression.  Immunoblotting of the lysates demonstrate that translation can be 
initiated from both methionines, as shown by detection of FXR protein from both 
constructs (Figure 3.3A). When either methionine is mutated, less protein is 
translated compared to wild type FXR and no protein is synthesized when both 
methionines are mutated (Figure 3.3A). Also the -1g>t variant translates only 37% of 
wildtype protein, indicating that this variant also causes reduced translation 
efficiency. In order to distinguish the proteins that are translated from M1 or M5, 
protein was synthesized in vitro containing the M1V or -1g>t mutations, and this was 
used for immunoblotting. No size difference could be observed with full length 
proteins, nor with constructs where an early stop codon was introduced after 36 or 15 
kD (Figure 3.3B). To establish the proteins that are translated from M1 or M5, and to 
determine the relative codon usage in wildtype FXR, the two isoforms were separated 
by 2-Dimensional (2D) gel electrophoresis. 2D gel electrophoresis was carried out 
using the in vitro synthesized 36 kD peptides containing the M1V, M5V or 
MIV/M5V mutations. The iso-electric focusing points of 36kD peptides for 
translation from M1 is pI=7.1 and for M5, pI=6.7. When either methionine is 
mutated, a shift in codon usage is observed (Figure 3.3C). However, M1 is 
predominantly used for initiation of translation of the in vitro synthesized wildtype 
peptide (Figure 3.3C).  
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Figure 3.3: Functional analysis of the -1 g>t and M1V mutation. 
(A) Immunoblot analysis of HEK293T cells transfected with FXR plasmids 
engineered to contain M1V, M5V, -1g>t or a combination of variants. Numbers 
indicate the relative expression as a percentage compared to wild type expression 
(ND:not detected; the upper band present in all lanes is a non-specific band). (B) 
Immunoblot analysis of in vitro synthesized FXR protein where an early stop codon 
has been introduced generating either a 36 kD peptide or a 15 kD peptide containing 
the indicated mutations. (C) 2-dimensional gel electrophoresis was carried out using 
the in vitro synthesized 36 kD peptides containing the indicated mutations. The 
positive end of the gel is on the left side. Experiments were repeated at least three 
times (n≥3). 
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In order to further investigate the effect of -1g>t and M1V on protein translation, 
transactivation assays were also performed. HEK293T cells were cotransfected with 
pSG5-RXRα/Gal4DBD-RXRα, pGL3, or pGL3-IBABP promoter, pCMV-Renilla, 
and expression vectors encoding wild type FXRα2 or FXRα2 harboring the M1V, 
M5V, -1g>t or a combination of mutations as indicated. On day 3, fresh medium 
with or without 50 µmol/L CDCA was added to the cells. After 24 hours, the reporter 
Firefly and Renilla luciferase activity were determined. Reporter assays show 
reduced CDCA-induced activity from the IBABP promoter using FXR expression 
plasmids containing the different mutations (Figure 3.4), which is consistent with 
reduced levels of FXR protein.  
 
 
 
Figure 3.4: Functional analysis of the -1 g>t and M1V mutation. 
HEK293T cells were co-transfacted with 0.5 ng FXR wild type/mutant expression 
plasmids, the RXR expression plasmid and the IBABP-pGL3 promoter construct. 
Cells were treated with or without 50 µmol/L chenodeoxycholic acid (CDCA) for 24 
hours and harvested for firefly luciferase assay. Renilla luciferase activity was used 
to correct for differences in tranfection efficiencies. Data are expressed relative to 
results for untreated HEK293T cells (n=3). 
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Transactivation assays were also performed to compare the consensus Kozak 
sequence with the wild type FXR and the -1g>t FXR Kozak sequences. HEK293T 
cells were cotransfected with the pRL-CMV and pGL3-control plasmid containing 
different Kozak sequences. The Consensus Kozak sequence is CCACC, the FXR 
wildtype sequence is TTTGG and the FXR-1g>t sequence is TTTGT (Figure 3.5A).  
The cells were harvested after 24 hours and assayed for Renilla and Firefly 
luciferase. The FXR WT sequence (TTTGG) is able to generate approximately 35% 
of luciferase protein compared to the plasmid with the consensus (CCACC) Kozak 
sequence (Figure 3.5B). When the FXR -1 g>t Kozak sequence (TTTGT) is 
compared to the wild type TTTGG, there is a further 33-40% reduction in translation 
efficiency after 24h (Figure 3.5B). 
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Figure 3. 5: Analysis of the FXR -1g>t variant. 
(A) The consensus Kozak sequence (CCACC) of the pGL3 vector was replaced with 
either the Kozak sequence of wild type FXR (TTTGG) or the FXR -1g>t Kozak 
sequence (TTTGT). The three different constructs were used in a luciferase reporter 
assay. B) HEK293T cells were transfected with the different Kozak plasmids 
(Consensus Kozak, CCACC; FXR wild type, TTTGG; FXR-1g>t, TTTGT). Cells 
were harvested and assayed for luciferase activity after 24h. Each bar represents the 
mean value ± SD in quadruplicates per group. Different letters indicate significant 
differences between groups (one-way ANOVA, P<0.001, n=3). 
A 
B 
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3.3.2 Treatment of Hepatic Cell Lines with Reproductive 
Hormones to Evaluate the M173T Variant 
Several cell lines (HepG2, HEK293T and Huh7 cells) were used to investigate the 
effect of estrogen and progesterone in reporter assays using the pGL3-IBABP 
promoter. Cells were transfected with pcDNA3.1, FXR WT or FXR M173T and 
treated with either 100 nM 17β-estradiol, 1 µM progesterone or both for 24 hours 
before developing the assay. HepG2 and HEK293T cells were less responsive to the 
hormonal treatment and they expressed the estrogen and progesterone receptors at a 
lower level. Therefore, for further experiments only the Huh7 cell line was used to 
examine the effect of reproductive hormones. Nevertheless, reporter assays did not 
show any significant changes in CDCA-induced activity from the IBABP promoter 
using FXR expression plasmids either containing the M173T mutation or wild type 
FXR (Figure 3.6). 
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Figure 3. 6: Influence of reproductive hormones in cell systems. 
Huh7 cells were cotransfacted with 0.5 ng FXR wild type/mutant expression 
plasmids, the RXR expression plasmid and the IBABP-pGL3 promoter construct. 
Cells were treated with 17β-estradiol (100 nM), progesterone (1 µM), both or just the 
solvent (ethanol).  Cells were also treated with or without 50 µmol/L 
chenodeoxycholic acid (CDCA) for 24h and harvested to determine the Firefly and 
Renilla luciferase activity. Renilla luciferase activity was used to correct for any 
differences in transfection efficiency. Data are expressed relative to results for 
untreated HEK293T cells. Experiments were repeated three times (n=3). 
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3.4 Summary and Conclusions 
This identification of functional variants in FXR implicates this nuclear receptor in 
human cholestatic disease. The work performed in this project demonstrates that 
M1V and -1g>t result in reduced target gene expression by reduced translation of 
FXR. The two variants detected in ICP cases, -1g>t and M1V, are positioned at the 
translation start site of FXRα1 and FXRα2. However, this amino terminus contains a 
second ATG codon 5 amino acids downstream of this first ATG. Furthermore, the 
mouse and rat Fxr gene only have the downstream ATG codon, raising the question 
of which methionine is used for initiation of translation. It has been shown that both 
ATG codons can be used in vivo and in vitro, but that M1 is used predominantly in 
humans. The -1g>t and M1V mutations result in reduced protein expression and 
reporter assays show decreased transactivation efficiency from the IBABP promoter. 
This indicates that these mutations present with a defect in translation efficiency. The 
M1V allele was detected in 1 case, indicating that this variant might be associated 
with ICP. On the other hand the -1g>t variant did not associate with ICP in the study, 
but it is possible that it plays a modifier role in the aetiology of cholestasis in 
conjunction with other loci. 
In order to investigate the effect of the M173T variant in protein translation, 
transactivation assays were performed. Reporter assays showed reduced CDCA-
induced activity from the IBABP promoter using FXR expression plasmids 
containing the mutation compared to the wild type one. However, treatment with 
reproductive hormones did not further affect the transactivation efficiency. A post-
doctorial fellow in the lab further characterized this mutation and demonstrated that 
M173T is important for normal function of FXR (Van Mil et al, 2007).   
In summary, a larger proportion of ICP cases had FXR variants compared to controls.  
The M1V variant was detected uniquely in 1 case and the M173T and -1g>t occur 
both in cases and controls. There is a significant association of M173T with ICP but 
this was not the case for -1g>t. Functional defects were demonstrated in either 
translation efficiency or activity for M1V, M173T and -1g>t. However, the control 
data demonstrate that pregnant women can have FXR variants without developing 
ICP, indicating that the variants are not fully penetrant and that interaction with 
additional modifier loci, additional mutations in hepatobilliary transporters, or 
environmental factors influence whether women with these variants develop ICP. 
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Epidemiological data are consistent with ICP having a complex aetiology, e.g. 
parous siblings of ICP cases have a 19 fold increased risk of developing the 
condition (Eloranta et al, 2001). As with other complex diseases the remaining 
genetic contribution is likely to be composed of a number of variants with a range of 
frequencies and penetrances. 
It is likely that raised estrogen and progesterone levels in pregnancy unmask the 
phenotype of ICP in susceptible individuals. ICP usually presents in the last trimester 
of pregnancy when hormone concentrations are 100-200 times higher than normal, 
and resolves 1 or 2 days after delivery, when levels of estrogen and progesterone 
return to normal (Kreek, 1987; Reyes & Sjovall, 2000). Further evidence for 
reproductive hormones causing a cholestatic phenotype is provided from studies of 
ICP patients who often present with cholestasis outside pregnancy when taking oral 
contraceptives or in the second half of the menstrual cycle (Williamson et al, 2004). 
In this study 5 women with FXR variants had cyclical itch, consistent with 
reproductive hormones unmasking a cholestatic phenotype when not pregnant. As 
the FXR variants detected are heterozygous and reduce rather than abolish FXR 
function, we believe that women can cope with one copy of the wild type allele in 
normal life but during pregnancy the liver is challenged and can no longer prevent 
cholestatic disease. Serum levels and urinary excretion of estrogens and their 
metabolites increase dramatically in pregnancy and have been shown to cause 
cholestasis (Green et al, 2000; Meyers et al, 1981). Studies have also demonstrated 
that mono-sulfated and disulfated progesterone metabolites are increased in pregnant 
women (Sjovall & Sjovall, 1970). A study by Vallejo et al demonstrated that a 
glucuronidate estrogen metabolite and a sulfated progesterone metabolite are both 
secreted into bile and they cause a reduction in bile flow and bile acid output in 
perfused rat liver (Vallejo et al, 2006). Hence, it is possible that women with only 
one copy of the wildtype allele could be more prone to cholestasis due to the 
increased burden on the liver from raised concentrations of estrogen and 
progesterone during pregnancy. 
FXR variants may also be implicated in the formation of gallstone disease. The 
susceptibility to gallstone formation is mainly determined by the relative 
concentrations of cholesterol, bile salts and phospholipids in bile. In the UK cohort, 6 
OC cases with FXR variants had symptomatic gallstones, and another 5 had a family 
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history of gallstones.  It is likely that either low bile acid or phospholipid 
concentrations in bile, as a consequence of reduced BSEP or MDR3 expression 
respectively, will result in supersaturation of cholesterol in these patients and their 
relatives due to reduced FXR function or expression.  Furthemore, there are several 
studies that show increased frequency of gallstones in pregnancy (Ko et al, 2005; 
Maringhini et al, 1993; Tsimoyiannis et al, 1994).  Gallstones in pregnant women are 
commonly asymptomatic, although 28% of cases with stones in an Italian study 
complained of biliary pain (Maringhini et al, 1993). Gallstones may co-exist with 
ICP, and this is likely to be because both conditions have shared genetic predisposing 
factors. Interestingly, ileal biopsies of non-obese women with cholesterol gallstone 
disease showed decreased FXR, IBABP and ASBT protein and mRNA levels, 
indicating that reduced FXR expression plays a role in human cholesterol gallstone 
disease (Bergheim et al, 2006). Furthermore, Fxr null mice fed a lithogenic diet for 1 
week showed turbid gallbladder and large aggregates of cholesterol precipitates, 
which was reversed when a synthetic Fxr ligand was given (Moschetta et al, 2004). 
This suggests that variants in FXR could be associated with cholesterol gallstone 
disease in women with co-existing ICP. The demonstration of ICP-associated 
variants that might reduce FXR function in affected women has clinical and 
scientific implications. Our data suggest that FXR variants play a role in ICP and 
could be of relevance to the aetiology of other cholestatic diseases.  
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4 Chapter 4                                                              
Influence of Reproductive Hormones on Bile Acid 
Homeostasis 
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4.1 Introduction 
The aetiology of ICP is multi-factorial and in Chapter 3, functional genetic variation 
in the principal bile acid sensor FXR was reported for the first time in an ICP 
population. While the evidence for a genetic component in the aetiology of ICP is 
compelling, only a relatively small number of cases can be attributed to genetic 
variation.  
There is human evidence that reproductive hormones may influence the aetiology of 
ICP. The disease is more common amongst twin pregnancies, where reproductive 
hormones levels are higher than in singleton pregnancies (Gonzalez et al, 1989; 
Reyes, 1997). Furthermore, individuals that have had the disease are at subsequent 
risk of developing cyclical cholestasis outside of pregnancy and can develop 
cholestasis when taking oral contraceptives or hormone replacement therapy (de 
Pagter et al, 1976). As a result of these observations, a number of reports have 
investigated the effects of reproductive hormones on bile acid responsive genes in 
rodents. The data indicate that estrogen reduces the expression of hepatic bile acid-
responsive transporter genes (summarized in table 4.1). These findings suggest that 
elevated levels of circulating estrogen during pregnancy could cause pro-cholestatic 
hepatic gene expression and increase the risk of pre-disposed individuals developing 
gestational cholestatic disease.  
This chapter will address the effects of reproductive hormone treatment on hepatic 
bile acid-responsive gene expression. The effects of administering the synthetic 17α-
ethinylestradiol (EE2) will be compared to the effects of administering physiological 
17β-estradiol (E2). Furthermore, acute responses will be compared to chronic 
exposure to estrogen. Finally, the models of Milligan and Cohen will be used to 
deliver pregnancy-levels of reproductive hormones to mice over a time course 
similar to that of gestation and the role of Fxr in mediating these effects will be 
investigated.  
Chapter 4                                                                                                                                         Results 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     116 
Table 4. 1: Influence of estrogen on hepatic gene expression and bile output 
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4.2 Results  
 
4.2.1 A commonly used vehicle (peanut oil) significantly affects 
the hepatic expression of bile acid-responsive genes. 
The effect of estrogen on hepatic bile acid transporter gene expression has been 
investigated in a number of studies (Table 4.1). However, these results are difficult to 
interpret because of a lack of consistency on the dose time course, isomer of estrogen 
administered or the species and sex of the rodent used (Table 4.1). The effect of 
some of these inconsistencies will be investigated here.  
Age and weight matched female C57bl/6 mice were ovariectomised and allowed to 
recover for 14 days. The mice were subsequently divided into groups that would 
receive estrogen treatment for one or five days. Animals received a daily 
subcutaneous injection of estrogen dissolved in a commonly used vehicle, peanut oil, 
or an equal volume of the vehicle alone. The synthetic estrogen 17α-ethinylestradiol 
(EE2) and the physiological isomer 17β-estradiol (E2) were administered at a dose of 
10µg/g/day (Table 4.1). In addition, E2 was administered at another lower, more 
physiologically relevant, dose of 5µg/g/day. RT-QPCR was used to determine the 
gene expression of hepatic bile acid-responsive genes including nuclear hormone 
receptors, bile acid transporters and bile acid biosynthesis enzymes. These genes 
were the bile acid responsive nuclear receptors Fxr and Pxr, the bile acid exporter 
Bsep, the bile acid importer Ntcp and two key genes in the pathway of bile acid 
biosynthesis Cyp7a1 and Cyp8b1. While many other proteins are required to 
maintain bile acid homeostasis, these genes are sufficient to provide an indication of 
whether bile acid homeostasis is affected by a particular treatment and whether the 
effect is pro-cholestatic. 
By comparing mice that received injections for one-day and for five-days, it was 
found that the administration of vehicle alone has a significant effect on hepatic bile 
acid-responsive gene expression (Figure 4.1). Compared to the level of expression at 
one-day, five-days of vehicle treatment significantly reduced the expression of the 
nuclear receptors Fxr (1.3-fold) and Pxr (2.4-fold). Furthermore, the expression of 
the bile acid transporters Bsep and Ntcp were also significantly lower following five 
days of peanut oil administration than following one day of injections. The effect of 
vehicle treatment was also determined on the expression of bile acid biosynthesis 
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enzymes. Strikingly, the expression of Cyp7a1, the rate-limiting enzyme in bile acid 
biosynthesis, was 8-fold lower following 5-days of peanut oil administration 
compared to at one-day. In contrast to Cyp7a1, the expression of Cyp8b1, which 
preferentially synthesizes CA over CDCA, was increased 80-fold in the five-day 
injected group compared to the one-day group. These findings clearly demonstrate 
that administration of peanut oil by subcutaneous injection has a major effect on 
hepatic bile acid-responsive gene expression. Peanut oil seems to have a pro-
cholestatic effect of some genes (Fxr, Pxr and Bsep) and an anti-cholestatic effect on 
others (Cyp7a1 and Ntcp). The magnitude of change in gene expression caused by 
peanut oil may hamper the correct interpretation of the effect of estrogen 
administration on these genes.   
Chapter 4                                                                                                                                         Results 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     119 
 
Figure 4.1: Vehicle (peanut oil) significantly effects the expression of bile acid-
responsive nuclear receptors, hepatic transporters and bile acid biosynthesis 
enzymes.  
Wild type mice were ovariectomised and injected with 100 µl of peanut oil for 1 day 
or 5 days. The relative levels of expression of Fxr, Pxr, Bsep, Ntcp, Cyp7a1 and 
Cyp8b1 genes were quantified RT-QPCR. The expression level of each gene shown 
is normalized against the expression of L-19 and each bar represents the combined 
average expression of that gene for five animals. Results are shown as mean ±S.E.M. 
(n=5) *p<0.05 compared to 1-Day treated animals. Two-tailed Student’s t test was 
used to determine differences between data groups. 
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4.2.2 The dose, duration of treatment and isomer of estradiol 
administered differentially affect hepatic bile acid-
responsive genes.   
Next, the effect of administering EE2 was compared to that of E2. Both EE2 and E2 
were administered at a dose of 10µg/g/day. Following five days of administration, 
the affect of EE2 and E2 on Fxr, Pxr, Bsep, Ntcp was relatively small (Figure 4.2). In 
contrast, when gene expression was determined after one-day, EE2 significantly 
repressed the expression of Fxr (2.2-fold), Bsep (2.8-fold) and Ntcp (1.2-fold). 
Administration of E2 for one-day also repressed the expression of Fxr, Bsep and Ntcp 
but these effects did not reach statistical significance. These findings demonstrate 
that acute, high doses of EE2 and E2 have similar effects on the expression of Fxr, 
Bsep and Ntcp but they are not maintained following longer-term administration.  
While the effect of estrogen on the expression of Fxr, Pxr, Bsep and Ntcp was 
relatively small, the effect on the expression of bile acid biosynthesis enzymes was 
more marked. Following one-day of treatment, both EE2 and E2 decrease the 
expression of Cyp7a1 (70-fold and 6-fold respectively) and increased the expression 
of Cyp8b1 (11-fold and 10-fold respectively) (Figure 4.2). However, at the five-day 
time point, the level of Cyp7a1 and Cyp8b1 was similar to vehicle and EE2 treated 
mice. Furthermore, despite being repressed compared to vehicle at one-day, the 
expression of Cyp7a1 was significantly higher in E2 treated mice than vehicle treated 
mice following five days of administration. Finally, Cyp8b1 was induced by E2 
treatment for one-day and repressed upon five days of administration. These data 
demonstrate that while both EE2 and E2 influence the expression of bile acid 
biosynthesis enzymes, the effect is time dependent because five-days of treatment 
was markedly different to one-day of treatment. Furthermore, the significant vehicle 
effect could be influencing the response of these genes to estrogen administration.  
Finally, the effect of a high 10µg/g/day and low 5µg/g/day dose of E2 was compared. 
The low dose can be considered more physiologically relevant and has been used by 
a number of studies (Table 4.1). There was no difference in the expression of Fxr, 
Pxr or Bsep between high and low dose of E2 at the one-day or five-day time point 
(Figure 4.2). In contrast, the level of Ntcp was higher following a low dose of E2 
after five days of treatment. The high and low dose of E2 had a similar effect on 
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Cyp7a1 and Cyp8b1 expression at the one-day time point, but this was less marked 
with the low dose. In addition, both the high and low doses of E2 similarly increased 
the expression of Cyp7a1 compared to vehicle after five days of treatment. 
Interestingly, five days of treatment with the low dose of E2 repressed Cyp8b1 90-
fold whereas the high dose only repressed its expression 2-fold. Taken together, 
these data demonstrate that the high and low doses of E2 have similar effects on the 
expression of the genes investigated here. However, as it is evident from the 
expression of Cyp8b1, the magnitude of effect was not consistently greater with the 
high dose of E2.  
In summary, subcutaneous injection experiments were conducted on ovariectomised 
females in order to determine the effect of estrogen on hepatic bile acid responsive 
gene expression. The results of these experiments have revealed marked vehicle 
effects on the expression of these genes. In many cases, the vehicle effect was 
significantly greater than any effect caused by the reproductive hormone treatment. 
Furthermore, differential effects on gene expression were found between one and 
five-days of treatment, between EE2 and E2 and between a high and low dose of E2. 
Together, these findings indicate that bile acid-responsive genes are differentially 
affected by the length, dose and isomer of estrogen administration. 
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Figure 4.2: Bile acid-responsive genes are differentially affected by the length, 
dose and isomer of estrogen administration. 
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Wild type mice were ovariectomised and injected with 100µl of peanut oil alone 
(vehicle), or with oil containing the synthetic 17α-ethinylestradiol (EE2) or 17β-
estradiol (E2). Mice were also injected with a low dose of E2 for 1 day or 5 days. 
Relative levels of expression of the genes were quantified using RT-QPCR. The 
expression level of each gene shown is normalized against the expression of L-19 
and each bar represents the combined average expression of that gene for 5 animals. 
*p<0.05 compared to vehicle treated animals. Two-tailed Student’s t test was used to 
determine differences between data groups. 
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4.2.3 Vehicle-effect is eliminated by delivering reproductive 
hormones by silastic implants 
Silastic implants have been used successfully to deliver doses of reproductive 
hormones that are capable of maintaining pregnancy in post-mating ovariectomised 
animals (Cohen & Milligan, 1993; Milligan & Finn, 1997). One advantage of using 
silastic implants to deliver reproductive hormones is that the peanut oil remains in 
the implant and this should therefore eliminate the vehicle effects that were observed 
following subcutaneous injection.  
In a preliminary experiment, potential vehicle effects were investigated in the silastic 
implant model. To this end, age and weight matched female mice were 
ovariectomised, allowed to recover for 14 days and implanted with subcutaneous 
silastic implants containing peanut oil. The expression of hepatic bile acid-responsive 
genes was determined by RT-QPCR following one-day or 18 days. As expected, the 
expression of Fxr, Pxr, Bsep, Ntcp, Cyp7a1 and Cyp8b1 was similar following one-
day and 18days of vehicle treatment (Figure 4.3). Therefore, using the silastic 
implants for delivering the hormones, eliminates the vehicle effect on these bile acid-
responsive genes. 
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Figure 4.3: Vehicle effect is eliminated by use of silastic implants. 
Wild type mice were ovariectomised and either implanted with silastic implants 
containing 100µl of peanut oil for 1- or 18-days. The relative levels of expression of 
the genes were quantified using RT-QPCR. Results are shown as mean ±S.E.M. 
(n=5). 
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4.2.4 Physiologically relevant doses of reproductive hormones 
significantly affect hepatic gene expression 
Silastic implants were used to deliver pregnancy levels of 17β-estradiol and 
progesterone to non-pregnant, ovariectomised mice at pregnancy levels for 18 days. 
This model was used in order to investigate the effect of pregnancy levels of 
reproductive hormones on the maternal liver without the other confounding factors of 
gestation, such as fetal and placental metabolites and altered endocrine environment.  
As expected, all animals that received the reproductive hormone implants displayed 
significant uterine swelling, demonstrating that the hormone treatment was effective 
(Cohen & Milligan, 1993). Hepatic microarrays were used to determine the genome-
wide gene expression effects of 17β-estradiol (E2) and progesterone (Pn) on the liver.  
Data from Affymetrix microarrays were processed using the Rosetta Resolver 
software suite for microarray analysis. Principal component analysis (PCA) on the 
whole data set demonstrates that vehicle treated mice separate from E+Pn treated 
mice along principal component 1 without overlap or outliers (Figure 4.4A). The 
PCA analysis demonstrates that the hormone treatment has a greater effect on liver 
transcription than inter-individual differences between animals.  
In subsequent analysis, liver-expressed genes that are affected >2-fold (p<0.01) by 
the hormone treatment were identified and subjected to hierarchal clustering. The 2D 
cluster again demonstrates that samples from vehicle and E+Pn treated mice cluster 
according to treatment group (Figure 4.4B). In addition, the 2D cluster identifies sub-
sets of genes that are up-regulated or down-regulated by the reproductive hormone 
treatment. For complete lists of genes changed by E+Pn see Appendix IV. 
Canonical pathway analysis was performed in order to identify metabolic pathways 
significantly affected by the hormone treatment. Because several small changes in 
gene expression can have a significant effect on the output of a metabolic pathway, a 
fold-change cut-off was not applied for this analysis. Rather, all genes significantly 
(p<0.01) affected by the hormone treatment were subjected to pathway analysis, 
these genes form the “query” bio-set. The query bio-set is compared to a “reference” 
bio-set which contains the genes known to function in a particular metabolic 
pathway. A p-value is assigned based on whether genes in the query bio-set are 
statistically over-represented in the reference bio-set. All metabolic pathways over-
represented in the hormone treated samples are presented in Figure 4.4C. As 
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expected, both Androgen And Estrogen Metabolism and C21-Steroid Hormone 
Metabolism are the most over represented metabolic pathways in the liver of E+Pn 
treated mice (Figure 4.4C).  
The microarray analysis identified Cldn1 and Igfbp1 as genes that were significantly 
repressed and significantly induced by the reproductive hormone treatments (Figure 
4.4D). These effects were some of the changes confirmed by RT-QPCR, 
demonstrating that the results of the microarray can be confirmed using a different 
technology.  
These supervised and unsupervised analysis of hepatic microarray data have 
demonstrated that treatment with physiological levels of reproductive hormone have 
a significant effect on overall, and pathway-specific, hepatic gene expression.  
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Figure 4. 4: Administration of estrogen and progesterone via silastic implants 
significantly affects hepatic gene expression. 
Mice were treated with implant containing vehicle or E+Pn and sacrificed following 
18-days. Hepatic microarrays were conducted and the data analysed using Rosetta 
Resolver software package. (A) Principal component analysis (PCA) demonstrating 
separation of vehicle and E+Pn treated samples. (B) 2-D hierarchal clustering of 
genes affected >2-fold, p<0.01. Red indicates samples above the mean level of 
expression and green denotes samples below the mean level of expression. (C) 
Canonical pathway analysis of metabolic pathways significantly over-represented by 
the effects of E+Pn (p>0.01). (D) RT-QPCR confirmation of array data, *p<0.01 
compared to vehicle treated. n=5. 
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4.2.5 Hepatic bile acid-responsive genes are affected by 
physiologically relevant reproductive hormone treatment 
Data presented in this chapter have demonstrated that estrogen, administered by 
subcutaneous injection, can affect the hepatic expression of bile acid-responsive 
genes. However, these effects may be complicated by significant vehicle effects. In 
addition, it was demonstrated that physiologically relevant doses of reproductive 
hormones delivered by silastic implants affect liver transcription with apparently 
minimal vehicle effect. The hepatic expression of bile acid-responsive genes was 
determined in the silastic implant experiment. For direct comparison with the 
injection experiments, the expression of the same six genes are presented in Figure 
4.2 and Figure 4.5. The E+Pn treatment had no effect on the expression of Fxr or 
Ntcp (Figure 4.5). By contrast, Pxr was up regulated (1.3-fold) and Bsep, Cyp7a1 
and Cyp8b1 were repressed (1.2, 1.9 and 1.9-fold, respectively) (Figure 4.5). 
Therefore, physiologically relevant doses of reproductive hormones, delivered by 
silastic implants over 18-days have pro-cholestatic (repression of Bsep) and anti-
cholestatic (repression of Cyp7a1 and induction of Pxr) effects on the liver. It is 
noted the magnitude of effect on the expression of these genes was relatively small 
(less than 2-fold).  
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Figure 4.5: Delivery of E+Pn for 18-days via silastic implants has some effect on 
hepatic bile acid responsive genes. 
Wild type mice were ovariectomised and either implanted with 100µl of peanut oil 
(vehicle), or implanted with both E2 and Pn (E+Pn) for 18 days. The relative levels 
of expression of the genes shown were quantified using RT-QPCR. Results are 
shown as mean ±S.E.M. (n=5) *p<0.05 compared to vehicle treated. Two-tailed 
Student’s t test was used to determine differences between data groups. 
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4.2.6 Fxr is not required to mediate the majority of the hepatic bile 
acid-responsive gene expression effects of reproductive 
hormones 
FXR directly and indirectly regulates the expression of a number of bile acid-
responsive genes, including Pxr, Bsep, Ntcp, Cyp7a1 and Cyp8b1. To investigate 
whether the effect of reproductive hormones on these bile acid-responsive genes was 
maintained in the absence of Fxr, the silastic implant experiment was conducted in 
Fxr-/- mice. The effects of hormone treatment on the expression of Pxr, Bsep and 
Cyp7a1 observed in wild-type mice were maintained Fxr-/- mice (Figure 4.6). In 
addition, Cyp8b1 was also repressed by E+Pn in both wild type and Fxr-/- mice but 
the effect did not reach statistical significance in the knockout animals (Figure 4.6). 
Therefore, the effect of reproductive hormones on the expression of these bile acid-
responsive genes is maintained in the absence of Fxr.  
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Figure 4.6: The effect of E+Pn on bile acid responsive genes are broadly 
maintained in Fxr-/- mice. 
Wild type and Fxr-/- mice were ovariectomised and either implanted with 100µl of 
peanut oil (vehicle), or implanted with both E2 and Pn (E+Pn) for 18 days. The 
relative levels of expression of the genes shown were quantified using RT-QPCR. 
Results are shown as mean ±S.E.M. (n=5 for WT and n=4 for Fxr-/-) *p<0.05 
compared to vehicle. Two-tailed Student’s t test was used to determine differences 
between data groups. 
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4.2.7 Differential effects of reproductive hormones on hepatic 
gene expression in wild type and Fxr-/- mice.  
While Fxr is not required to mediate the effects of reproductive hormones on sub-sets 
of bile acid responsive genes, it is possible that global gene expression is 
differentially affected by E+Pn in wild-type and Fxr-/- mice. To address this 
possibility, microarray data from Fxr-/- mice treated with E+Pn were compared to the 
array data generated in wild-type animals.     
Preliminary analyses demonstrated that the E+Pn treated samples separated from 
vehicle treated sample in PCA analysis of the Fxr-/- mice. A Venn diagram was 
generated to compare the genes affected (>2-fold, p<0.01) by the hormone treatment 
in wild type and in Fxr-/- mice (Figure 4.7). Fewer genes were affected in the Fxr-/- 
mice (44 genes) than in the wild-type mice (80 genes) (Lists of genes in Appendix 
IV). This could be due to the fact that only 4 mice were used per group for the Fxr-/- 
mice compared to 5 mice for the wild-type animals, resulting in fewer genes having a 
statistically significant effect.  
In the Fxr-/- mice, 2D clustering was performed on genes affected 2-fold (p<0.01) 
and demonstrated that the samples form vehicle-treated mice clustered together, as 
did the samples from E+Pn treated mice (Figure 4.7). Additionally, the cluster 
demonstrates that several genes affected by the hormone treatment in the wild-type 
mice were similarly affected in the Fxr-/- mice.   
Large sub-sets of genes were identified from the Venn diagram that were affected by 
the reproductive hormone treatment in wild-type but not in Fxr-/- mice. It is also 
possible that Fxr is required to mediate the reproductive hormone effects on the 
expression of sub-sets of genes. To investigate this possibility, canonical pathway 
analysis was conducted in the wild type and Fxr-/- mice and it was found that a 
number of pathways significantly affected in the wild type mice were not affected in 
the Fxr-/- animals. While greater inter-individual variability can account for a number 
of these pathways, it is noteworthy that the most affected pathway in the normal 
mice, namely Androgen and Estrogen Metabolism, was not significantly over 
represented in the Fxr-/- mice (Table 4.2), suggesting that Fxr is required for the 
reproductive hormone effects of this pathway. Table 4.3 shows the genes in the 
pathway of Androgen And Estrogen Metabolism that are affected by the reproductive 
hormone treatment in wild type animals. Table 4.4 shows the genes in the pathway of 
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Androgen And Estrogen Metabolism that are affected by the reproductive hormone 
treatment in Fxr-/- animals. Table 4.3 and Table 4.4 suggest that Fxr is required to 
mediate the effects of reproductive hormones on the expression of hepatic genes 
involved in Androgen And Estrogen Metabolism.   
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Figure 4.7: Microarray analysis demonstrates differential hepatic effects of 
E+Pn in wild type and Fxr-/- mice. 
(A) Venn diagrams of number of genes affected by E+Pn treatment in wild-type and 
Fxr-/- mice. (B) 2D cluster of genes affected >2-fold, p<0.01 by E+Pn in Fxr-/- mice. 
Red denotes genes expressed above the mean and green denotes genes expressed at a 
level below the mean. Gene symbols highlighted in red were also similarly affected 
in wild type mice. (n=4) 
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Table 4.2: The pathway of Androgen and Estrogen metabolism is significantly 
affected in the liver of wild-type mice treated with E+Pn but not in the liver of 
Fxr-/- mice treated with E+Pn.   
Wild Type   Fxr -/-  
     
Pathway Name P-value Pathway Name P-value 
Androgen and estrogen 
metabolism 1.8243E-12 Arachidonic acid metabolism 3.52E-05 
C21-Steroid hormone metabolism 2.0333E-12 Stilbene, coumarine and lignin biosynthesis 3.10E-04 
Arachidonic acid metabolism 7.5757E-07 C21-Steroid hormone metabolism 4.01E-04 
Stilbene, coumarine and lignin 
biosynthesis 4.5880E-05 Phenylalanine metabolism 5.59E-04 
Phenylalanine metabolism 1.1046E-04 Pyrimidine metabolism 2.54E-03 
Pyruvate metabolism 3.6308E-04 Purine metabolism 8.98E-03 
Nitrogen metabolism 4.0415E-03   
Galactose metabolism 4.5953E-03   
Fatty acid metabolism 5.2924E-03   
Glycerolipid metabolism 9.0160E-03   
Biosynthesis of vancomycin 
group antibiotics 9.2366E-03   
 
 
Chapter 4                                                                                                                                         Results 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     137 
Table 4.3: Genes of the Androgen and Estrogen Metabolism pathway 
significantly affected by E+Pn treatment in wild type mice.  
Primary Sequence 
Name 
Sequence Description Fold 
Change 
Gale galactose-4-epimerase, UDP -2 
Akr1b7 aldo-keto reductase family 1, member B7 2 
Cyp8b1 cytochrome P450, family 8, subfamily b, polypeptide 1 -2 
Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1 2.5 
Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 2.5 
Wwox WW domain-containing oxidoreductase -2.5 
 
Table 4.4: Genes of the Androgen and Estrogen Metabolism pathway 
significantly affected by E+Pn treatment in Fxr-/- mice.  
 
Primary Sequence 
Name 
Sequence Description 
Fold Change 
Cyp2c39 cytochrome P450, family 2, subfamily c, polypeptide 39 -23 
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4.2.8 There is little evidence that reproductive hormones activate 
Fxr.   
A targeted analysis of the microarray data was conducted in order to determine 
evidence of Fxr-activation in response to reproductive hormone treatment. While a 
number of direct and indirect Fxr-target genes were affected by the E+Pn treatment 
in wild type animals, there was not a consistent pattern of Fxr-activation. For 
example, while one Fxr-target gene Shp is induced (1.6-fold) by E+Pn, another Fxr-
target, Bsep, is repressed (1.2-fold). These findings suggest that while E+Pn 
treatment may activate Fxr to some extent, this can only be explained if the effect is 
target-gene dependent. 
In wild type mice, repression of Cyp7a1 by E+Pn is consistent with the induction of 
Shp (Figure 4.8). However, in mice lacking Fxr, E+Pn represses Cyp7a1 with no 
effect on Shp gene expression (Figure 4.8). This finding demonstrates that the 
reproductive hormone effects on the expression of Cyp7a1 are both Shp and Fxr 
independent.   
Well-characterised Fxr target genes display a reproducible pattern of expression. 
These genes are basally repressed in Fxr-/- mice and are not induced in these animals 
in response to treatment with Fxr ligands (Moschetta et al, 2004). Shp displays this 
pattern of expression following the reproductive hormone treatment administered 
here but the Fxr-dependent induction of Shp in response to reproductive hormones 
does not subsequently cause Fxr-dependent repression of Cyp7a1 or Ntcp, suggesting 
that the E+Pn effects on these genes are, indeed Fxr and Shp independent.  
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Figure 4.8: Potential role for Fxr in the E+Pn-mediated repression of hepatic 
Cyp7a1. 
Wild type and Fxr-/- mice were ovariectomised and either implanted with 100 µl of 
peanut oil (vehicle), or implanted with both E2 and Pn (E+Pn) for 18 days. Hepatic 
mRNA expression of Shp and Cyp7a1 in wild type and Fxr-/- mice following vehicle 
and E+Pn treatment. (n=5 for WT and n=4 for Fxr-/-) *p<0.05 compared to vehicle. 
#p<0.05 compared to wild type. 
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4.3 Summary and Conclusions 
There is evidence that reproductive hormones contribute to the aetiology of ICP. For 
these reasons, several studies have investigated the effects of estrogen administration 
on hepatic bile acid responsive gene expression (Table 4.1). These studies have 
found that estrogen represses the expression of hepatic transporter gene expression in 
an apparently pro-cholestatic manner. High levels of circulating estrogen during 
pregnancy have therefore been suggested to increase the risk of susceptible 
individuals of developing gestational cholestatic disease. However, these studies 
have a number of weaknesses, some of which were initially investigated in this 
chapter.  
17β-estradiol is a natural occurring estrogen that is rapidly metabolised and excreted. 
As a result, three approaches are commonly used to increase the longevity of the 
hormone in the serum. First, the synthetic estrogen 17α-ethinylestradiol is often 
administered because it is metabolised more slowly than the natural estrogen isomer 
17β-estradiol. Second, the hormone is usually administered by subcutaneous 
injection, suspended in peanut oil, rather than delivered to the peritoneum in solution. 
Finally, very high doses of estrogen are administered, usually by daily injection over 
a number of days. Data presented in this chapter clearly demonstrate that altering 
these experimental conditions can have a major effect on the outcome of the 
experiment and potentially cast doubt on the interpretation of studies administering 
estradiol in this manner.  
Initially, it was shown here that vehicle alone can have a greater effect on hepatic 
bile acid-responsive gene expression than the hormone treatment itself. In published 
reports on the effect of reproductive hormones on the liver, there have been no 
comments on the potential vehicle effects. The vehicle used here was the same as 
that used in a number of other studies, peanut oil (Crocenzi et al, 2005; Yamamoto et 
al, 2006). In this chapter, a total of 100µl of vehicle was injected each day and 
evidence from the limited number of genes assayed by RT-QPCR suggests that this 
regimen has a significant effect on liver metabolism. Given that bile acids are the 
product of hepatic cholesterol catabolism and that lipids are ligands of receptors that 
control the pathway of cholesterol biosynthesis such as PPARα, it is perhaps not 
surprising that injection of peanut oil affects hepatic genes involved in bile acid 
homeostasis. Because the vehicle effect was so marked, it is possible any effect 
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caused by reproductive hormone treatment will be masked, or at least difficult to 
interpret.   
In subsequent experiments, the effects of two isomers of estrogen on hepatic bile 
acid responsive gene expression were compared, as were two concentrations of 17β-
estradiol. It was found that specific gene expression effects of 17α-ethinylestradiol 
were not maintained when 17β-estradiol was administered at the same dose. In 
addition, the effects of administering a high dose of 17β-estradiol were not 
maintained when a lower, more physiologically relevant dose was injected. Finally, it 
was found that acute responses to one-day of treatment with estrogen were not 
maintained following five-days of administration. Despite the fact that only the 
expression of six genes was assessed (two nuclear receptors, bile acid transporters 
and biosynthesis enzymes); this is a greater number of genes than studied in the 
majority of reports. A number of published findings were replicated in this study, 
namely the repression of Bsep and Ntcp by one-day treatment with 17α-
ethinylestradiol (Geier et al, 2003; Green et al, 2000; Simon et al, 2004; Yamamoto 
et al, 2006). Specific conclusions on the effect of estrogen, when delivered by 
injection, have been avoided in this chapter because of the marked effects of vehicle, 
dose, time course and isomer of estrogen administered. Indeed, these finding call in 
to question the conclusions drawn by a number of reports that conclude that estrogen 
has pro-cholestatic hepatic gene expression effects. The pattern of gene expression 
presented here is not robust enough between treatments to conclude that estardiol has 
either pro- or anti-cholestatic effects on the liver. Together, these findings 
demonstrate that administration of estrogen by subcutaneous injection is not a 
reliable method for determining the effects of reproductive hormones during 
pregnancy on hepatic bile acid responsive genes. 
The silastic implant models of Miligan and Cohen (Cohen & Milligan, 1993; 
Milligan & Cohen, 1994; Milligan & Finn, 1997) are more promising for the 
investigation of the effects of pregnancy levels of reproductive hormones on hepatic 
bile acid homeostasis. The vehicle used for the implants was the same as the 
injections but it remained within the implants and therefore, unlike the injections, did 
not affect hepatic gene expression. Hepatic microarrays were conducted on E+Pn 
treated wild type mice and revealed that pregnancy levels of reproductive hormones 
have a significant effect on global, and pathway-specific, gene expression. This 
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result demonstrates that the liver is a reproductive hormone responsive tissue. The 
pathway of androgen and estrogen metabolism was the most over-represented 
pathway in the E+Pn treated mice. Because cholesterol serves as a precursor to the 
pathway of both bile acid biosynthesis and androgen and estrogen metabolism, this 
finding suggests that reproductive hormones could affect bile acid biosynthesis. 
However, while a number of the genes involved in androgen and estrogen 
metabolism are expressed in the liver, and hence included in these analyses, it is not 
known whether these genes have a functional role in the liver. Future experiments 
using liver microsomes are required to determine the ability of the liver to conduct 
key reactions in steroidogenesis, and the effect of pregnancy levels of reproductive 
hormones on these reactions.  
Targeted gene expression analysis demonstrated that the expression of bile acid 
responsive genes (Pxr, Bsep, Ntcp, Cyp7a1 and Cyp8b1) were affected by the 
physiologically relevant reproductive hormone implant treatment. The effects on the 
expression of these bile acid-responsive genes was relatively small however and the 
biological significant of the magnitude of these changes are not known. The 
magnitude of effect was also considerably smaller than many of the changes caused 
by injection of estradiol and there was again no pattern for pro- or anti-cholestatic 
gene expression in the E+Pn treated mice. The implant model is designed to mimic 
the reproductive-hormone state of pregnancy, but it is possible that pregnancy-
specific reproductive hormone metabolites could be pro-cholestatic. In addition, fetal 
or placental metabolites could sensitise the maternal liver to the pro-cholestatic 
action of these reproductive hormones. Despite the fact that the genes presented in 
this section are direct or indirect targets of Fxr, it was found that the effect of 
reproductive hormones on their expression was largely maintained in mice lacking 
Fxr. Therefore, the bile acid receptor Fxr is not required to maintain the effects of 
pregnancy-levels of reproductive hormones on the expression of hepatic Pxr, Bsep, 
Ntcp, Cyp7a1 or Cyp8b1. It is possible that other nuclear receptors, for example the 
estrogen receptor (ER) could be mediating these gene expression effects, but there 
are no data presented here, or in the literature, to support this suggestion.  
Microarrays were performed on Fxr-/- mice treated with the reproductive hormone 
implants. The array data were used in two ways. First, to compare the global gene 
expression effects of reproductive hormones in wild type and Fxr-/- mice. Second, to 
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screen all hepatic genes for evidence of Fxr-activation by reproductive hormones. 
The reproductive hormones in wild type and Fxr knockout animals differentially 
affected sub sets of genes. This could be due to greater inter-individual variation in 
the Fxr-/- mice that would, in unsupervised analysis with a p-value cut-off, cause 
misinterpretation of the data. However, it was found that the pathway of androgen 
and estrogen metabolism was the most affected pathway in the wild-type mice but 
was not significantly affected by the reproductive hormones in the Fxr-/- mice. 
Indeed, the level of significance of this pathway in the wild type mice suggests that 
Fxr is required to mediate the gene expression effects of reproductive hormones on 
the this pathway. Determining whether this is the case should be an area of future 
work.  
A reproductive hormone-responsive Fxr target gene is expected to be basally 
repressed in Fxr-/- mice and induced upon hormone treatment in wild type but not 
Fxr-/- mice. Analysis of the array data identified only one example of such a gene, the 
known Fxr target Shp. However, as discussed above, other known Fxr targets were 
not induced by the reproductive hormone treatment. In addition, despite Fxr being 
required for the reproductive hormone-mediated induction of Shp, the repression of 
Cyp7a1 occurred in response to hormones in both wild type and Fxr-/- mice. This 
finding suggests that either the induction of Shp in the wild type mice has no 
functional effect or that the repression of Cyp7a1 occurs by Shp-independent 
mechanisms.  
No consistent pro-cholestatic gene expression effects or any conclusive evidence for 
Fxr-activation were found in response to reproductive hormone treatment. 
Reproductive hormones alone are therefore unlikely to be the primary signal causing 
pro-cholestatic gene expression during pregnancy. However, there is human evidence 
that some individuals do develop cyclical cholestasis or cholestasis while taking oral 
contraceptives (de Pagter et al, 1976). The data presented in this chapter strongly 
indicate that these effects could be due to specific levels of circulating reproductive 
hormones or the length of exposure to them. Furthermore, alterations in diet or 
diurnal cycles during the menstrual cycle or while taking oral contraceptives could 
contribute to disturbing the entero-hepatic circulation of bile acids without direct 
effect of reproductive hormones on the liver. In addition, it was found that the 
hormones had a significant effect on liver metabolism. It remains possible therefore, 
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that in combination with other circulating factors during pregnancy such as fetal and 
placental metabolites, reproductive hormones could form a component of signal that 
causes abnormal bile acid homeostasis during pregnancy.  
The findings presented in this chapter are important because they show that 
information on the role of reproductive hormones on liver metabolism has been 
based on experiments conducted using methods that may not be reliable. Further 
work is clearly needed to understand the role of reproductive hormones in the 
aetiology of ICP.  
 
  
 
 
 
 
 
 
5 Chapter 5                                                             
Reduced FXR Function May Account for Bile Acid 
Accumulation during Pregnancy 
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5.1 Introduction 
Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease of 
pregnancy (Abedin et al, 1999; Heinonen & Kirkinen, 1999) and is characterised by 
liver impairment, raised maternal serum bile acids and pruritus. It is associated with 
fetal distress, spontaneous prematurity and unexplained intrauterine death 
(Laatikainen & Tulenheimo, 1984; Reid et al, 1976; Reyes, 1982; Rioseco et al, 
1994; Williamson et al, 2004). ICP resolves spontaneously after delivery but affected 
individuals are at subsequent risk of developing liver diseases such as gallstones, 
non-alcoholic fatty liver disease and cholecystitis (Ropponen et al, 2006). The 
aetiology and pathogenesis of ICP are poorly understood. 
Bile acids are synthesised in the liver via a multi-enzymatic process. Bile is required 
for the solublisation and absorption of dietary fat and fat-soluble vitamins and is the 
major route of cholesterol elimination (Russell, 2003). Bile acids affect hepatic and 
systemic triglyceride, cholesterol, energy and glucose homeostasis (Ma et al, 2006; 
Watanabe et al, 2006; Watanabe et al, 2004; Yamagata et al, 2004; Zhang & 
Edwards, 2008). Due to their intrinsic toxicity, bile acid biosynthesis and transport is 
tightly regulated. Bile acids also regulate their own biosynthesis (Russell, 2003).  
Bile acid responsive nuclear receptors display considerable redundancy but FXR is 
required for the basal maintenance of the enterohepatic circulation and the hepatic 
response to cholestatic challenge (Kok et al, 2003; Sinal et al, 2000). Bile acid-
activated Fxr directly induces the hepatic bile acid exporters BSEP and MDR3 
(Ananthanarayanan et al, 2001; Plass et al, 2002) as well as the sulphating enzyme 
SULT2A1 and glucuronidation enzyme UGT2B4 (Barbier et al, 2003; Echchgadda et 
al, 2004)). FXR indirectly represses the expression of the bile acid importer NTCP 
(Denson et al, 2001) and the synthesis enzyme CYP7A1 (Goodwin et al, 2000) 
through the induction of the hepatic transcriptional repressor SHP (Lu et al, 2000) 
and the intestinal hormone FGF-19 (Holt et al, 2003). As presented in chapter 3, 
functional variants of the FXR gene have been identified and other reports have 
demonstrated genetic variation in its target genes BSEP and MDR3 in an ICP 
population  (Dixon et al, 2008; Dixon et al, 2000; Jacquemin et al, 1999; Mullenbach 
et al, 2005; Mullenbach et al, 2003; Painter et al, 2005; Pauli-Magnus et al, 2004; 
Van Mil et al, 2007). However, genetic variation accounts for only a small 
proportion of cases.  
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Total serum bile acids are raised during human pregnancy and a significant 
proportion of normal individuals develop mild biochemical cholestasis without 
developing symptomatic disease (Castano et al, 2006; Lucangioli et al, 2009). 
Furthermore, most individuals who are genetically predisposed to ICP are 
asymptomatic outside pregnancy. It has therefore been suggested (Van Mil et al, 
2007) that pregnancy is period of bile acid stress during which individuals with 
functional variants of bile acid responsive genes or experiencing unrelated biliary 
events are at increased risk of developing pathological intrahepatic cholestasis. It is 
not known why an apparent loss of bile acid homeostasis develops during pregnancy 
(Castano et al, 2006) although high levels of reproductive hormones have been 
suggested as contributory factor. Estrogen and progesterone have been shown to 
induce cholestasis in rodent models (Ochs et al, 1986; Yamamoto et al, 2006). As it 
is not clinically justifiable to obtain liver biopsies from ICP or control pregnant 
women, there is no direct evidence of the response of the liver to normal pregnancy 
and to the high concentration of bile acids that can occur in pregnant women. 
Therefore, it is not known whether components of the enterohepatic circulation, 
including FXR, respond to the gestational rise in serum bile acids or are the cause of 
it. Two reports have unexpectedly demonstrated reduced hepatic nuclear hormone 
expression during pregnancy in rodents (He et al, 2007; Sweeney et al, 2006).  
In order to understand the molecular pathology of ICP, the primary events that 
expose individuals to risk of developing ICP have to be studied.  In this chapter, 
mouse models will be used to investigate the effect of normal and cholestatic 
pregnancy on bile acid homeostasis. Mice implanted with estrogen and progesterone 
will also be utilised to study the effect of reproductive hormones on bile acid 
homeostasis. 
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5.2 Results 
 
5.2.1 Raised Serum and Hepatic Bile Acids in Pregnant Mice. 
Serum bile acids rise in humans (Castano et al, 2006) during gestation. In order to 
determine whether bile acids are raised in mice during pregnancy, serum and hepatic 
bile acids were determined in non-pregnant and pregnant animals. The levels of bile 
acids were also evaluated and compared in the serum and liver in two models of 
cholestasis, one of bile acid overload (cholate-fed animals) and a genetic model of 
cholestasis (Fxr-/-). 
It was demonstrated that hepatic and serum bile acids were raised in long-term 
cholate-fed and in Fxr-/- animals (Figure 5.1A and 5.1B), which is in line with 
previous published reports (Huang et al, 2006; Yang et al, 2007). Subsequently, it 
was demonstrated that in normal pregnant mice, hepatic bile acid concentrations 
were significantly higher (15-fold, p<0.05) than in non-pregnant controls (Figure 
5.1A), as were the serum bile acids, rendering gestation as a mild cholestatic state. 
Indeed, the hepatic bile acids in pregnant mice were measured at levels comparable 
(i.e. not significantly different) to those in cholate-fed or Fxr-/- mice.  
Alanine aminotransferase (ALT) is a liver enzyme that is released into the circulation 
during hepatic damage and is routinely used to monitor liver injury. Raised hepatic 
bile acids were associated with a significant increase in serum ALT levels in 
pregnant, cholate-fed and Fxr-/- mice (Figure 5.1C) but in all cases, the values 
remained within the normal range (<40U/L).  
Hence, normal pregnancy in mice is characterised by high serum and hepatic bile 
acids and serum ALT, similar to the levels found in two cholestatic models, of Fxr 
absence and bile acid overload. 
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Figure 5.1: Raised hepatic and serum bile acid levels during pregnancy, in 
cholate-fed and Fxr-/- mice. 
Wild type (Control), Fxr-/- and cholate-fed (CA-fed) mice were mated and sacrificed 
on day 1 of pregnancy in order to control for cycling differences. Pregnant mice were 
killed on the 18th day of pregnancy. Cholate fed mice received the modified diet for 
30 days. (A) Hepatic bile acids. (B) Serum bile acids and (C) Serum ALT. Results 
are shown as mean ±S.E.M. (n=6) *p<0.05 compared to controls. Two-tailed 
Student’s t test was used to determine differences between data groups. 
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5.2.2 Serum and Hepatic Biochemical Changes Induced by 
Pregnancy, Bile Acid Overload and Fxr Deficiency. 
Several other biochemical parameters were investigated in the models of cholestasis 
and normal pregnancy in order to investigate the effect of raised bile acids in the 
liver. Serum and hepatic cholesterol and triglycerides were determined in non-
pregnant, pregnant and Fxr-/- animals (Figure 5.2A and 5.2B). Due to the limited 
amount of serum that can be obtained form mice, free fatty acids were only measured 
in the liver (Figure 5.2C).  
Pregnancy only affected the levels of serum triglycerides, where a small but 
significant increase was demonstrated (Figure 5.2B). This is not necessarily an effect 
of the raised bile acids during pregnancy, but may be an adaptation of the high 
metabolic demand during gestation. As expected, cholate feeding had a significant 
effect on the concentration of cholesterol both in the serum and liver (Figure 5.2B). 
Bile acids are the end product of cholesterol metabolism in the liver. Therefore, 
overloading the system with bile acids resulted in down-regulation of cholesterol due 
to inhibition of bile acid synthesis. This adaptive mechanism is necessary to avoid 
accumulation of cholesterol in the liver. Hepatic triglycerides were also decreased in 
the livers of cholate-fed mice compared to controls, which was also likely to be a 
result of inhibited bile acid synthesis.  
Fxr-/- mice have a reduced concentration of cholesterol in the liver and increased 
levels in the serum when compared to the controls (Figure 5.2A). Increased levels of 
cholesterol in the serum of Fxr-/- mice have been previously reported and are linked 
to the role of Fxr in lipid metabolism (Sinal et al, 2000). On the other hand, 
decreased concentration of hepatic cholesterol contradicts the report by Sinal et al 
who showed increased hepatic cholesterol levels (Sinal et al, 2000). This disparity 
could be explained by difference in the strain of mice or because of differences in the 
construction of the knockout mice. However, the reduction in hepatic cholesterol in 
the Fxr-/- mice is very small and could be an artefact. Nevertheless, it should be noted 
that Fxr-/- mice have raised bile acids due to increased bile acid synthesis as 
demonstrated by Sinal et al (Sinal et al, 2000). Increased synthesis therefore, could 
result in some reduction of cholesterol concentration in the liver.  
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Figure 5.2: Differential effects on hepatic and serum biochemical markers by 
pregnancy, bile acid overload and Fxr deficiency. 
(A) Hepatic and serum cholesterol concentration. (B) Hepatic and serum triglyceride 
levels. (C) Hepatic free fatty acids. Results are shown as mean ±S.E.M. (n=6) 
*p<0.05 compared to controls. Two-tailed Student’s t test was used to determine 
differences between data groups. 
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5.2.3 Hepatic Metabolic Profiling of Pregnant, Cholate-fed and 
Fxr-/- Mice. 
Using magic angle spinning 1H nuclear magnetic resonance (NMR) experiments on 
intact liver tissue, the metabonomic effects of pregnancy were compared to those 
caused by cholate-feeding or the absence of Fxr. These experiments were conducted 
in collaboration with Dr Jane Cox and Dr Jeremy Cobbold. 
Partial least squares discriminant analysis (PLS-DA) separated each model-group 
from the control-group with 100% accuracy on cross-validation with a statistically 
significant predictive ability (Table 5.1), demonstrating that the metabolite profile of 
the liver is significantly affected by pregnancy, following cholate-feeding and in 
mice lacking Fxr. 
Subsequently, the spectral regions contributing most to each model were identified 
and the primary and major discriminators were assigned (Table 5.1). Six 
discriminators were found to contribute to all of the models (Table 5.1). It was 
assessed whether these were positively or negatively correlated with each model 
state, and for all six discriminators the correlation was the same in the pregnant and 
Fxr-/- models while this was not the case in the cholate-fed model (Figure 5.3A). 
These findings indicated that pregnancy and Fxr-deficiency have a similar effect on a 
sub-set of resonances while cholate feeding has distinct effects.  
Finally, NMR data were analysed to assess the relative and absolute levels of a 
number of parameters that have been associated with hepatic disease or altered 
metabolic state. For example, increased total lipid-to-water ratio, decreased 
polyunsaturation indices (PUI) and decreased total choline (tcho) are associated with 
non-alcoholic fatty liver disease. Indeed, it was demonstrated that total lipid, PUI, 
tcho:lipid ratio and the PC+GPC/tCho ratio were significantly affected by the 
cholate-feeding. However, in pregnant or Fxr-/- mice, despite also having raised 
hepatic bile acids (Figure 5.1A), these parameters were not significantly affected 
(Figure 5.2B).   
Therefore, analysis of metabolomic data generated from intact liver tissue 
demonstrated that pregnancy has a similar effect on a subset of resonances to that 
seen in the absence of Fxr. These effects are distinct to those seen following cholate 
feeding. 
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Table 5. 1: Partial least squares discriminant analysis (PLS-DA) of model vs 
control mice with list of metabolites contributing to the discrimination between 
groups. 
Model Leave-
one-out 
accuracy 
Q2 Major discriminators 
Pregnant 100% 0.95 Allylic lipid, n-ene lipid; methylene to a-
methylene-to-carboxyl lipid; methylene lipid; 
methyl lipid; diallylic lipid; glucose, glycogen; a-
methylene-to-carboxyl lipid 
Cholate-
fed 
100% 0.99 Methyl lipid, Allylic lipid; PtC; methylene to a-
methylene-to-carboxyl lipid; methylene lipid; 
diallylic lipid; a-methylene-to-carboxyl lipid; n-ene 
lipid 
FXR-/- 100% 0.77 n-ene lipid , Allylic lipid; methyl lipid; methylene 
to a-methylene-to-carboxyl lipid; methylene 
lipid; diallylic lipid; glycogen; glyceryl of lipid; 
PtC 
All analyses used 1 factor and 2 orthogonal signal corrections. Metabolites are listed in order of 
decreasing influence on the model. Lipid CH3CH2 (methyl); lipid (CH2)n (methylene); lipid 
CH2CH2CO (methylene to a-methylene to carboxyl); lipid CH=CHCH2CH2 (allylic); lipid CH2CH2CO 
(a-methylene to carboxyl); lipid CH=CHCH2CH=CH (diallylic- “PUFA”); lipid CH=CH (n-ene 
group); tCho, total choline; Cho, choline; PC, phosphocholine; GPC, glycerophosphocholine; PtC, 
phosphatidylcholine. Those listed in bold were correlated with each model state. This analysis was 
performed by Dr Jeremy Cobbold. 
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Figure 5.3: Hepatic metabolic profiling of pregnant, cholate-fed and Fxr-/- mice 
using magic angle spinning 1H NMR. 
(A) Analysis of the positive or negative correlation of commonly affected resonances 
to each model. (B) Total lipid (%) = 100* (CH3 +CH2)/(water + CH3 +CH2); PUI 
(Polyunsaturation index) = 100* (CH=CHCH2CH=CH)/ (CH=CHCH2CH=CH + 
CH=CHCH2CH2 + CH3CH2  + (CH2)n ); tCho:lipid = 100* (tCho)/ (CH=CHCH2CH=CH + 
CH=CHCH2CH2 + CH3CH2  + (CH2)n );(PC+GPC)/tCho = (PC+GPC)/tCho. 
Chapter 5                                                                                                                                         Results 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     155 
5.2.4 Microarray Analysis on the Livers of Pregnant, Cholate-fed 
and Fxr-/- Mice. 
In order to evaluate the effect of pregnancy on the transcriptome of the liver and to 
compare this with the models of bile acid overload and Fxr-deficiency, a microarray 
gene expression experiment was conducted. The transcriptional profile of the liver in 
the cholate-fed model should be a response to the increased levels of bile acids, 
whereas in the Fxr-/- mice the raised levels of bile acids are the cause of any 
alteration in the transcriptional profile in the liver of these animals. Therefore, the 
changes in the transcriptome in wild type pregnant animals will be compared to those 
that occur in the other two models in order to identify whether the hepatic gene 
expression changes in pregnancy are likely to contribute to their bile acid phenotype 
or are a response of it.  
Principal-component analysis (PCA) of the entire dataset was conducted and it was 
established that the arrays from control, pregnant, cholate-fed and Fxr-/- mice 
clustered according to experimental group without overlap or outliers (Appendix V). 
These unbiased analyses of the datasets demonstrated that each model significantly 
affects global hepatic transcription. Subsequently, pregnancy was found to 
significantly affect the expression of 508 liver-expressed genes, cholate feeding 
affected 266 genes and in mice lacking Fxr, 144 genes were affected (>2-fold, 
p<0.01) (for complete lists of genes see Appendix IV).  
Further analysis of the microarray data using the rosetta Resolver canonical pathway 
analysis was performed to investigate whether gene expression effects were over-
represented in specific metabolic pathways. A fold-change was not set for this 
analysis, but the biosets generated contained genes affected by each condition with a 
confidence threshold of p<0.01. This analysis revealed that despite differences in the 
number of genes affected under each condition, there was marked similarity in the 
metabolic pathways affected by the three models (Figure 5.4A). Although the order 
of the five most affected pathways is different between groups, it is notable that the 
pathways affected in each group are similar. Subsequently, to define the functional 
networks of the differentially expressed genes, data were analyzed using Ingenuity 
Pathway Analysis (IPA). These investigations revealed that a gene-network associated 
with “Cholestatic Liver Disease” was the most statistically over-represented network 
in the pregnant, cholate-fed and Fxr-/- mice (Figure 5.4B). Therefore, global 
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expression analysis demonstrates that pathways and networks regulated under 
conditions of bile acid overload or genetic cholestasis were also significantly affected 
by pregnancy.   
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Figure 5.4: Hepatic microarray analysis of pregnant, cholate-fed and Fxr-/- 
mice. 
(A) Significantly changed biological functions according to canonical pathway 
analysis performed for the three different experimental groups. (B) Results of 
Ingenuity Pathway Analysis (IPA) of significantly (p<0.05) affected genes. A 
significant score for each network was calculated using a p-value calculation and is 
displayed as the negative algorithm of that p-value. This score indicates the 
likelihood that the assembly of a set of focus genes in a network could be explained 
by random chance alone. 
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Venn diagrams and hierarchal clustering were used to explore potential similarities 
and differences between the groups at the transcriptional level. Pregnancy and 
cholate feeding affected 508 and 266 genes (2-fold, p<0.01) respectively. Of the 734 
genes changed in either pregnancy or cholate feeding, only 53 genes were affected 
by both pregnancy and cholate-feeding (Figure 5.5A). Although the proportion of the 
genes altered is low, it is still higher than what would expect by chance alone.   
Hierarchal clustering was performed on the commonly affected genes (53) to 
determine whether pregnancy regulated these in a similar, or dissimilar manner to the 
regulation by cholate-feeding. As expected, individual samples from non-pregnant 
controls, pregnant and cholate-fed mice clustered according to experimental group. 
Pregnancy and cholate-feeding had the same effect on approximately half of their 
commonly affected genes (Figure 5.5B). Therefore, pregnancy and cholate-feeding 
do not have a similar effect on the regulation of this sub-set of genes because this 
proportion of similarly regulated genes is as would be expected by chance alone. 
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Figure 5.5: Common gene regulation during pregnancy and cholate feeding. 
The expression of probe sets from livers of wild type and cholate-fed mice were 
directly compared using the Resolver software. (A) Venn diagram of genes affected 
(≥2 fold, p<0.01) in pregnancy and cholate-fed mice were created in order to identify 
commonly affected genes. (B) Commonly affected genes as identified from Venn 
diagrams were subjected to 2D hierarchical clustering. Red denotes genes expressed 
above the mean and green denotes genes expressed at a level below the mean. Gene 
names in black represent genes similarly affected by pregnancy and cholate feeding, 
whereas pink text denotes genes that are differentially affected. 
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Hepatic microarray data from Fxr-/- and pregnant mice were also compared. In the 
Fxr-/- mice, 144 genes were found to be differentially expressed (2-fold, p<0.01) 
compared to wild type non-pregnant controls. Of these, only 27 genes were 
commonly affected by pregnancy in wild type mice (Figure 5.6A). As with the 
previous comparison, the proportion of commonly affected genes was greater than 
expected by chance alone.  
Hierarchical clustering of these 27 genes revealed that 80% of the genes regulated by 
pregnancy and Fxr-deficiency were similarly affected under both conditions (Figure 
5.6B), indicating common regulation of this sub-set.  
Unsupervised microarray analysis showed that pregnancy has a major effect on the 
maternal hepatic transcriptome. Furthermore, these data suggest that the effects of 
pregnancy and Fxr deficiency are similar.   
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Figure 5.6: Common gene regulation during pregnancy and in the absence of 
Fxr. 
The expression of probe sets from wild type and Fxr-/- null livers were directly 
compared using the Resolver software. (A) Venn diagrams of genes affected (≥2 
fold, p<0.01) in pregnant and Fxr-/- mice were created in order to identify commonly 
affected genes between these treatment groups. (B) Commonly affected genes as 
identified from Venn diagrams were then subjected to 2D hierarchical clustering. 
Red denotes genes expressed above the mean and green denotes genes expressed at a 
level below the mean. Gene names in black text represent genes similarly affected by 
pregnancy and absence of Fxr, whereas pink text denotes genes that are differentially 
affected. 
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5.2.5 Pro-cholestatic Hepatic Gene Expression in Pregnant Mice. 
To determine whether hepatic genes respond to the accumulation of bile acids during 
pregnancy or whether the effects of pregnancy are pro-cholestatic, networks of genes 
known to maintain bile acid homeostasis were analyzed. Many of these genes were 
also in the Ingenuity Pathway Analysis (IPA) network of Cholestatic Liver Disease. 
RT-QPCR was used to confirm changes detected in the microarray (Table 5.2).  
As expected, the data were consistent with Fxr-activation in the cholate-fed mice and 
reduced Fxr function in mice lacking Fxr. As such, cholate-feeding induced intestinal 
Fgf15 (15-fold, p<0.01, Table 5.3) and hepatic Shp and Bsep expression while 
Cyp7a1 and Ntcp expression was reduced (Table 5.2). Notably, despite clear 
evidence of Fxr-activation, cholate-feeding did not increase the hepatic mRNA 
expression of Fxr. As expected Fxr-/- mice had high expression of Cyp7a1, and low 
expression Bsep, Shp and Mdr1a (Mdr3 in humans) (Table 5.2).  
Despite the presence of high hepatic bile acids, there was little evidence of Fxr-
activation in pregnant mice. As was the case following cholate feeding, the mRNA 
expression of Fxr was only modestly affected by pregnancy (-1.2-fold, p<0.05) and 
there was no effect of Fxr protein expression (Appendix VI). The rate-limiting 
enzyme in bile acid biosynthesis, Cyp7a1 was modestly, but significantly up-
regulated (1.6-fold, p<0.01) during pregnancy while the expression of its negative 
regulator, Shp, was repressed (-2.8-fold, p<0.01) (Table 5.2). Furthermore, 
pregnancy significantly reduced expression of the hepatic importers, Ntcp and Oatp4, 
and hepatic exporters, Bsep, Mdr1a, Mrp3 and Oatp2 (Table 5.2). Therefore, the 
transcriptional effects of pregnancy resemble a state of reduced Fxr-function rather 
than an Fxr-dependent response to bile acid overload. The data also imply the 
existence of gestational signals that perturb the feedback regulation of bile acid 
homeostasis.  
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Table 5. 2: Hepatic bile acid-responsive gene expression in pregnant, CA-fed 
and Fxr-/- mice. 
 
 Pregnant Cholate-feeding Fxr-/- 
BA Synthesis 
Cyp7a1  1.6 (1.6) -41.3 (-57) 1.8 (2.5) 
Cyp8b1 1.6 (1.7) -84.4 3.4 (5.4) 
Cyp27a1 -1.4 -1.2 -1.3 
Portal BA Uptake  
Ntcp (Slc10a1) -1.7 (-1.6) -1.9 (-1.7) -1.2 (-1.9) 
Oatp1 (Slco1a1) NS -4.9 NS 
Oatp4 (Slco1b2) -1.8 -1.2 NS 
BA Hydroxylation 
Cyp3a11 -1.2 1.7 NS 
BA Sulphation 
Ugt2b4 NS NS NS 
Sult2a1 NS NS NS 
Biliary BA Export 
Bsep (Abcb11) -1.4 (-1.5) 1.6 (1.8) -2.0 (-2.0) 
Mdr1a (Abcb1a) -1.9 5.1 -2.1 
Mrp2 (Abcc2) NS NS NS 
Alternative BA Export 
Oatp2 (Slco1a4) -3.5 1.9 -1.4 
Mrp3 (Abcc3) -11.5 (-9.4) 1.7 (1.8) NS (NS) 
Mrp4 (Abcc4) NS 2.2 NS 
Ostα/β NS NS NS 
Nuclear Receptors/Cofactors  
Fxr (Nr1h4) -1.2 -1.3 NA 
Shp (Nr0b2) -2.6 (-3.0) 4.6 (4.2) -2.8 (-2.4) 
Pxr (Nr1i2) NS 1.8 -1.6 
Car (Nr1i3) NS -1.4 NS 
Pparα  NS -1.4 -1.2 
Hnf4α 
Lrh-1 (Nr5a2) 
1.3 
-1.3 
1.2 
-1.3 
NS 
1.4 
Pgc1a (Ppargc1a) -1.7 NS -1.8 
Fold changes are relative to control. Figures in brackets are results from RT-QPCR. 
All fold changes are significant (p<0.05). NS, not significantly affected. NA, not 
applicable.    
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RT-QPCR was used to investigate the transcriptional alteration of pregnancy, cholate 
feeding and Fxr deficiency in the intestine. There was minimal effect of pregnancy 
on the transcription of bile acid-responsive genes in terminal ileum (Table 5.3). Only 
the bile acid exporter was significantly induced in pregnancy. As expected, cholate 
feeding caused a striking increase in the expression of Ffg15. On the other hand, 
FXR deficiency caused a substantial down-regulation of Ibabp, the gene proposed to 
facilitate bile acid transfer and efflux from the enterocyte. This is in line with reports, 
which propose IBABP as a direct target of FXR (Grober et al, 1999). 
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Table 5. 3: Intestinal bile acid-responsive gene expression in pregnant, CA-fed 
and Fxr-/- mice. 
 
 Pregnant Cholate-feeding Fxr-/- 
BA Import 
Asbt NS NS 1.5 
BA flux 
Ibabp NS 3.2 -24 
BA efflux 
Mrp3 2.3 NS NS 
Ostα NS NS -2.59 
Ostβ NS 2.1 NS 
Apical excretion of BA 
Mrp2 NS NS NS 
BA signalling 
Fgf15 NS 11.8 NS 
Fold changes are relative to control. All fold changes are significant (p<0.05).  
NS, not significantly affected.  
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5.2.6 Pregnancy Levels of Estrogen and Progesterone are not 
Causing the Pro-cholestatic Gene Expression Seen in 
Pregnancy.  
In order to determine whether reproductive hormones are sufficient to drive pro-
cholestatic gene expression during pregnancy, silastic implants were used to deliver 
pregnancy levels of reproductive hormones. Compared to vehicle treatment, the 
reproductive hormones caused uterine swelling in all mice, demonstrating that they 
had a physiologically relevant effect on a known hormone-responsive tissue (Cohen 
& Milligan, 1993). Consistent with the effects of pregnancy, Bsep was slightly (-1.2-
fold), but significantly, reduced by the reproductive hormones. However, while 
several other bile acid-responsive genes were affected following reproductive 
hormone treatment and during pregnancy, the two conditions had opposing effects on 
their expression. Mrp3 and Shp were repressed in pregnant mice (-11-fold and -2.6-
fold respectively (p<0.05)) but they were induced following estrogen and 
progesterone treatment (1.2-fold and 1.6-fold respectively (P<0.05)). Furthermore, 
Cyp7a1 was induced by pregnancy (1.6-fold, p<0.05) and repressed by the 
reproductive hormone treatment (-1.6-fold, p<0.05). These findings demonstrate that 
the effects of pregnancy on bile acid regulated genes are not maintained in a model 
that mimics the estrogen and progesterone changes that occur during gestation. 
However, it is possible that high levels of estrogen and progesterone contribute to the 
pro-cholestatic gene expression effects of pregnancy. 
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5.2.7  Reduced Hepatic Expression of Cholesterol Biosynthetic 
Genes in Pregnant Mice. 
Bile acids can influence cholesterol homeostasis in the liver and therefore a more 
targeted analysis was performed. As described in section 1.2.2, the hepatic 
cholesterol pool was changed, due to differential rates of bile acid biosynthesis, in 
the different models. Indeed, it was shown that the hepatic cholesterol pool was 
increased (p<0.01) in mice fed cholic acid (Cyp7a1 decreased) and reduced (p<0.05) 
in mice lacking Fxr (Cyp7a1 increased) (Figure 5.7A). In contrast to the cholate-fed 
and Fxr-/- mice, the hepatic bile acid phenotype of pregnancy was not associated with 
alterations in the liver cholesterol pool (Figure 5.7A).  
Subsequent targeted analysis of the array data to the cholesterol biosynthesis 
pathway revealed reduced gene expression in the pregnant and cholate-fed animals. 
Following cholate-feeding, 13 out of 19 cholesterol biosynthetic genes were 
significantly repressed (>2-fold, p<0.05) whereas in Fxr-/- mice, none of the genes 
were significantly affected (Figure 5.7B). Surprisingly, it was found that 6 of the 19 
genes in the cholesterol biosynthesis pathway were significantly (>2-fold, p<0.05) 
down-regulated during pregnancy, including the rate-limiting enzyme Hmgcr (Figure 
5.7B). For most genes, the magnitude of gene expression change was greater in the 
cholate-fed mice than in pregnant animals. Therefore raised hepatic bile acids during 
pregnancy are associated with repression of hepatic cholesterol biosynthetic genes in 
normal mice. However, more work is needed to determine whether this is a direct 
effect of the increased levels of the bile acids. 
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Figure 5.7: Pregnancy represses the expression of cholesterol biosynthetic genes.  
(A) Hepatic cholesterol content. (B) Outline of the genes involved in the biosynthetic 
pathway of cholesterol. The fold-changes of all significantly affected genes when 
compared to controls are depicted for each model. The fold-changes result from 
analyses of the microarray data, where p<0.05 is considered statistically significant. 
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5.2.8 FXR-activation Prevents Hepatic Bile Acid Accumulation in 
Pregnant Mice. 
The results obtained using MAS-NMR and micro arrays indicate that hepatic bile 
acids accumulate in pregnant mice as a result of pro-cholestatic gene expression 
resembling reduced Fxr-function. To further investigate this possibility, it was 
assessed whether the cholate-diet, which potently activated Fxr, is sufficient to 
prevent further accumulation of hepatic bile acids during pregnancy. Pregnancy was 
maintained with no effect on fetal number or weight in the long-term cholate-fed 
mice. It was found that in cholate-fed mice, hepatic bile acids (Figure 5.8A), serum 
ALT (Figure 5.8B) and hepatic cholesterol (Figure 5.8C) were not further affected by 
pregnancy. Furthermore, in this model, gestation did not cause repression of 
cholesterol biosynthetic genes (Figure 5.8D) and there was no pregnancy-associated 
induction of Cyp7a1 or Cyp8b1 (Figure 5.8E). While the pregnancy-associated 
alterations in expression of a number of genes (e.g. Ntcp, Oatp2, Oatp4, Bsep and 
Mrp3) were maintained in long-term cholate fed mice (Figure 5.8E), the level of their 
expression remained anti-cholestatic compared to chow-fed animals (Table 5.2). 
Together, these data suggest that potent activation of Fxr during pregnancy prevents 
the pro-cholestatic gene expression from manifesting in a phenotype of hepatic bile 
acid accumulation.    
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Figure 5.8: Fxr-activation prevents further hepatic bile acid accumulation 
during pregnancy in cholate-fed mice. 
Wild type mice were mated and sacrificed at day 1 of pregnancy in order to control 
for cycling differences (non-pregnant). Pregnant mice were killed on the 18th day of 
pregnancy. Both non-pregnant and pregnant cholate-fed mice received the modified 
diet for 30 days. (A) Hepatic bile acids. (B) Serum ALT. (C) Hepatic cholesterol 
levels of non-pregnant and pregnant mice on a normal diet and cholic acid 
supplemented diet. (D) The effect of pregnancy on genes of the cholesterol 
biosynthetic pathway in control and cholate-fed pregnant mice compared to the 
appropriate non-pregnant controls. Fold-changes are indicated for significantly 
affected genes as found by microarray analyses. (E) The effect of pregnancy on 
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selected bile acid responsive genes in pregnant control and cholate-fed mice when 
compared to their non-pregnant controls. Fold-changes are depicted for significantly 
affected genes. (NS:not significantly affected). The fold-changes have been 
confirmed by RT-QPCR and the results are shown in brackets, where applicable. 
Indicated fold changes are significant (p<0.05). 
Results are shown as mean ±S.E.M. (n=6) *p<0.05 compared to control diet, 
♯p<0.05 compared to non-pregnant. 2-way ANOVA was used to determine 
differences between data groups. 
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5.2.9 FXR-/- Mice do not Develop High Hepatic Bile Acids During 
Pregnancy.  
Non-pregnant Fxr-/- mice have increased serum and hepatic bile acids and decreased 
hepatic cholesterol content compared to non-pregnant wild type animals. It was 
noted that during wild type pregnancy, the mice developed pro-cholestatic gene 
expression changes that were similar to those in mice lacking Fxr. Therefore, 
pregnancy could be a state of reduced Fxr function. In order to test this hyposthesis, 
it was investigated whether gestational pro-cholestatic gene expression and the 
accumulation of hepatic bile acids are maintained in mice lacking Fxr.  
Pregnancy was maintained in Fxr-/- mice with no effect on fetal number or weight. In 
support of the proposal that pregnancy causes reduced Fxr-function, it was 
demonstrated that Fxr-/- mice did not develop a further rise in hepatic bile acids 
during pregnancy (Figure 5.9A). However, the magnitude of increase in serum ALT 
levels was considerably larger in pregnant Fxr-/- mice than observed in wild types 
(Figure 5.9B). Consistent with having no effect on hepatic bile acids, hepatic 
cholesterol levels were also unaffected by pregnancy in Fxr-/- mice (Figure 5.9C).  
Because hepatic bile acids and cholesterol content were unaffected by pregnancy in 
mice lacking Fxr, there was no repression of cholesterol biosynthetic genes in this 
group (Figure 5.9D). Furthermore, pregnancy in Fxr-/- mice did not reduce the 
expression of Fxr target genes Bsep, Mdr1a, Oatp1, Oatp2, Shp, Pgc1α, nor did it 
induce the expression of Cyp8b1, which was the case in wild type animals (Figure 
5.9E). Surprisingly, the small pregnancy effect on Cyp7a1 was maintained in the Fxr-
/- mice (Figure 5.9E). It was also noted that the alternative exporter Mrp4 was 
induced by pregnancy in the Fxr-/- but not the wild type animals (Figure 5.9E) and 
this could contribute to preventing the accumulation of hepatic bile acids in these 
mice. Together, these findings broadly support the proposal that a gestational signal 
reduces Fxr function and inhibits feedback regulation of the enterohepatic 
circulation. 
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Figure 5.9: Cholestatic gene expression and raised hepatic bile acids are not 
maintained during pregnancy in Fxr-/- mice. 
Wild type (WT) and Fxr-/- mice were mated and sacrificed on day 1 of pregnancy in 
order to control for cycling differences (Non-pregnant). Pregnant mice were killed on 
the 18th day of pregnancy. (A) Hepatic bile acids. (B) Serum ALT. (C) Hepatic 
cholesterol levels. (D) The effect of pregnancy on genes of the cholesterol 
biosynthetic pathway in pregnant wild type and Fxr-/- mice compared to their non-
pregnant controls. Fold-changes are indicated for significantly affected genes as 
found by analyses of microarray data. (E) The effect of pregnancy on selected bile 
acid responsive genes in pregnant wild type and Fxr-/- mice compared to their non-
pregnant controls. Fold-changes are depicted for significantly affected genes. (NS: 
not significantly affected). The fold-changes have been confirmed by RT-QPCR and 
the results are shown in brackets. Indicated fold changes are significant (p<0.05). 
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Results are shown as mean ±S.E.M. (n=6) *p<0.05 compared to control diet, 
♯p<0.05 compared to non-pregnant. 2-way ANOVA was used to determine 
differences between data groups. 
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5.3 Summary and Conclusions 
Serum bile acids are raised in normal pregnancy in humans (Castano et al, 2006) and 
as described in this chapter, their concentrations are also increased in the serum and 
liver of pregnant mice. The hepatic bile acids are increased at levels comparable to 
those in cholate-fed and Fxr-/- mice during pregnancy. Analysis of bile acid profiles 
in humans revealed that primary bile acids are contributing most to the increase 
(Castano et al, 2006). Perturbed FXR-function during pregnancy may explain the 
normal rise in serum bile acids observed in pregnant humans. In addition, decreased 
FXR function is in agreement with the genetic aetiology of ICP and could explain 
why gestation unmasks cholestatic disease in predisposed individuals. Individuals 
with variation in FXR or its target genes (BSEP, MDR3) would be more susceptible 
to cholestasis in pregnancy, as their expression and function would be further 
reduced. Therefore, the cholestatic nature of pregnancy would expose these 
individuals to an increased risk for developing gestational cholestatic disease. 
Hepatic microarrays and targeted gene expression analysis were utilised to 
investigate the response of the liver to the high concentrations of bile acids. This 
analysis revealed that the gene expression effects of pregnancy on the maternal liver 
were pro-cholestatic and resembled a state of reduced Fxr function. The Fxr mRNA 
expression was reduced, as was the expression of its target genes Bsep, Shp and 
Mdr1a (MDR3 in humans) the actions of which help to maintain bile acid 
homeostasis. In addition, Cyp7a1 and Cyp8b1 that are normally indirectly repressed 
by Fxr were induced in the livers of pregnant mice. On the other hand, in cholate-fed 
mice the expression of biosynthetic genes Cyp7a1 and Cyp8b1 were greatly 
downregulated (-41.3 and -84 respectively), whereas import (Ntcp, Oatp1/4) was 
repressed and export (Bsep, Mdr1a) was induced, demonstrating FXR activation and 
adaptive responses to diminish bile acid toxicity. Also, in mice fed a cholate diet, 
there was no accumulation of hepatic bile acids during pregnancy, which suggests 
that potent activation of Fxr and its target genes prevented the effects of pregnancy 
on bile acid homeostasis. In agreement, hepatic bile acids were not raised during 
pregnancy in Fxr-/- mice. The gene expression profile of non-pregnant Fxr-/- mice 
was similar to that of pregnancy; increased expression of bile acid synthesis genes 
and decreased export. These findings indicate that pregnancy causes perturbed 
hepatic bile acid homeostasis in mice and that this could be caused by a state of 
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reduced Fxr function. Interestingly, pregnancy had no effect on intestinal bile acid 
responsive genes, including Fgf15. 
Pregnancy repressed significantly the expression of the multiple drug resistance 
protein Mrp3 (-11 fold). The exact function of Mrp3 is not known but it has been 
shown to have role in the alternative export of bile acids from the hepatocytes 
(Hirohashi et al, 1999; Hirohashi et al, 2000). The striking down-regulation of Mrp3 
expression could have an additive effect on the rise of bile acids in the liver during 
pregnancy. Reduced function of Fxr and its target genes would result in disrupted 
bile secretion into the canaliculus, therefore would cause accumulation of bile acids 
in the hepatocytes. An adaptive reaction to the build up of bile acids would be the 
induction of alternative transport routes. However in wild type pregnancy there was 
no stimulation of alternative bile acid export as demonstrated by the repression of 
Mrp3 as well as Oatp2 (-3.5 fold). Interestingly, the expression of the genes involved 
in alternative bile acid export, including Mrp3, Oatp2 and Mrp4 were significantly 
induced in the livers of bile acid fed mice. This is in line with other reports, which 
have shown that Fxr activation induces overall gene expression of alternative 
basolateral bile acid transporters Mrp3 and Mrp4, specific for divalent bile acid 
conjugates and of the bidirectional bile acid transporter Ostα/Ostβ (Zollner et al, 
2006b). In Fxr-/- mice only the expression of Oatp2 was reduced, while Mrp3, Mrp4 
and Ostα/β did not change significantly, which demonstrates that high hepatic bile 
acids did not induce the alternative transport routes in this model either. These data 
further support the notion that enterohepatic components do not respond to the raised 
bile acids during pregnancy, instead their expression profile is pro-cholestatic. In 
agreement, the hepatic metabolic profiling showed that the correlation of the 
different discriminators was the same for the pregnant and Fxr-/-  mice, while this 
was not the case for the cholate-fed mice. 
Furthermore, the cholestatic nature of pregnancy may explain in part the mode of 
action of UDCA, which is commonly used to treat ICP (Glantz et al, 2005; 
Williamson, 2001). Although a number of mechanisms have been proposed for the 
mode of action of UDCA (Ikegami & Matsuzaki, 2008), Fxr-activation may be a 
component of its protective mechanism. UDCA is a weak FXR ligand in vitro but 
can activate FXR in vivo (Zollner et al, 2003a). Therefore, activation of FXR by 
UDCA could prevent or reverse the colestatic effects of pregnancy. Also, it has been 
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demonstrated that UDCA can increase the expression of membrane transporters 
membrane including BSEP, MDR3 and MRP4 in human liver. These genes have 
been shown to be regulated by FXR. Also, induction of these genes by UDCA results 
in amelioration of cholestasis-induced liver damage suggesting that repression of 
these transporters could have an important role in ICP.   
Reproductive hormones are also implicated in the aetiology of ICP (Arrese et al, 
2008) and a number of rodent studies have demonstrated that high doses can cause 
cholestasis (Ochs et al, 1986; Yamamoto et al, 2006). In this study, pregnancy levels 
of reproductive hormones were delivered over a time course similar to that of 
pregnancy in mice. However, these experiments failed to reproduce the pro-
cholestatic gene expression observed during pregnancy, suggesting that reproductive 
hormones alone are unlikely to be the primary modulator of Fxr-function during 
gestation.  
More work is necessary in order to confirm the indications for reduced Fxr function 
during pregnancy. For instance, treatment of pregnant mice with the specific FXR 
agonist GW4064 should prevent the accumulation of hepatic bile acids during 
gestation. Furthermore, the signal responsible for the pro-cholestatic gene expression 
has not been identified. Pregnancy is a complex process with many factors been 
altered during its course, and therefore identifying this signal will be very difficult.  
Recent evidence has demonstrated that Fxr influences lipid metabolism, energy 
homeostasis and glucose metabolism (Thomas et al, 2008). The adaptive 
maintenance of these processes is essential during pregnancy. In humans, gestation is 
a highly insulin-resistant state that exists in order to ensure stable glucose levels and 
fetal nutrient supply (Sugden & Holness, 2008). It has been suggested that insulin 
has an inhibitory affect on Fxr function (Zhang et al, 2004b). It is therefore plausible 
that gestational insulin resistance, required to maintain normal pregnancy, inhibits 
Fxr function and disrupts bile acid homeostasis, causing cholestasis in predisposed 
individuals. However, the role of insulin in modulating Fxr function remains a matter 
of debate (Duran-Sandoval et al, 2005; Thomas et al, 2008).    
 The secondary bile acid LCA is also a potential signal that may inhibit Fxr function 
during pregnancy. In humans, the concentration of LCA is raised during pregnancy. 
It has been shown that LCA can reduce the expression of BSEP through FXR as it 
acts as a FXR antagonist (Yu et al, 2002a). LCA levels could increase during 
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pregnancy as a result of increased food intake and cholesterol catabolism in the 
adipose tissue. Bile acids are the end product of cholesterol metabolism in the liver 
and increased cholesterol would result in higher bile acid production and flux in the 
enterohepatic circulation. Therefore, higher amounts of LCA would be produced by 
the intestinal bacteria. Nevertheless, additional experiments are required to verify 
this hypothesis.  
In agreement with other published reports (Datta et al, 2006; Miyata et al, 2008), bile 
acid overload significantly decreased cholesterol biosynthetic genes in order to 
prevent accumulation of hepatic cholesterol due to inhibited synthesis of bile acids. 
Indeed, hepatic cholesterol content is increased in cholate-fed mice supporting the 
need for a homeostatic mechanism to reduce the harmful effects raised hepatic 
cholesterol. On the other hand, pregnancy reduced the expression of six out of 
nineteen genes in the cholesterol biosynthetic pathway, whereas the bile acid 
synthesis was slightly increased and the hepatic content of cholesterol did not 
change. These data suggest that there might be an increased flux of cholesterol from 
other tissues. This is supported by other reports that show that late pregnancy is a 
highly catabolic state, with increased insulin resistance allowing for greater substrate 
availability for fetal growth (Butte, 2000; Freemark, 2006; Herrera, 2000). Another 
plausible explanation for the down-regulation of cholesterol biosynthesis would be 
an adaptive response to high bile acids, which would prevent the flux of metabolites 
through this pathway. In Fxr-/- mice the expression of the cholesterol biosynthesis 
genes does not change and the cholesterol content decreases significantly probably as 
a result of increased bile acid synthesis. However, pregnancy is a complex process 
characterised by increased metabolic demand and high availability of nutrients, 
therefore more experiments would be necessary in order to draw firm conclusions for 
these differential effects of pregnancy and Fxr deficiency on cholesterol metabolism.  
Using physiologically relevant animal models, the effects of pregnancy on liver 
metabolism and bile acid homeostasis have been investigated. In pregnant mice, the 
hepatic bile acids rise to levels comparable to those in mice fed cholic acid or mice 
deficient of Fxr. Both metabonomic and transcriptomic profiling showed similarities 
between pregnant wild type mice and Fxr null mice. Moreover, hepatic gene 
expression was pro-cholestatic in pregnant mice and resembled a state of reduced 
Fxr-function. In agreement with two reports describing reduced hepatic nuclear 
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receptor expression during pregnancy in rodents (He et al, 2007; Sweeney et al, 
2006) there was a slight reduction in Fxr mRNA expression, but this was not 
replicated at the protein level. Importantly however, it was demonstrated that bile 
acid-mediated Fxr activation prevented the gestational accumulation of hepatic bile 
acids and Fxr-/- mice did not develop raised hepatic bile acids during pregnancy. 
Together, the results indicate that gestation is a state of reduced Fxr function in mice, 
which results in a pre-cholestatic phenotype in the livers of pregnant mice. These 
findings provide novel insights into how intrahepatic cholestasis of pregnancy can 
occur in normal individuals and why gestation unmasks this phenotype in those that 
harbour a genetic predisposition to the disease. 
 
 
  
 
 
 
 
 
 
6 Chapter 6                                                             
Redundant Pathways Occur in Pregnancy to 
Ensure Liver Growth 
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6.1 Introduction 
Pregnancy has been widely studied and changes in intermediary metabolism have 
been described. It is characterised by a complex endocrine-metabolic adaptation 
process including impaired insulin sensitivity, pancreatic islet expansion, moderate 
rise in blood glucose and changes in the levels of circulating free fatty acids, 
triglycerides, cholesterol, bile acids and phospholipids. These changes reflect a 
physiological adaptation of the maternal organism to meet energy demand of the 
growing fetus, detoxification of toxic by-products and preparation for delivery and 
lactation. The stress on the maternal liver is further demonstrated by pregnancy-
specific liver diseases including ICP, HELLP (haemolysis, elevated liver enzymes 
and low platelet count) syndrome and acute fatty liver of pregnancy (Hay, 2008). 
The need for increased hepatic capacity in rodents is achieved by a significant 
increase in liver size (Paschkis & Cantarow, 1958). Despite being first noted in 1939, 
the mechanism by which the liver of pregnant mice almost doubles in size compared 
to their non-pregnant littermates is poorly understood. Some early studies on mice 
have proposed that the liver growth is achieved with no increase in hepatocyte 
number and without an increase in liver DNA content (Hollister et al, 1987). 
However, the limitations of the techniques available at the time and the descriptive 
nature of the study have not shed light in the mechanism underlying pregnancy 
induced liver growth.  
Two cellular phenomena, hyperplasia (increased number of cells) and hypertrophy 
(increased cell size) are the processes by which the liver can achieve growth. 
Hyperplasia has been studied widely in hepatocytes, mainly in liver regeneration 
after hepatectomy and during postnatal liver growth.  The adult hepatocytes are 
quiescent and highly differentiated cells. They have a long half-life and rarely divide 
with only one out of 20,000 hepatocytes going through mitosis (Steer, 1995). 
Nevertheless, the hepatocyte has the capacity to re-enter the cell cycle and go 
through cell division unlike most other differentiated cell types. Remarkably, 70% 
hepatectomy in mice is accompanied by hepatocyte hyperplasia that restores liver 
mass within a few days after surgery (Fausto, 2000; Michalopoulos & DeFrances, 
1997). After hepatectomy nearly all hepatocytes exit G0 at the same time and enter 
the cell cycle. The liver lobes left after surgery grow until they achieve the size of the 
original liver and then they immediately stop (Steer, 1995). Several growth factors 
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(HGF, TGFα, EGF) and cytokines (IL6, TNFα) have been shown to play a key role 
in the process of regeneration (Fausto, 2000). In addition, increased bile acid levels 
accelerate the process of liver regeneration following partial hepatectomy, while 
decreased levels and absence of the nuclear receptors Fxr, Car or Pxr inhibit re-
growth (Dai et al, 2008; Huang et al, 2006). Also, treatment of mice with 
supraphysiological doses of 17α ethinylestradiol causes liver growth achieved by 
hepatocyte hyperplasia (Yamamoto et al, 2006).   
During pregnancy the levels of reproductive hormones and bile acids increase 
(Castano et al, 2006; Ochs et al, 1986; Vilatoba et al, 2005), making them plausible 
candidates for the signal driving gestational hepatomegaly. However it is not known 
whether pregnancy levels of estrogens or bile acids are sufficient to drive liver 
growth. Pregnancy is also associated with alterations in a number of other metabolic 
parameters, including insulin, IGF, growth hormone and placental lactogens (Butte, 
2000; Freemark, 2006; Herrera, 2000), which are likely to contribute to gestational 
liver enlargement. These factors play important roles in maintaining physiological 
adaptations during pregnancy and are likely to have additive and complementary 
roles on driving liver growth. 
In the work described in this chapter, the cellular and molecular mechanisms 
underlying pregnancy-induced liver growth will be described. In addition, the role of 
physiological concentrations of reproductive hormones, bile acids and the nuclear 
receptors Fxr and Pxr in gestational liver enlargement will be investigated. These 
studies will provide novel insights into the temporal control of maternal liver growth 
and the mechanisms and signals driving gestational liver enlargement.  
 
Bryn Owen was responsible for the maintenance, experiments and data analysis 
conducted on Pxr-/- mice. 
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6.2 Results 
 
6.2.1 Pregnancy levels of estrogen and progesterone alone are 
not causing liver growth. 
In order to determine the contribution of reproductive hormones and bile acids in 
gestational liver enlargement, three mouse models were used. The liver weight and 
serum bile acids were analysed in pregnant mice (18 days in pregnancy), in long-
term cholate fed mice (30 days) and in mice that received silastic implants containing 
pregnancy levels of 17β-estradiol (E2) and progesterone (Pn) for 18 days.  
Liver weight was increased by 66% (p<0.01) in 18-day pregnant mice compared to 
non-pregnant controls (Figure 6.1A). The increase in liver weight was accompanied 
by a 7-fold increase (Figure 6.1B) in total serum bile acids (p<0.01). Furthermore, 
feeding a cholate supplemented diet resulted in a similar increase in liver weight 
(63% (p<0.01)) (Figure 6.1A) in these mice, whereas serum bile acids increased by 
14-fold (p<0.01, Figure 6.1B). Hence, pregnancy and cholate feeding cause liver 
growth accompanied by increased levels of bile acids.  
Reproductive hormones at levels similar to those found in pregnancy were 
administered in ovariectomised mice for 18 days. The hormones were delivered via 
silastic implants and peanut oil was used as the vehicle. Uterine swelling was 
observed in the mice receiving the hormones, indicating that the treatment was 
effective. As shown in Figure 6.1A and 6.1B, the hormone treatment (or vehicle) had 
no effect on liver weight or serum bile acids. 
These data demonstrate that reproductive hormones alone cannot cause liver growth. 
Therefore, E2 and Pn are unlikely to be the principal signal driving hepatomegaly in 
pregnancy. On the other hand, both pregnant and cholate fed mice present with 
increased liver weight and raised serum bile acids, suggesting that bile acids may 
have a role in mediating gestational liver enlargement. 
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Figure 6.1: Pregnancy and cholate feeding are associated with liver growth and 
increased levels of bile acids. 
Wild type mice were mated and sacrificed on day 18 of pregnancy (pregnant), fed a 
0.5% cholic acid diet (cholate) or were ovariectomised and received implants 
containing 17β-estradiol and progesterone (E+Pn) or vehicle for 18 days. (A) Liver 
weight and (B) total serum bile acids 
Results are shown as mean ±S.E.M. (n=12 pregnant and cholate fed mice and n=5 
E+Pn treated). *p<0.05 compared to controls. 1-way ANOVA was used to determine 
differences between data groups. 
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6.2.2 Pregnancy-induced hepatomegaly in mice is achieved by 
hepatocyte hypertrophy. 
Although pregnancy-induced liver growth has been previously described (Hollister et 
al, 1987; Paschkis & Cantarow, 1958), the reports are old and incomplete. Total 
protein was extracted from the livers of non-pregnant and pregnant mice to 
investigate whether the increase in liver size is functional or just a result of increased 
cellular water content. There was no difference in the total protein per gram of tissue 
between non-pregnant and pregnant mice (p=0.89, data not shown), indicating that 
the change in liver size is associated with increased protein content, consistent with it 
having a functional effect. 
Liver growth can be achieved by cell hyperplasia, cell hypertrophy or both. 
Inspection of H&E stained liver sections showed a significant increase in hepatocyte 
cross-sectional area. In order to quantify the increase in cell size, the number of 
hepatocytes per microscope field were counted. Typically a number of hepatocytes 
are bi-nucleate making identification of individual hepatocytes difficult. 
Immunostaining of liver sections with β-catenin was performed to visualise the cell 
membrane (Figure 6.2A), thereby facilitating the accurate identification and counting 
of the number of hepatocytes per microscope field. Hepatocytes were counted in 10 
microscope fields (x40 magnification) per animal (n=6). The number of hepatocytes 
was reduced by 19% (p<0.01) in pregnant mice compared to non-pregnant controls 
(Figure 6.2B). Reduction in the number of hepatocytes suggests increased cross-
sectional surface area in pregnant mice compared to controls, consistent with 
hypertrophy.   
 
 
 
 
 
 
 
 
 
 
Chapter 6                                                                                                                                         Results 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     186 
 
 
 
 
Figure 6.2: Gestational liver growth is caused by hepatocyte hypertrophy. 
Mice were mated and sacrificed on the day of conception (non-pregnant) or the day 
18 of pregnancy (pregnant). (A) Representative image of liver sections (5µm) that 
were stained for β-catenin in order to visualise the borders of the cells (x40 
magnification). (B) Number of cells per microscope field.  
Results are shown as mean ±S.E.M. (n=6) p<0.05 compared to non-pregnant 
controls. Two-tailed Student’s t test was used to determine differences between data 
groups. 
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Hepatocyte hypertrophy appears to account for the bulk of the change in liver size 
when calculated to volume. However, hepatocyte proliferation was also assessed for 
having a role in liver growth during pregnancy. Ki-67 was used as a marker of cell 
cycle progression. Ki-67 antigen is a cell cycle related protein expressed by 
proliferating cells in all phases of the active cell cycle (G1, S, G2 and M phase) and 
it is absent in resting cells (G0). On the other hand phospo-histone-H3 was used as a 
specific marker for cell division (mitosis). Liver sections from pregnant and non-
pregnant controls were stained for both proteins and the positive cells were counted 
and expressed as a proportion of the total cell number per microscope field. 
Pregnancy resulted in a 10-fold (p<0.01) increase in the proportion of Ki-67 positive 
hepatocytes (Figure 6.3A) without affecting the proportion of hepatocytes 
undergoing cell division (Figure 6.3B). These data demonstrate that pregnancy cause 
the hepatocytes to enter the cell cycle without concomitant cell division. The 
apoptotic index of the liver was also investigated. TUNEL staining on liver sections 
of pregnant and non-pregnant controls did not show any differences on the 
proportion of apoptotic hepatocytes (Figure 6.3C).  
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Figure 6.3: Pregnancy causes hepatocyte cell cycle entry without causing 
mitosis. 
Mice were mated and sacrificed on the day of conception (non-pregnant) or the day 
18 of pregnancy (pregnant). Liver sections (5µm) were stained for Ki-67, phosph-
histone-H3 and assessed for apoptosis. (A) Ki-67, (B) mitotic cells (phospho-histone-
H3 positive cells) and (C) apoptotic cells were expressed as a proportion of total cells 
per microscope field (x40 magnification).  
Results are shown as mean ±S.E.M. (n=6) p<0.05 compared to non-pregnant 
controls. Two-tailed Student’s t test was used to determine differences between data 
groups. 
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To check whether polyploidy (i.e. DNA replication without cell division) contributes 
to the hypertrophy, the DNA content of the livers in pregnant and non-pregnant 
controls was also assessed. The DNA content was quantified using two methods; 
quantitative fluorescent imaging and FACS analysis. Both methods have been 
previously published to determine in vivo the DNA content (Fabregat et al, 1996; 
Toyoda et al, 2005). Liver sections were stained with Hoechst 33342 and imaged in 
greyscale. Hoechst 33342 is a dye that binds the DNA stoichiometrically. Cell 
profiler software, with manual screening was used to identify hepatocyte nuclei and 
sum the fluorescent intensity of each pixel within the nucleus as a measure of the 
DNA content of that nucleus. Binucleate hepatocytes were also identified but no 
difference was found between pregnant animals and non-pregnant controls. 
Binucleate hepatocytes and cells with overlapping nuclei were not included in the 
analysis to avoid artefacts in fluorescent intensity. Quantitative fluorescent imaging 
of Hoechst stained hepatocyte nuclei demonstrated that pregnancy caused the 
emergence of a cell population containing twice the DNA content of controls (Figure 
6.4A). In order to confirm these results, FACS analysis was performed. A small fresh 
piece of liver was used to isolate the cells. In brief, the liver tissue was gently 
crushed in PBS solution and filtered through a fine mesh in order to get a suspension 
of single hepatocytes. The crude-isolated primary cells were then stained with 
propidium iodide (PI) and subjected to FACS analysis. FACS analysis also showed 
an increase in DNA content in pregnant mice compared to non-pregnant controls. 
Figure 6.4C shows that pregnancy causes a significant rise (p<0.01) in hepatocytes 
containing higher amounts of nuclear DNA. Therefore, pregnancy in mice results in 
entry of the hepatocytes into the cell cycle, DNA synthesis and arrest prior to 
mitosis.  
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Figure 6.4: Pregnancy increases hepatocyte nuclear content. 
(A) Histogram of hepatocyte nuclear DNA content from six non-pregnant and six 
pregnant mice, 1,500 nuclei were assessed from each group. (B) Example traces of 
non-pregnant and pregnant wild type mice after FACS analysis and (C) Average 
proportion of hepatocytes in Bin 1 (low DNA) content and Bin 2 (high DNA content)  
Results are shown as mean ±S.E.M. (n=6) p<0.05 compared to non-pregnant 
controls. Two-tailed Student’s t test was used to determine differences between data 
groups. 
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The data presented so far indicate that pregnancy has a significant effect on the cell 
cycle. Therefore, the effect of pregnancy was investigated on the expression of 
several regulators of the cell cycle. Western blots were performed on pooled total 
liver protein extracts from six non-pregnant and six pregnant mice. Pregnancy 
induced the hepatic expression of the tumour suppressor p53 approximately two fold 
when compared to non-pregnant controls (Figure 6.5). Degradation of p27 is known 
to be required for cyclin D1 mediated cell cycle progression and while pregnancy 
caused a marked decrease of p27 expression, the expression of cyclin D1 was also 
reduced by pregnancy (Figure 6.5). The expression of p21, which inhibits cell cycle 
progression and is controlled by p53 in the posttranscriptional level, was unaffected 
by pregnancy (Figure 6.5). Gapdh protein was used as the housekeeping gene, 
demonstrating that equal amounts of protein were subjected to western blot analysis 
for each group. Hence, pregnancy has complex effects on cell cycle regulators, by 
both inducing and inhibiting their expression.  
 
In summary, the phenotypic changes of pregnancy-induced liver growth were 
described. Pregnancy clearly modulates the expression of cell cycle regulators, and 
causes the normally quiescent hepatocytes to enter the cell cycle and synthesise DNA 
without undergoing mitosis. In conclusion, pregnancy-induced liver growth is mainly 
achieved by hepatocyte hypertrophy.   
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Figure 6.5: Pregnancy modulates the expression of cell cycle regulators. 
Pooled samples from six mice per group were subjected to western blot analysis. 
Here, the protein levels of cell cycle regulators and loading control (GAPDH) are 
shown. Western blots were repeated three times. 
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6.2.3 Bile acid feeding causes liver growth by hepatocyte 
hyperplasia.  
As demonstrated in the previous section (section 1.2.2) bile acids could be implicated 
in the liver growth observed during pregnancy. In order to investigate the role of bile 
acids in this process, the mechanisms of cholate-induced liver growth will be studied 
and compared to those occurring during pregnancy.  
Female wild type mice were fed a 0.5% cholic acid supplemented diet for one, three, 
seven or thirty days. The liver growth was monitored and expressed as a proportion 
of body weight (Figure 6.6A). The bulk of the liver growth occurred between three 
and seven days, whereas prolonged cholate feeding for 30 days did not result in 
further increase in liver mass (Figure 6.6A). These findings indicate that bile acids 
cause rapid, but limited, liver growth in mice.  
In pregnancy, the liver growth is achieved by hepatocyte hypertrophy, as 
demonstrated by the increase in hepatocyte size (Figure 6.2B). However in mice fed 
a cholate diet, hepatocyte size was not significantly affected (Figure 6.6B) Most of 
the increase in the liver mass happens by day 7 of feeding a cholate-supplemented 
diet. Counting of hepatocytes in mice fed a control or cholate diet did not reveal any 
differences in the number of cells per microscope field (Figure 6.6B). Hence, 
hepatocyte hypertrophy does not contribute to hepatomegaly caused by bile acid 
overload. In order to investigate whether hyperplasia plays a role in liver growth in 
this model, cell cycle progression and mitosis were assessed. Therefore, Ki-67 and 
phospo-histone-H3 immunostaining was performed on the livers of mice fed either a 
control or cholate diet. The proportion of Ki-67 positive cells was increased by 
approximately 30% (p<0.001) between three and seven days of feeding, which 
parallels the increase in liver mass seen between these time points (Figure 6.6C). On 
the other hand, the proportion of Ki-67 positive hepatocytes decreased between 
seven and thirty days of feeding (Figure 6.6C), which is in line with the lack of 
significant change in liver size. Nevertheless, the number of cells stained positive for 
Ki-67 is significantly higher after 30 days of feeding compared to control-fed or 
cholate-fed for one and three days. The proportion of phospho-histone-H3 positive 
mitotic figures also increased significantly between three and seven days of feeding 
(Figure 6.6D). Interestingly, the increase in mitotic figures was not as striking as the 
increase of Ki-67 positive cells, which suggests that the major mitotic events take  
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Figure 6. 6: Bile acid feeding causes liver growth by hepatocyte hypertrophy. 
Mice were fed a control or a 0.5% cholic acid supplemented diet for one, three, seven 
or thirty days. (A) Liver weight presented as a proportion of body weight. (B) 
Number of hepatocytes per microscope field (x40 magnification). (C) Ki-67 positive 
and  (D) mitotic (phospho-histone-H3 positive) cells expressed as a proportion of 
total cells per microscope field (x40 magnification). 
Results are shown as mean ±S.E.M. (n=6) *p<0.05 compared to controls. 1-way 
ANOVA was used to determine differences between data groups. 
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place between day three and seven of  cholate feeding. Therefore, these findings 
demonstrate that unlike pregnancy, bile acid feeding causes liver growth by 
hepatocyte hyperplasia rather than hepatocyte hypertrophy.  
The DNA content was also quantified in the livers of mice fed a cholate diet, in order 
to determine whether liver ploidy can be affected by bile acid overload. As was the 
case during pregnancy, the average hepatocyte nuclear DNA content was also 
increased in mice fed a cholate diet (Figure 6.7A).  
The expression of cell cycle regulators was assessed during the time-course of 
cholate feeding by western blot (figure 6.7B), which showed significant changes. 
The expression of the cell cycle promoter cyclin D1 increased after three days of 
cholate feeding and remained higher compared to controls, even after continuation of 
feeding the cholate-supplemented diet up to 30 days (Figure 6.7B). The tumour 
suppressor p53 was unaffected after one day of feeding. However, its expression was 
considerably reduced after three days and remained lower than controls, despite a 
small increase after 30 days of cholate feeding (Figure 6.7B). The protein expression 
of the growth inhibitor p27 was reduced after one day, but its expression was 
restored to control levels after 30 days. Finally, p21, which is a cell cycle inhibitor, 
was induced after three days of cholate feeding and further increased following seven 
and 30 days (Figure 6.7B). Increase in the expression of a cell cycle inhibitor is in 
line with the inhibition of liver growth between these two time points (Figure 6.6A). 
Overall, these data demonstrate that cell-cycle promoting changes take place after 
short-term cholate feeding, whereas long-term feeding results in more growth 
inhibiting changes possibly to prevent further liver growth.  
In conclusion, cholate feeding causes liver enlargement by hyperplasia and is 
therefore different to pregnancy-induced liver growth. However, both cholate feeding 
and pregnancy lead to cell cycle progression and polyploidy. In addition, the 
expression of cell cycle regulators seems to be affected and differentially regulated 
by both pregnancy and bile acid overload.  
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Figure 6. 7: Bile acid feeding alters hepatocyte ploidy and expression of cell-
cycle regulators. 
Mice were fed a control or a 0.5% cholic acid supplemented diet for one, three, seven 
or 30 days. (A) Histogram of hepatocyte nuclear DNA content of control-fed (n+6) 
and 30-day cholate fed mice (n=6); 2000 nuclei from each group were used for the 
analysis. (B) Pooled samples from six mice per group were subjected to western blot 
analysis. The protein levels of cell cycle regulators and loading control (GAPDH) are 
shown. Western blots were repeated three times. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6                                                                                                                                         Results 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     197 
6.2.4 Gestational liver growth takes place independent of bile 
acids and the nuclear receptors Pxr and Fxr.  
Although liver growth is achieved by different mechanisms during pregnancy and in 
cholate feeding, cell cycle progression and polyploidy are common features. In order 
to further investigate whether bile acids play a role in pregnancy-induced liver 
growth, gestational liver enlargement was investigated in wild type mice, long-term 
cholate fed mice and in knockout mice for the nuclear receptors Fxr or Pxr. 
In long-term cholate fed animals, pregnancy caused a further increase in serum bile 
acids (76%) and liver weight (37%) (Figure 6.8A and 6.8B). Therefore, pregnancy 
signals a second wave of liver growth in mice.  Both non-pregnant and pregnant 
animals received the cholate-supplemented diet for the same amount of time (30 
days). There were no differences noted in either fetal number or weight after 
prolonged cholate feeding.  
As expected, non-pregnant Fxr-/- mice had slightly higher bile acids than non-
pregnant wild type mice (Figure 6.8A). However, neither Fxr-/- nor Pxr-/- animals 
developed raised serum bile acids during pregnancy (Figure 6.8A). Despite no 
significant changes in serum bile acids in pregnancy, both Fxr-/- and Pxr-/- mice were 
found to undergo gestational liver enlargement that is not significantly different to 
that observed in wild type animals (Figure 6.8B).  
These results demonstrate that pregnancy can cause raised serum bile acids and a 
second wave of liver growth in long-term cholate fed animals. Pregnancy-induced 
liver enlargement in Fxr-/- and Pxr-/- mice occurred in the absence of raised serum 
bile acids suggesting that bile acid signalling via these receptors is not required to 
induce or maintain liver growth.  
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Figure 6.8: Pregnancy induced liver growth in cholate-fed, Fxr-/- and Pxr-/- mice, 
which was not accompanied by a raise in bile acid levels for all groups. 
Wild type, Fxr and Pxr knockout mice were mated and killed on the day of 
conception (Non-pregnant) or on day 18 of pregnancy (Pregnant). Non-pregnant and 
pregnant 0.5% cholate fed mice received the supplemented diet for 30 days. (A) 
Total serum bile acid levels. (B) Liver weight. 
Results are shown as mean ±S.E.M. (n=6) *p<0.05 compared to wild type, ♯p<0.05 
compared to non-pregnant. 2-way ANOVA was used to determine differences 
between data groups. 
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6.2.5 Hepatocyte hypertrophy and hyperplasia contribute to 
pregnancy-induced liver growth in Fxr-/- mice. 
Bile acids, Fxr and Pxr are implicated in liver regeneration after partial hepatectomy, 
suggesting that they could have a role in liver growth. In these studies, it was 
demonstrated that the normal mechanisms of regeneration were not maintained after 
hepatectomy in the Fxr-/- and Pxr-/- mice, but the phenotype was mild and redundant 
pathways compensated for liver growth to be achieved. Therefore, the mechanism of 
pregnancy-induced liver growth in the absence of Fxr or Pxr and in cholate fed mice 
could differ. Although there were no differences in the pregnancy-induced liver size 
the mechanisms of gestational liver growth were investigated in Fxr-/-, Pxr-/- and 
cholate-fed mice. 
Long-term cholate-fed animals undergo gestational liver growth by similar 
mechanisms to wild type mice on control diet. This was shown by a decrease in the 
number of hepatocytes per microscope field (Figure 6.9A) and increased Ki-67 
staining (Figure 6.9B). Pregnancy had no effect on the proportion of mitotic figures 
(Figure 6.9C) or apoptotic cells (Figure 6.9D) in cholate fed animals. Cholate feeding 
increased nuclear DNA content but pregnancy had no further effect on hepatocyte 
DNA content in these mice (Figure 6.10A), indicating that cell cycle progression is 
terminated prior to S-phase. Overall, the normal mechanisms of gestational liver 
growth are maintained in cholate-fed animals, except that the hepatocytes do not 
undergo further DNA synthesis during pregnancy. Pregnancy had similar effects on 
the expression of cyclin D1, p21 and p53 in normal fed and long-term cholate fed 
mice but the upregulation of p27 was only seen in the cholate-fed animals (Figure 
6.9B).   
Non-pregnant Pxr-/- mice have a reduced number of cells per microscope field 
(Figure 6.9A), indicating that these animals have larger hepatocytes basally. 
Interestingly, the Pxr-/- mice exhibit higher levels of the cell cycle inhibitor p21 
Figure 6.10B). The proportion of Ki-67 positive cells (Figure 6.9B) and the mitotic 
figures (Figure 6.9C) were also decreased in Pxr-/- compared to non-pregnant wild 
type mice, whereas the DNA content (Figure 6.10A) and apoptotic cells (Figure 
6.9D) did not change. Nevertheless, the mechanisms by which pregnancy-induced 
liver growth is achieved in the Pxr-/- pregnant mice do not differ compared to wild 
types. The hepatocyte size (Figure 6.9A) and the proportion of Ki-67 positive cells  
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Figure 6.9: Redundant mechanisms ensure liver growth during pregnancy, in 
the presence of high serum bile acids or in the absence of Fxr. 
Wild type, Fxr and Pxr knockout mice were mated and killed on the day of 
conception (Non-pregnant) or on day 18 of pregnancy (Pregnant). Non-pregnant and 
Pregnant 0.5% cholate fed mice received the supplemented diet for 30 days. (A) 
Number of hepatocytes per microscope field (x40 magnification). (B) Ki-67 positive 
and (C) mitotic (phospho-histone-H3 positive) and (D) apoptotic cells expressed as a 
proportion of total cells per microscope field (x40 magnification). 
Results are shown as mean ±S.E.M. (n=6) *p<0.05 compared to wild type, ♯p<0.05 
compared to non-pregnant. 2-way ANOVA was used to determine differences 
between data groups. 
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(Figure 6.9B) were similarly increased by pregnancy when compared to wild type 
mice, whereas the proportion of mitotic figures and apoptotic cells were not altered 
(Figure 6.9C and 6.9D). Pregnancy did not differentially affect the cell cycle 
regulators in Pxr-/- mice compared to wild types (Figure 6.10B). 
In Fxr-/- mice, the pregnancy-associated increase in hepatocyte size was reduced 
compared to wild types (Figure 6.9A). Furthermore, the proportion of mitotic figures 
was significantly increased by pregnancy (Figure 6.9C) and there was no significant 
effect on nuclear DNA content (Figure 6.10A) in Fxr-/- mice. These data indicate that 
pregnancy-induced liver growth is accomplished by hyperplasia and “some” 
hypertrophy in the absence of Fxr. The Fxr-/- mice were the only group to have a 
raised proportion of apoptotic cells, which was exacerbated by pregnancy  (Figure 
6.9D). Cyclin D1 and p53 were similarly affected by pregnancy in wild type and Fxr-
/- mice whereas pregnancy induced the expression of p27 and p21 in the Fxr-/- mice. 
p27 was the only protein differentially regulated in pregnant Fxr-/- mice (Figure 
6.10B). These data indicate that mice lacking Fxr exhibit different mechanisms for 
achieving pregnancy-induced hepatomegaly. 
Finally, it can be concluded that the normal mechanism of gestational liver 
enlargement is broadly maintained in Pxr-/- and cholate fed mice. In mice lacking Fxr 
however, pregnancy-induced hepatocyte hypertrophy is blunted and liver growth is 
achieved by adaptive hyperplasia. 
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Figure 6.10: Differential regulation of DNA content and expression of cell-cycle 
regulators between wild type, Fxr-/-, Pxr-/- and cholate-fed mice. 
Wild type, Fxr and Pxr knockout mice were mated and killed on the day of 
conception (Non-pregnant) or on day 18 of pregnancy (Pregnant). Non-pregnant and 
Pregnant 0.5% cholate fed mice received the supplemented diet for 30 days. (A) 
Hepatocyte nuclear DNA content. 100 nuclei per animal (n=6 per group) were 
assessed to determine the DNA content. (B) Pooled samples from six mice per group 
were subjected to western blot analysis. The protein levels of cell cycle regulators 
and loading control (GAPDH) are shown. Western blots were repeated three times.  
Results are shown as mean ±S.E.M. (n=6) *p<0.05 compared to wild type, ♯p<0.05 
compared to non-pregnant. 2-way ANOVA was used to determine differences 
between data groups. 
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6.2.6 Gestational liver growth may be driven by a placenta-
derived lactogenic hormone. 
The data presented so far demonstrate that increased levels of bile acids during 
pregnancy are not essential for driving liver growth. In addition, pregnancy levels of 
reproductive hormones alone do not cause hepatomegaly. Pxr-/- mice undergo 
pregnancy-induced liver growth by similar mechanisms to the wild type mice, 
whereas Fxr is required for normal gestational liver enlargement.   
The possibility of a fetal or placental signal driving liver growth was therefore 
examined. Maternal liver weight was determined in pregnant mice with naturally 
varying numbers of viable implantation sites. Pregnant mice had between 5 and 12 
fetuses. Interestingly, 56% (R2) of the observed variation in liver weight can be 
attributed to the number of fetuses indicating that the signal driving pregnancy-
induced liver growth may be of fetal or placental origin (Figure 6.11A, p<0.001). 
Pregnancy causes the net liver weight to increase, but when the liver weight is 
expressed as a ratio of liver/body weight, then there is no difference between non-
pregnant and pregnant mice (Figure 6.11B). This could suggest that the liver grows 
as a response to the increased maternal body weight. Interestingly, analysis of liver 
size on the 12th day of pregnancy shows that significant liver growth has occurred at 
mid-gestation despite little change in maternal body weight (Figure 6.11B) 
demonstrating that the liver does not simply sense and respond to changes in 
maternal body mass. In addition, measurement of maternal liver size at 16 days after 
parturition shows that liver size is maintained, and increases during lactation but 
decreases if the pups are removed so that lactation stops (Figure 6.11B). These 
findings suggest that there is a signal driving liver growth independent of maternal 
body weight.  
In mice, the placental development is completed by day 14 of pregnancy when the 
fetus is only 10% of its mass in parturition. The fact that the maternal liver size is 
already significantly increased at day 12, when fetal growth is still very limited, 
suggests that a placental signal might be responsible for driving gestational liver 
growth at least in the early stages. Placenta is responsible for the production of many 
factors necessary for the maintenance of pregnancy. From mid-gestation and until 
delivery, the placenta in mice produces lactogens (Figure 1.7). After delivery and 
during lactation, lactogens are then produced by the pituitary (Soares, 2004).  
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Figure 6.11: The signal driving liver growth during pregnancy could be of 
placental origin. 
Wild type mice were mated and killed on the day of conception (non-pregnant) or on 
the day 18 of pregnancy (pregnant). Animals were also killed 16 days after giving 
birth and either left with the pups (16D post-partum lactating) or the pups were 
removed (16D post-partum non-lactating). 
(A) Number of fetuses in utero against liver weight in wild type animals. (B) Liver 
weight expressed as a percentage of body weight in wild type animals at day 12 and 
day 18 of pregnancy and in animals at day 16 after giving birth that were allowed 
either to lactate or not (pups were taken away). Results are shown as mean ±S.E.M. 
(n=6) *p<0.05 compared to non-pregnant, ♯p<0.05 compared to 12-day pregnant. 1-
way ANOVA was used to determine differences between data groups. 
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Analysis of mRNA expression levels in the maternal liver shows that the growth 
hormone receptor (Ghr) and prolactin receptor (Prlr) are significantly increased 
during pregnancy and to a similar extent in control mice (4.7- and 7.6-fold), long-
term cholate fed animals (3- and 5.7-fold), Fxr-/- (3.4- and 5.7-fold) and Pxr-/- (3.6- 
and 7.3-fold) animals (Figure 6.11A and 6.11B). Basally, Fxr-/- mice express lower 
levels of Ghr and Prlr than wild type mice but pregnancy induces their expression at 
the same magnitude as in the wild type animals (Figure 6.11A and 6.11B). Ghr and 
Prlr increase during pregnancy at the same level in wild type, Fxr-/-, Pxr-/- and 
cholate-fed mice which correlates with the comparable levels of gestational liver 
enlargement seen in these mice. It is conceivable therefore that placental lactogens, 
which are detectable in serum from early to mid gestation, may initiate gestational 
liver growth. 
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Figure 6.12: Pregnancy induces the expression of prolactin and growth hormone 
receptors. 
Wild type, Fxr and Pxr knockout mice were mated and killed on the day of 
conception (Non-pregnant) or on day 18 of pregnancy (Pregnant). Non-pregnant and 
Pregnant 0.5% cholate fed mice received the supplemented diet for 30 days. (A) 
Growth hormone receptor (Ghr) and (B) Prolactin receptor (Prlr) mRNA expression. 
Results are shown as mean ±S.E.M. (n=6) *p<0.05 compared to wild type, ♯p<0.05 
compared to non-pregnant. 2-way ANOVA was used to determine differences 
between data groups. 
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6.3 Summary and Conclusions 
In this study, novel insights were provided into potential signals driving pregnancy-
induced liver growth in mice. It was demonstrated that pregnancy causes liver 
growth by hepatocyte hypertrophy while cholate feeding induces hyperplasia. Cell 
cycle progression and polyploidy were observed in both models. The bile acid 
receptors Fxr and Pxr are not essential to achieve pregnancy-induced liver growth 
but the principal bile acid sensor Fxr is required to maintain the normal mechanism 
of gestational liver growth in mice. Liver growth during pregnancy occurs in Fxr-/- 
mice by both hypertrophy and hyperplasia. By demonstrating altered mechanisms of 
gestational hepatomegaly in the absence of Fxr, it was shown that adaptive 
mechanisms exist to ensure gestational liver growth and increased functional 
capacity.  
Reproductive hormone levels increase considerably during pregnancy and there are 
data demonstrating that administration of E2 (Yamamoto et al, 2006) or Pn (Ochs et 
al, 1986) cause liver toxicity accompanied by hepatomegaly. In addition there are a 
few studies reporting that estrogen plays a vital role in liver regeneration. In male 
rats, the serum levels of estradiol are raised in the first six hours following 
hepatectomy (Francavilla et al, 1989; Liddle & Farrell, 1993; Liddle et al, 1992). It 
has been suggested that this may facilitate the initial stages of liver regeneration 
(Eagon et al, 1985). Fisher et al. demonstrated that the administration of 17β-
estradiol induced the rapid translocation of the cytoplasmic estrogen receptors to the 
nucleus of the hepatocytes (Fisher et al, 1984). Francavilla et al found some blockage 
of the regeneration process after administration of tamoxifen, an antagonist of 
estrogen receptor (Francavilla et al, 1986). Mizushima et al. reported improved liver 
function after estrogen treatment of rats following hemorrhagic trauma (Mizushima 
et al, 2000). Interestingly, administration of estradiol reduces the serum level of 
interleukin-6, whereas vehicle treatment led to increased levels of interleukin-6 
(Mizushima et al, 2000). For these reasons, pregnancy levels of 17β-estradiol and 
progesterone were delivered to mice via silastic implants over a time course similar 
to that of pregnancy but no effect was observed on liver size. This suggests that the 
previously reported E2 and Pn-induced hepatotoxicity and hepatomegaly are likely to 
be a result of the supra-physiological concentrations administered. Also, the role of 
estrogen in the regeneration process after hepatectomy seems to be part of a feedback 
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mechanism between estrogen and other factors such as interleukin 6. Therefore, 
reproductive hormones alone are unlikely to be the primary liver growth-promoting 
signal during pregnancy.  
Bile acids are raised during pregnancy in humans (Castano et al, 2006) and can drive 
liver growth in rodents at relatively low serum concentrations (Huang et al, 2006). In 
this study, it was shown that pregnancy also increases total serum bile acids in wild 
type mice. In addition, pregnancy results in liver growth of a similar magnitude to 
long-term feeding of a 0.5% cholate supplemented diet. In agreement with previous 
reports (Huang et al, 2006), and using independent assays, it was demonstrated that 
cholate-feeding caused liver growth by cell proliferation that was accompanied by 
hepatocyte polyploidy. Pregnancy also caused cell cycle entry and polyploidy but in 
contrast to the cholate-feeding, only hepatocyte hypertrophy was observed without 
evidence of mitosis.  
Polyploidisation is an important process in both normal and pathological liver 
physiology and growth. Also, regulation of polyploidy is important in normal 
physiology and pathological conditions, as it is thought to indicate terminal 
differentiation and senescence (Sigal et al, 1995) and to lead to both progressive loss 
of cell pluripotency and significantly decreased replication capacity (Gorla et al, 
2001). There are several theories about the occurence of polyploidy in the normal 
liver. It has been proposed that polyploid cells originate from the fusion of 
multinucleated cells, as studies have demonstrated that the number of multinucleated 
cells decrease in response to induction of hepatic polyploidy (Brodsky & Uryvaeva, 
1977; Gupta, 2000). However this has not been confirmed and further investigation 
is required. In this study, there were no significant differences observed in the 
prevalence of multinucleated cells between non-pregnant and pregnant animals in 
any of the models studied. Another theory involves the fate of cells when mitotic 
progression is perturbed and the cells arrest in the S phase. In this situation, cells can 
continue to synthesize DNA in the same nucleus but in the absence of mitosis 
because of disruption for example of the centromere assembly, which would lead to 
loss of cytokinetic ability (Gupta, 2000). Occurrence of such mechanisms during 
pregnancy could well alter the replication capacity of hepatocytes. However, it 
should be noted that this has not been studied.  
Hollister et al reported that pregnancy does not affect liver DNA content (Hollister et 
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al, 1987). However in the current study it was clearly shown the hepatocyte DNA 
content is increased during pregnancy. This is not a new phenomenon for the liver 
when there is increased metabolic demand. As expected hepatocytes show 
considerable DNA synthesis in the liver during fetal development (Gupta, 2000). 
During the first 3 weeks after birth, liver mass increases rapidly in association with 
hepatocellular DNA synthesis. Approximately 9% of the hepatocytes show evidence 
of DNA synthesis at this stage. However, increases in DNA synthesis and liver mass 
are not accompanied by high mitosis rates in these hepatocytes. Within 6 weeks of 
birth, DNA synthesis is only detected in a small number of hepatocytes, at levels 
similar to those observed in the adult liver. These findings indicate that liver growth 
after birth is achieved mainly by hepatic hypertrophy, during which hepatocytes 
accumulate increased amounts of DNA, probably as an adaptive response to 
increasing metabolic requirements (Gupta, 2000). Interestingly, increased 
polyploidisation has been reported in association with cell hypertrophy in other cell 
types including in smooth-muscle cells following exposure to hypertensive stress, 
acinar cells of the breast during lactation and endometrial cells of the uterus during 
pregnancy (Biesterfeld et al, 1994; Printseva & Tjurmin, 1992). These findings 
suggest that there are external stimuli that induce polyploidy and increased DNA 
synthesis during cellular hypertrophy. It should also be noted that hepatic polypoidy 
is present in disease state, as for example in the advancement of liver injury to 
cirrhosis and in many human carcinomas in tumorigenesis as well as during 
regeneration after hepatectomy (Gupta, 2000).  
These observations of altered ploidy and cell cycle progression were supported by 
the differential changes in the protein expression of cell cycle regulators during 
pregnancy. Despite evidence of cell cycle entry and increased DNA content in both 
conditions, pregnancy and cholate-feeding had differential effects on cyclin D1, p21 
and p53 expression but a similar effect on p27 expression. P53 protein expression 
does not change in mice fed a cholate diet, whereas the expression of p21 and 
cyclinD1 increases in these animals compared to pregnancy. Pregnancy seems to be a 
process that causes controlled cell cycle entry and alters the expression of cell cycle 
regulators in a dissimilar manner to bile acid overload in mice. 
 
Chapter 6                                                                                                                                         Results 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     210 
Because both cholate feeding and pregnancy cause cell cycle progression and DNA 
replication, the effects of pregnancy on long-term cholate fed mice and in mice 
lacking the bile acid receptors Fxr and Pxr were assessed. In long-term cholate fed 
mice, pregnancy causes a second wave of liver growth, which occurred in the 
absence of increased DNA content and in the presence of increased expression of 
tumour suppressors p53. Basally, Fxr-/- mice have raised bile acids compared to wild 
type mice that could be toxic for the liver and also contribute to the proliferative 
capacity of the liver seen during pregnancy. Bile acids did not further increase in Fxr-
/- mice during pregnancy but hepatocyte proliferation contributed significantly to the 
pregnancy-induced liver growth. These findings demonstrate that adaptive 
mechanisms, independent of Fxr and bile acid signalling, exist to ensure gestational 
liver growth. In addition, Pxr-/- mice did not develop gestational hypercholaemia but 
underwent pregnancy-induced liver enlargement, further demonstrating that raised 
serum bile acids are not required to achieve this growth.  
Another interesting finding of this study is that liver size increases as a linear 
function of fetal number, indicating that the signal driving gestational liver growth is 
of fetal or placental origin. Liver size is disproportional to body weight during mid-
gestation, demonstrating that the liver is not simply responding to changes in 
maternal mass. Fetal weight increases linearly from day-14 until parturition while 
placental weight increases from day-6 to day-14, after which no further development 
occurs (Iguchi et al, 1993), indicating that the stimulator of gestational liver growth 
is likely to be of placental origin. Hepatic expression of the Ghr and Prlr was up-
regulated to a similar extent in all the pregnancy models, therefore stimuli acting 
through the Ghr and Prlr are plausible signals driving pregnancy-induced liver 
growth. Placental lactogen I and II (PL-I and PL-II) replace pituitary growth 
hormone and prolactin from the 8th day of gestation (Ogren & Talamantes, 1988). 
Placental lactogens are capable of stimulating pancreatic islet cell growth and 
proliferation in vivo (Vasavada et al, 2000); this is also an established model of an 
organ that responds, by growth, to the increased metabolic demands of pregnancy 
(Gupta et al, 2007; Karnik et al, 2007). The significant increase in liver weight by the 
12th day of gestation and the temporal release (Ogren & Talamantes, 1988) of 
placental growth factors suggests that PL-I may drive the early phase of pregnancy-
induced liver growth in mice. A second phase of liver enlargement during lactation 
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suggests that lactogens, in this case of extra-placental origin, could be capable of 
driving hepatomegaly. However, it is unlikely that only one factor is solely 
responsible for pregnancy-induced liver growth. A variety of mechanisms and 
multiple interactions are likely to exist for driving liver growth during such a 
complex physiological process as pregnancy. Recently a report by Celton-Morizur et 
al demonstrated that the insulin/Akt pathway controls a cell division program that 
generates of binucleated tetraploid liver cells in neonatal mice. Therefore, it is 
proposed that insulin has a role in liver growth at this point (Celton-Morizur et al, 
2009). Insulin rises significantly during pregnancy, which suggests that it could have 
a role gestational hepatomegaly. Insulin levels rise during gestation as a response to 
the increased insulin resistance observed in late pregnancy. The insulin resistance of 
pregnancy results from increases in hormones and inflammatory cytokines, including 
placental growth hormone, cortisol, progesterone, TNFα, placental lactogens and 
prolactin (Arumugam et al, 2008). Therefore, it is unlikely that only one factor is 
responsible for pregnancy-induced liver growth and most possibly a complex 
pathway with feedback regulation of mutiple factors accounts for this phenomenon.  
In summary, it was demonstrated that gestational liver enlargement, as a result of 
hepatocyte hypertrophy, is independent of reproductive hormones, bile acids or the 
nuclear receptor Pxr. In the absence of Fxr however, the normal mechanisms of 
gestational liver enlargement are not maintained and growth is achieved primarily by 
hyperplasia. Finally, placental signals are likely to mediate gestational hepatomegaly. 
Understanding the mechanisms and signals regulating pregnancy-induced liver 
growth could lead treatments to increase the metabolic capacity of the liver. These 
treatments would be beneficial during gestational and non-gestational periods of 
increased hepatic stress, for example during acute fatty liver of pregnancy, small-for-
size liver transplantation, recovery from hepatic resection and support following 
increased metabolic or toxic insult. 
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7.1 Functional Variants of the Central Bile Acid Sensor in Intrahepatic 
Cholestasis of Preganancy. 
FXR is a transcription factor, which has been shown to have a critical role in bile 
acid, glucose and lipid homeostasis. Despite the compelling evidence that this 
nuclear receptor plays a regulatory role in a variety of different metabolic processes 
this was the first study to demonstrate functional variation in FXR and its relationship 
to human disease. Dr Saskia van Mil performed the mutational analysis in an ICP 
population and the appropriate controls and identified four variants; namely -1g>t, 
M1V, W80R and M173T in an ICP population (Van Mil et al, 2007). The work 
performed in this thesis describes the functional effects of theses variants. The 
variants -1g>t and M1V are positioned at the translational start site of FXRα1 and 
FXRα2. This amino terminus contains two ATG codons with five amino acids 
between them. By using in vivo and in vitro assays it was shown that both ATG 
codons can be used, but the first one is predominantly used in humans. These 
mutations also resulted in decreased protein expression and a reduction in 
transactivation efficiency, which suggests a defect in translation.  
In addition, the M173T mutation has a decreased ability to induce transcription via 
the IBABP promoter as was shown using reporter assays. The M173T variation is 
positioned in the second zinc finger of the DBD of FXR. This motif is involved in 
the formation of the FXR/RXR heterodimer and for making DNA contacts 
(Devarakonda et al, 2003). A change of the methionine to a threonine at this position 
would result in an extra hydrogen bond, therefore making the FXR/RXR/DNA 
complex more stable. This could have a negative effect on transcription, as 
association and dissociation of this complex is necessary for induction of 
transcription (Metivier et al, 2003). This is in line with the finding of reduced ability 
of the M173T variant to induce transcription. Estrogen and progesterone have been 
proposed to unmask the phenotype in ICP and there is evidence from rodent studies 
that they can cause cholestasis. However, treatment with estrogen and progesterone 
did not further affect the transactivation efficiency of M173T variant. The M173T 
was the only variant that was found to have a significant association with ICP. 
However, this variant is rare and studies using larger cohorts are needed to further 
study the significance of this variant in ICP.  
Chapter 7                                                                                                                                   Discussion 
­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ 
_______________________________________________________________     214 
The W80R variant was not investigated in this thesis, but work by Dr Saskia Van Mil 
showed that this variant did not cause a functional defect of the FXR protein. 
All of the FXR variants described are detected heterozygously which means that they 
do not completely eliminate FXR function. This is consistent with the phenotype of 
ICP. Women who develop ICP are asymptomatic outside pregnancy. This suggests 
that one copy of FXR is sufficient for the normal hepatic function. In contrast, the 
liver is challenged during gestation and then one copy of the wild type FXR may not 
be enough to confer protection against cholestatic disease.  
Although this is not direct evidence that these FXR variants result in lower hepatic 
FXR expression and activity in ICP patients, it is an important finding and it will 
stimulate further studies on cholestasis and other metabolic diseases. 
 
7.2 Influence of Reproductive Hormones on Bile Acid Homeostasis 
There are human data that implicate reproductive hormones in the aetiology of ICP. 
These come from findings that the disease is more common amongst twin 
pregnancies where reproductive hormones are higher than in singleton pregnancies 
and the fact that some women who have had ICP develop cyclical cholestasis outside 
of pregnancy or while taking oral contraceptives (de Pagter et al, 1976; Gonzalez et 
al, 1989).  
Several studies in rodents have investigated the effects of estrogen administration on 
the expression of genes that maintain bile acid homeostasis in the liver (Arrese & 
Accatino, 2003; Bossard et al, 1993; Crocenzi et al, 2005; Geier et al, 2003; Green et 
al, 2000; Simon et al, 2004; Stieger et al, 2000; Yamamoto et al, 2006). Data 
presented in this thesis question the conclusions of these reports. The consensus from 
the literature is that estrogen has pro-cholestatic effects on the hepatic expression of 
bile acid transporters. To a large degree, these findings were replicated in this thesis. 
However, by conducting the experiments using additional control and experimental 
groups, a number of confounding factors were identified that could lead to inaccurate 
interpretation of the data.  
There is no consensus in the literature about the dose, isomer, duration of treatment 
or vehicle used for estrogen administration. In addition, there is also no agreement on 
the species, strain or sex of rodent used. In this thesis, ovariectomised female mice 
were used for studies of estrogen treatment. These mice were considered to be a 
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better model than using male animals or non-ovariectomised females. While 
administration of estrogen did affect the expression of bile acid responsive genes, 
there was no pattern for pro- or anti-cholestatic gene expression. Furthermore, and 
perhaps more importantly, it was found that there was a major vehicle effect and the 
results differed significantly depending upon the dose, isomer and duration of 
treatment. Indeed these parameters had such a major effect on the outcome that 
definitive conclusions about the effect of estrogen on these genes could not be 
drawn. Therefore, subcutaneous administration of estrogen suspended in peanut oil is 
not a reliable method for investigating the effects of reproductive hormones on liver 
metabolism.  
As an alternative to the injections, the models of Milligan and Cohen were used to 
deliver reproductive hormones (Cohen & Milligan, 1993; Milligan & Cohen, 1994; 
Milligan & Finn, 1997). Silastic implants have been used in this way to determine 
the minimal hormone requirements to maintain pregnancy in post-mating 
ovariectomised mice (Milligan & Finn, 1997). Therefore, the reproductive hormones 
were delivered to the mice at pregnancy levels. In addition, the vehicle remained in 
the implant and had no effect on hepatic bile acid responsive genes. This thesis 
provides the first report of physiologically relevant doses of reproductive hormones 
on liver metabolism and then specifically on bile acid responsive genes.  
Pregnancy levels of estrogen and progesterone had a significant effect on global 
hepatic gene expression. This was determined by unsupervised microarray principal 
component analysis of microarray data. In addition, specific metabolic pathways, 
including androgen and estrogen metabolism, were significantly affected by the 
hormone treatment. There are very few data suggesting that the liver is a 
reproductive hormone responsive tissue, however the data presented here suggest 
that it is. In addition, several steroidogenic enzymes are expressed in the liver and 
their expression is altered by the reproductive hormone treatment, demonstrating that 
they are actively regulated in this tissue. Interesting future experiments should be 
conducted to determine whether the liver has a steroidogenic capacity and whether 
this capacity is modified during pregnancy or in response to reproductive hormones.  
Global microarray analysis was also conducted in reproductive hormone treated Fxr-
/- mice. Fewer genes were affected in the knockout animals than in wild type animals 
but this could have been due to greater inter-individal variation in the Fxr-/- mice. 
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However, data on the androgen and estrogen metabolism pathway is a potential area 
of future work as despite being highly significantly affected by the reproductive 
hormones in the wild type mice, it was not affected in the Fxr-/- animals.  
It was investigated whether the physiologically relevant reproductive hormone 
treatments had pro-cholestatic hepatic gene expression effects. No clear pattern of 
pro- or anti-cholestatic gene expression was found in response to reproductive 
hormone challenge. On the whole, the magnitude of gene expression effect was 
small. While Bsep was slightly repressed by the treatment, which is a pro-cholestatic 
effect, Shp was induced and Cyp7a1 repressed, which are anti-cholestatic effects. 
Finally, it was found that Fxr is not required to mediate most of the effects of the 
hormones on the bile acid responsive genes.  
Therefore, pregnancy levels of reproductive hormones significantly affect liver 
metabolism and bile acid responsive gene expression. However, it is unclear from the 
data presented here whether this level of hormone exposure is pro- or anti- 
cholestatic or whether Fxr plays a major role in mediating the changes. The data 
presented in this thesis highlight the lack of knowledge on the effect of reproductive 
hormones on bile acid homeostasis. Future experiments are clearly required but these 
should be conducted using methodologies that are physiologically relevant and 
minimizing confounding factors. It is also possible that pregnancy-specific 
reproductive hormone metabolites may be pro-cholestatic. In addition, the interaction 
of reproductive hormones with other gestational factors such as fetal metabolites may 
interact to promote dysregulated bile acid homeostasis in pre-disposed individuals.  
 
7.3 Reduced FXR Function May Account for Bile Acid Accumulation 
during Pregnancy. 
Despite an increase in circulating blood volume of roughly 40%, serum bile acid 
concentrations are raised in normal pregnant women (Castano et al, 2006). Data 
presented in this thesis demonstrate that this also occurs in pregnant mice. These 
findings indicate perturbed bile acid homeostasis during normal pregnancy that could 
result in gestational cholestatic disease in predisposed individuals.  
Serum bile acid levels can increase for a number of reasons. An increase in the total 
bile acid pool caused by enhanced bile acid biosynthesis would cause elevated serum 
bile acids. Reduced bile acid excretion or enhanced bile acid absorption from the 
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intestine could also account for raised serum bile acids. Reduced hepatic bile acid 
uptake would result in accumulation of bile acids in the serum. Finally, prevention of 
bile flow out of the liver/gallbladder would induce alternative efflux pathways in the 
liver that would export bile acids into the blood rather than to the intestine. Raised 
serum bile acids could therefore be a result of efficient mechanisms in the liver 
preventing the hepatic accumulation of bile acids. Liver tissue from normal pregnant 
women is unavailable, and it is therefore not known whether hepatic bile acids are 
raised, or why serum bile acids rise during pregnancy in humans. However, data 
from normal pregnant mice presented in this thesis may help explain the cause of the 
raised serum bile acids in normal pregnant women.  
Despite an increase in liver size, hepatic bile acid concentrations were found to be 
significantly higher in pregnant mice than in non-pregnant controls. Indeed the level 
of bile acids were similar in pregnant mice as in Fxr-/- and cholate-fed animals. This 
raised the intriguing question of whether hepatic and intestinal gene expression in 
pregnant mice is pro-cholestatic (responsible for causing the raised hepatic bile 
acids) or anti-cholestatic (a response to the raised hepatic bile acids). Bile acid-
responsive gene expression in the intestine was largely unaffected by pregnancy. 
This suggests that Fgf15 signaling from the intestine to the liver is intact and also 
that intestinal bile acid absorption is unaffected by pregnancy. By contrast, in the 
liver, gene expression was pro-cholestatic with enhanced expression of bile acid 
biosynthesis enzymes and reduced expression of bile acid transporters. Indeed, the 
pattern of hepatic gene expression during pregnancy resembled that in non-pregnant 
Fxr-/- mice. Therefore, despite the presence of raised hepatic bile acids, no evidence 
was found of Fxr-activation during pregnancy, suggesting that gestational factors 
perturb Fxr function.      
Pregnancy experiments were conducted in both long-term cholate-fed and Fxr-/- 
mice. Hepatic bile acids were not raised and there was far more limited evidence of 
pro-cholestatic gene expression in both groups. These findings support the 
suggestion that hepatic bile acids are increased in pregnant mice as a result of Fxr 
dysfunction. However, other experiments are required to confirm this. The cholate-
diet was here administered as an activator of Fxr but it also activates other nuclear 
receptors and causes a basal increase in bile acids. Administration of the potent and 
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specific Fxr ligand GW4064 would be better than cholate feeding as a model of Fxr-
activation and this should be done in future.   
The signal causing pro-cholestatic gene expression during pregnancy has not been 
identified in this work. Reproductive hormones are a plausible signal but the data 
presented here demonstrate that these compounds alone are not sufficient to drive 
pro-cholestatic gene expression. Identifying the signal is an important area of future 
work. There is some evidence in the literature that insulin and the secondary bile acid 
lithocholic acid can inhibit Fxr function and the serum levels of these compounds are 
raised during pregnancy (Castano et al, 2006; Herrera, 2000). These compounds 
could therefore contribute to a signal causing raised hepatic bile acids in pregnant 
mice. Treating primary hepatocytes with serum from non-pregnant and pregnant 
animals and assessing gene expression would at least answer the question of whether 
the signal is a circulating factor. If this was found to be the case, a number of simple 
experiments could be conducted to determine the type of molecule driving the effect. 
These experiments could include boiling the sample to denature proteins and 
charcoal stripping the serum to remove steroid molecules. Ultimately, it could be 
possible to correlate changes in gene expression to molecules identified by analytical 
techniques such as mass spectroscopy or nuclear magnetic resonance.   
Anecdotal evidence that the effects of pregnancy on the liver were similar to a state 
of Fxr-deficiency came form analyses of global metabolic and gene expression 
experiments. These are the first such studies conducted on the liver during pregnancy 
and a number of interesting observations were made. Metabolomic profiling of the 
livers from pregnant mice, using intact tissue NMR, revealed a number of significant 
effects but disease-associated parameters were normal. Therefore, despite the rapid 
liver growth that occurs in pregnant mice, the metabolic composition of the tissue is 
broadly normal. 
Hepatic microarrays revealed that pregnancy had a major effect on transcription in 
the maternal liver. Indeed, almost half of the liver-expressed genes were significantly 
affected (p<0.05) in the pregnant mice. At this level of statistical significance, there 
are many false positives in this gene set but even with a highly stringent Bonferoni 
adjusted p-value, there were over 1,000 significantly affected genes. Pathway 
analysis also revealed that the effects of pregnancy were not on random gene groups 
because several metabolic pathways were statistically over-represented in the 
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affected gene list. Furthermore, ingenuity pathway analysis identified a gene cluster 
associated with cholestatic liver disease as being the most over represented cluster in 
the pregnant mice. It is perhaps not surprising, given the metabolic demand on the 
liver, that pregnancy has such a major effect on its transcriptional program. It would 
be interesting to determine whether pregnancy has such a large affect on other 
maternal tissues or whether the liver is among the most affected organs.  
It is not known whether humans develop raised serum bile acids during pregnancy 
due to reduced FXR function or whether liver gene expression is pro-cholestatic 
during this period. However, a gestational pertubation in FXR function is in line with 
the genetic aetiology of ICP because individuals with functional variants of FXR or 
its target genes are at increased risk of developing the disease. Urdodeoxycholic acid 
(UDCA) is the primary treatment for ICP. While there is considerable debate 
regarding the mechanisms by which UDCA ameliorates cholestasis, this bile acid is a 
ligand for FXR in vivo. Therefore, activation of FXR by UDCA may form a 
component of the mechanism by which UDCA prevents cholestasis of pregnancy. 
The data presented here also suggest that specific activators of FXR could be 
developed as new treatments for cholestasis. Indeed, one such ligand, INT777 is 
currently undergoing clinical trial for the treatment of gallstones. INT777 also has 
the potential to be used to treat ICP. However, it would be necessary to establish 
whether the drug has any adverse fetal effects before using it.  
 
7.4 Redundant Pathways Occur in Pregnancy to Ensure Liver Growth. 
Hepatocytes retain the ability to enter the cell cycle and proliferate in response to 
mitogenic stumuli (Steer, 1995). The liver is therefore able to increase in size in 
response to increased metabolic demand, re-grow following hepatic injury, 
experimental or therapeutic resection. Liver regeneration following experimental 
resection has been extensively studied, as has hepatomegaly induced by toxic 
challenge such as chronic exposure to ethanol (Fausto, 2000; Michalopoulos & 
DeFrances, 1997). Gestation is a physiologically normal event that increases the 
metabolic demand on the maternal liver and causes liver enlargement in rodents 
(Hollister et al, 1987; Paschkis & Cantarow, 1958). This important physiological 
event has been incompletely described and no information is known regarding the 
signals that drive the growth or the pathways that transduce the signal.  
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Several studies have noted increased liver weight in late pregnant animals but the 
change in liver weight was thought to occur in proportion to changes in maternal 
body weight. Indeed, it was found that liver to body weight ratio in late pregnant 
animals is the same as in non-pregnant controls. Based on these data alone, one could 
argue that the maternal liver simply senses and responds to maternal body weight and 
that gestational liver growth is therefore not dissimilar to organ enlargement that 
occurs during normal developmental growth. However, in this thesis, it was found 
that during mid gestation, on the 12th day post conception, maternal liver weight is 
disproportional to maternal body weight. This is a novel and an important finding 
that demonstrates that the liver does not simply sense and respond to changes in 
maternal body weight. This finding also suggests the presence of a specific growth 
promoting signal that is present, and active, during the first half of pregnancy. It was 
also found here that maternal liver weight is proportional to fetal number. This 
finding suggests that the liver enlargement occurs in order to meet the increased 
metabolic demands of the fetuses and also suggests that the signal driving gestational 
liver enlargement may be fetal or placental in origin.  
The possibility that liver growth during pregnancy is a result of increased water 
content or infiltration of cells other than hepatocytes was excluded. Liver 
enlargement during pregnancy is therefore likely to be functional and a result of 
either hepatocyte proliferation (hyperplasia) or hepatocyte growth (hypertrophy). In 
agreement with the one study describing some aspects of gestational liver 
enlargement, pregnancy was here found to increase hepatocyte size (Hollister et al, 
1987). In subsequent analyses, pregnancy was found to cause a significant increase 
in the proportion of Ki-67 positive hepatocytes, demonstrating that gestational 
signals cause normally quiescent mature cells to enter the cell cycle. However, 
pregnancy had no effect on the proportion of phospho-histone-H3 positive mitotic 
figures. Together, it was concluded that pregnancy causes cell cycle entry and arrest 
prior to mitosis.  
Polyploidy is common in hepatocytes (Gupta, 2000). The process of ployploidization 
has recently been found to occur during the suckling to weaning transition in rodents 
and is though to be an adaptive response to increased exposure to dietary toxins 
during this period. Indeed in humans and in rodents, hepatic polyploidization occurs 
in response numerous hepatotoxic challenges and is though to be a rapid mechanism 
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of increasing metabolic capacity of the cells without committing large amounts of 
energy to cell division. As a result of these findings, and the fact that the Ki-67 
staining data suggested cell cycle entry, hepatocyte DNA content was measured in 
pregnant mice. Two published methods, on biological replicates, were used measure 
cellular DNA content. Quantitative analysis of Hoechst stained hepatcyte nuclei and 
FACS analysis of propriduim iodide stained isolated hepatocytes.  Despite both 
techniques being rather crude, they clearly demonstrated increased average 
hepatocyte nuclear DNA content in the pregnant mice. Therefore, pregnancy causes 
hepatocte cell cycle entry, progression through DNA replication and arrest prior to 
mitosis.  
Because of the marked alterations in cell cycle events induced in the pregnant mice, 
the protein expression of a number of known cell cycle regulators were assessed. 
Pregnancy affected the expression of these proteins but there was no clear pattern for 
cell cycle promoting or cell cycle inhibiting changes. This is possibly a reflection of 
the complex cellular events observed in these mice, namely cell cycle progression 
and arrest prior to mitosis. However, this is the first detailed description of the 
cellular events that contribute to gestational liver growth and is one of the few 
reports describing a physiologically normal event in adult mice that causes normally 
quiescent cells to enter the cell cycle, grow, replicate their DNA and arrest prior to 
mitosis.  
No effort has been made to identify the signals or the signalling pathways that are 
required to maintain gestational liver enlargement. Pregnancy is known to cause 
dramatic changes in many factors that are known to affect liver morphology. These 
factors include insulin, IGF-I, reproductive hormones, growth hormone and lactogen 
signalling as well as hyperphagy (Butte, 2000; Freemark, 2006; Herrera, 2000). 
Changes in the serum profiles of these factors could contribute to gestational liver 
growth and future work should investigate this possibility. However, these studies 
could prove difficult because these factors are also required to drive other metabolic 
adaptations that are required to maintain pregnancy such as insulin resistance. In this 
thesis, the potential role of reproductive hormones and bile acids in driving 
gestational liver growth was investigated. The rationale for conducting these 
experiments is that levels of circulating reproductive hormones are raised 
dramatically during pregnancy and that estrogen can cause liver growth in rodents 
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(Yamamoto et al, 2006). In addition serum bile acid levels rise during pregnancy in 
humans and bile acids cause liver growth in rodents and are required for the normal 
mechanisms of hepatic recovery form partial resection.   
The silastic implant model of Milligan and Cohen was used to deliver pregnancy 
levels of reproductive hormones to mice. Because this treatment had no effect on 
liver size it is unlikely that reproductive hormones alone cause liver growth during 
pregnancy. By contrast, pregnancy caused a significant increase in serum bile acid 
levels in mice, suggesting that they might contribute to causing liver growth during 
pregnancy. It was found that while cell cycle entry and polyploidy were common to 
both pregnancy and cholate feeding, bile acids cause liver growth by cell 
proliferation, which is in contrast to gestational liver growth. In addition, normal 
liver growth occurred in pregnant Pxr-/- mice despite no increase in serum bile acids 
in these animals. The reason why Pxr-/- mice do not develop raised serum bile acids 
during pregnancy is an area of future work but these finding demonstrate that Pxr is 
not required for normal gestational liver growth and that raised serum bile acids are 
also not required for normal liver growth. The bile acid receptor Fxr is required for 
the normal mechanisms of liver regeneration following partial hepatectomy (Huang 
et al, 2006). Here, it was found that serum bile acids do not increase in pregnant Fxr-
/- mice but in contrast to Pxr-/- mice mice, the normal mechanism of gestational liver 
growth is not maintained in mice lacking Fxr. It was found that hypertrophy and 
polyploidy was blunted in the Fxr-/- mice mice and that hyperplasia makes a 
significant contribution to gestational hepatomegaly in these mice. Fxr is therefore 
required to maintain the normal mechanisms of pregnancy-induced liver growth in 
mice. As a result, this is the first report of any molecule, receptor or signal that is 
implicated in gestational liver growth.  
Mice lacking Fxr develop spontaneous hepatocellular carcinoma in old age. This is 
thought to be a result of uncontrolled hepatocyte proliferation caused by raised serum 
bile acids in these mice. The fact that Fxr-/- mice mice undergo gestational liver 
growth by cell proliferation could put these mice at even higher risk of developing 
hepatocellular carcinoma in later life. This would be an interesting area of future 
work.  
The primary signal driving gestational liver growth has not been identified. However 
the data presented suggest that this signal is unlikely to be bile acids or reproductive 
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hormones. The fact that significant liver growth has occurred by the 12th day of 
gestation and hepatic growth hormone and prolactin receptor expression data suggest 
that lactogens of placental origin may make a significant contribution of pregnancy 
induced liver growth. Further experiments are required to determine the contribution 
of these lactogens to gestational liver growth. However these studies will prove 
difficult because of the complexity of alterations in circulating factors in pregnant 
mice. Indeed, it is unlikely that a single factor or signalling pathway is responsible 
for driving liver growth during pregnancy. 
 
7.5 Overall conclusions  
This thesis has investigated novel aspects on the role of FXR during gestation, with a 
focus on intrahepatic cholestasis of pregnancy. Genetic variation in FXR was 
recently identified for the first time, and in an ICP population (Van Mil et al, 2007). 
These variants were characterized and found to affect FXR function in vitro. 
Subsequently, experiments were conducted in normal and Fxr-/- mice to provide 
insights in to the potential causes of gestational cholestasis. Reproductive hormones 
are implicated in the aetiology of ICP and published reports have found that estrogen 
administration has pro-cholestatic hepatic gene expression effects in mice (Arrese & 
Accatino, 2003; Bossard et al, 1993; Crocenzi et al, 2005; Geier et al, 2003; Green et 
al, 2000; Simon et al, 2004; Stieger et al, 2000; Yamamoto et al, 2006). These 
findings were replicated here but they were not maintained when estrogen was 
administered, along with progesterone, at physiologically relevant concentrations and 
over a time course similar to that of pregnancy. Reproductive hormones alone are 
therefore unlikely to be the primary cause of gestational cholestasis. The increased 
metabolic demand on the maternal liver during pregnancy is best visualized by a 
marked increase in maternal liver weight in mice. Gestational liver growth has been 
characterized in detail for the first time in this work and this is also the first report of 
any component (FXR) that is required to maintain the normal mechanisms that drive 
this process. Finally, it was found that pregnancy causes the accumulation of bile 
acids in the liver due to pro-choleststic hepatic gene expression. Despite the raised 
hepatic bile acids, there is no evidence of Fxr activation in pregnant mice. Indeed, 
evidence is presented here that suggests that Fxr function is impaired during 
gestation. 
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Pregnancy has significant, but poorly understood, effects on the maternal liver. This 
thesis provides new information on how the liver responds to the demands of 
pregnancy and demonstrates that FXR may play an important role in mediating some 
of these adaptations.  
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Appendix I 
 
 
 
 
 
 
Supplementary Figure 1: Plasmid maps 
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Supplementary Table 1. Primers used for plasmid generation. 
 
 
 
 
  
Appendix II 
Fxr-/- mice were generated and validated by Chitage Mataki in the laboratory of Dr 
Kristina Schoonjans and Professor Joan Auwerx and supplied under an MTA with 
the university of Strasbourg.  
 
Supplementary Figure 2: Generation and validation of mice with a targeted 
mutation in the Fxr gene.  
(A) Map of the Fxr genomic locus. LoxP sites (grey triangles) are indicated. Boxes 
represent the respective exons. (B-C) Efficient recombination of the Fxr locus as 
indicated by the almost complete absence of Fxr mRNA (n=5)(B) and protein (n=3) 
(C) levels in the liver of Fxr-/- mice. 
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Appendix III 
 
Supplementary Table 2. FXR genotyping primers 
 Forward Primer Reverse Primer 
WT GAAGCACACTCACAGATGTCAAATGC AGATGCTGTTAGGTGGTCAGCTCAG 
KO GAAGCACACTCACAGATGTCAAATGC ATGTGTTCTAAGCTAGACATGGCCG 
 
 
Supplementary Table 3. RT-QPCR primers 
 
 
Gene name Forward Primer Reverse Primer 
Abca1  TCCTCATCCTCGTCATTCAAA GGACTTGGTAGGACGGAACCT 
Abcg5  TCAATGAGTTTTACGGCCTGAA GCACATCGGGTGATTTAGCA 
Abcg8  TGCCCACCTTCCACATGTC ATGAAGCCGGCAGTAAGGTAGA 
Asbt  TCCTTGGCTGGACTAGCTGGTCAA CTGAGTGTTCTGCATTCCAGTTTC 
Bsep  AAGGTACATCTGCCTTAGACACAGAA CAATACAGGTCCGACCCTCTCT 
Car  GGAGGACCAGATCTCCCTTC ATTTCATTGCCACTCCCAAG 
Ccnd1 GGGCACCTGGATTGTTCT CACCGGAGACTCAGAGCA 
Cyclophilin TGGAGAGCACCAAGACAGACA TGCCGGAGTCGACAATGAT 
Cyp7a1  AGCAACTAAAACAACCTGCCAGT GTCCGGATATTCAAGGATGCA 
Cyp8b1  TAGCCCTCTTTCCTCCACTCATA GAACCGATCGAACCTAAATTCCT 
Cyp17a1  TAGCAATCGATGGGTAAAAT TCCGAAGGGCAAATAACTGG 
Fgf15  GAGGACCAAAACGAACGAAATT ACGTCCTTGATGGCAATCG 
Fxr TCCGGACATTCAACCATCAC TCACTGCACATCCCAGATCTC 
Gadd45b  GTTACTCAAGCAGTCACTCCCC TCTTCAGGCTCACCTCTCTCTC 
Ghr  GATTTTACCCCCAGTCCCAGTC GACCCTTCAGTCTTCTCATCCACA 
Hmgcr  CATTCCAGCCAAGGTGGTGAG CAAGATGTCCTGCTGCCAAGG 
Ibabp  TGAGAGTGAGAAGAATTACGATGAGTTC TTACGTCCCCTTTCAATCACG 
Igfbp1  CGCCTGCGTGCAGGAGTCTG AGAGCCTTCGAGCCATCATA 
L19 GGAAAAAGAAGGTCTGGTTGGA TGATCTGCTGACGGGAGTTG 
Mdr1  GG ATTGCCTACCTGTTGG GCTTTCTGTGGACACTTCTG 
Mdr2  CTCGTTAACATGCAGACAGCAG GACCAGGGAGAACATGTTACAC 
Mrp2  GGTTCCTGTCCATGTTCTGGATT GCAGCTGAGGATTCAGAAACAAA 
Mrp3  GCAGCAGAACCAAGCATCAAG GACCGCATCCTCACCTGG 
Mrp4  GGTTGGAATTGTGGGCAGAA TCGTCCGTGTGCTCATTGAA 
Ntcp  GAAGTCCAAAAGGCCACACTATTGT ACAGCCACAGAGAGGGAGAAAAG 
Oatp1  TGATACACGCTGGGTCGGTG GCTGCTCCAGGTATTTGGGC 
Oatp2  GTTGCAACCCATGGGGTCAGATG GCTGGTCAGGATATTCACTCCTG 
Ostα  CTGAGCATATAGTGGGCCTGTTC AGCTGCGCTCTTCTCAGAAATT 
Ostβ  TGACAAGCATGTTCGTCCTGAG TTCTTTGTCTTGTGGCTGCTTC 
Prlr  CATCACAGTAAATGCCACGAACGAA AAAGATGCAGGTCATCATGCTATAA 
Pxr GCCTGGAGAGTGGCATGAA TCCCTCTTCTTCCTCTTGATCAA 
Shp  CGATCCTCTTCAACCCAGATG AGGGCTCCAAGACTTCACACA 
Vdr  ATGACCTGTGAAGGCTGCAAG GGCAGGTGAACAGGGCC 
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Appendix IV 
Additional microarray data are presented on supplementary compact disk that 
accompanies this thesis. The files contain all liver expressed genes that are affected 
(p<0.05) under each condition.  
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Appendix V 
 
A 
 
B 
 
Supplementary Figure 3: Principal Copmponent Analysis of micro-array data 
Every circle represents an animal and therefore a chip from the array (A) Non-
pregnant and pregnant on either a control or cholic acid diet clusteraccording to 
experimental group without overlap or outliers. (B) Non-pregnant and pregnant wild 
type or Fxr-/- mice cluster according to experimental group without overlap or 
outliers.
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Appendix VI 
 
 
 
 
Supplementary Figure 4: Hepatic Fxr protein is unaffected by pregnancy or 
choalte feeding. 
Western blot of total cellular protein probed with α-FXR and α-βactin. 
